Introduction

Front. Immunol.

Frontiers in Immunology

Front. Immunol.

1664-3224

Frontiers Media S.A.

10.3389/fimmu.2025.1617140

Immunology

Review

The complement system in human pregnancy and preeclampsia

Kumar

Vijay

^* ^† Stewart

John H.

Department of Surgery, Laboratory of Tumor Immunology and Immunotherapy, Medical Education Building-C, Morehouse School of Medicine, Atlanta, GA, United States

Edited by: Paola Triggianese, University of Rome Tor Vergata, Italy

Reviewed by: Guilherme Ramires De Jesús, Rio de Janeiro State University, Brazil

Konstantine Halkidis, University of Kansas Medical Center, United States

*Correspondence: Vijay Kumar, vijkumar@msm.edu; vij_tox@yahoo.com

†ORCID: Vijay Kumar, orcid.org/0000-0001-9741-3597

19 08 2025

2025

1617140

23 04 2025 23 07 2025

2025

Kumar and Stewart

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Human pregnancy is a complex condition that poses significant challenges for women due to the necessity of a uterus for key processes such as fertilization, embryo implantation, fetal development, and childbirth. These processes are governed by immunological factors and accompanied by various physiological changes. For a successful pregnancy, maternal immune reprogramming is crucial because the developing embryo is considered a semi-allograft. Any immunological alteration during pregnancy induces recurrent pregnancy loss and other fetal–maternal health issues, including preeclampsia. However, despite advances in reproductive immunology, the exact immunopathogenesis of preeclampsia remains unclear. The complement system (CS) is an evolutionarily ancient and critical innate immune component that plays a significant role in maintaining immune homeostasis. The current article discusses the critical role of the CS in human pregnancy and how its dysregulation predisposes pregnant women to preeclampsia. The article introduces the concept of the Th1 to Th2 immunological shift as a prerequisite for a successful pregnancy and the evolution of decidualization via transposable elements, which recruit genes responsible for the process in the endometrium. The immune system plays a critical role in decidualization. The second section discusses the CS signaling pathway, its negative regulators, and the roles of the C3a/C3aR and C5a/C5aR1/C5aR2 or C5L2 axis in immune homeostasis. The third section elaborates on the role of the CS in the establishment of human pregnancy, such as fertilization, implantation, and fetal development. The fourth section describes maternal CS signaling alteration during successful human pregnancy. The fifth section describes the role of CS signaling in preeclampsia, including its systemic and local (placental) alterations and the responsible mechanisms. The article closes with future perspectives and a summary that describes important complement-based approaches for diagnosing and treating preeclampsia.

human pregnancy preeclampsia CS placenta immunoregulation immune homeostasis

section-in-acceptance

Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders

1 Introduction

Human pregnancy occurs in the very specialized organ, the uterus, which protects the developing embryo and fetus through its mucosal lining or decidua, making human pregnancy a unique immune challenge that further develops trained immunity with subsequent pregnancies (1–4). The maternal–fetal interaction during human pregnancy is an example of fetal allograft acceptance by the pregnant female as indicated by the shift from a pro-inflammatory Th1 immune response to an anti-inflammatory Th2 immune response ( Figure 1 ) (5, 6). Furthermore, the maternal innate immune system plays a critical role in the successful outcome of human pregnancy. For example, uterine natural killer (uNK) cells are critical for the early embryonic establishment and spiral artery formation (1, 7). Along with the local uterine immune microenvironment, systemic factors, such as hormonal status and cytokine (pro- and anti-inflammatory) levels governing the systemic and local immunological status, determine pregnancy success (1). The details of fetal–maternal immune interactions during human pregnancy have been discussed elsewhere (4, 8–10).

Figure 1

Representation of Th1 to Th2 immunological shift during pregnancy. Normal/healthy non-pregnant adult woman exhibiting pro-inflammatory Th1 immune response to maintain immune homeostasis and fight against invading pathogens and other foreign particles. However, during pregnancy, this pro-inflammatory Th1 immune response shifts to anti-inflammatory Th2 immune response to support pregnancy or developing embryo/fetus, which is an allograft for a pregnant woman.

Illustration comparing two female figures. The left shows a normal adult female with a Th1 pro-inflammatory stage of the immune system. The right depicts a pregnant female with a fetus, representing a Th2 anti-inflammatory stage, highlighting the shift necessary for a healthy pregnancy and fetal development.

The complement system (CS) is a component of the innate immune system. It is composed of more than 50 humoral components (fluid-phase proteins present in the blood, saliva, lymph, and interstitial fluids), which recognize pathogens and interact with antibodies (Abs)/immunoglobulins (IgG and IgM) and their cognate receptors expressed on different immune cells to maintain immune homeostasis (11, 12). Evolutionarily, the CS is one of the most ancient and primitive components of innate immunity (12, 13). For example, the complement component C3 and factor B genes comprising the central components of the CS originated at least 1,000 million (one billion) years ago (MYA) (13). Furthermore, developmental evolution studies focusing on the origin of pregnancy indicate that the recruitment of genes ancestrally expressed in other organ and tissue systems into endometrial expression transmitted new functions to the uterine endometrium, such as immune regulation and fetal–maternal signaling for a healthy pregnancy (14). The transposable elements (TEs) evolved/amplified prior to the divergence of eutherian mammals were critical for recruiting these genes to the endometrium to induce the development of decidualization, as indicated by the deposition of binding sites for master transcriptional regulators of endometrial stromal cell type identity and progesterone responsiveness to numerous genes across the genome (14). For example, the progesterone receptor (PGR) is the principal transcriptional effector of progesterone signaling and decidualization (14). Thus, decidualization in mammalian pregnancy has also evolved from acquiring genes from other organs required to maintain immune balance for normal functioning. The CS is one of the most ancient components of the innate immune system; therefore, it is critical to understand its role in human pregnancy and preeclampsia.

2 CS as a critical component of the immune system

The CS is composed of circulating or humoral components and its receptors called complement receptors (CRs), such as C1q, which is a pattern recognition receptor (PRR) of the complement component C1 (C1 is composed of C1r, C1q, and C1s) and mediates the complement recognition of surface-bound immunoglobulin (Ig) G and IgM, CR1 (CD35), CR2 (CD21), CR3 (CD11b/CD18 or Mac1), CR4 (CD11c/CD18), CRIg (VSIG4, expressed on Kupffer cells and several other tissue-resident macrophages), C3aR, C5aR1 (CD88), and C5aR2 or C5L2 (12, 15, 16). The liver is a major producer of circulating CS components (17, 18). However, epithelial, endothelial, and immune cells, such as neutrophils, monocytes and macrophages, dendritic cells (DCs), mast cells, B cells, and T cells, also produce different CS components or proteins (19). CS activation is a rapid innate immune response against invading pathogens, including microbe/pathogen-associated molecular patterns (MAMPs/PAMPs) and death/damage-associated molecular patterns (DAMPs), aimed at containing the infection and inflammation.

The CS activation further activates innate immune cells by promoting phagocytosis by producing opsonins, which induce opsonization, and the stimulation of different CRs (C3aR, C5aR1, and C5aR2) expressed on innate and adaptive immune cells, further activating both (innate and adaptive) arms of the immune system to maintain immune homeostasis. The CS activation pathway diverges mainly into three pathways: 1) classical CS activation, 2) lectin or mannan-binding lectin (MBL) pathway, and 3) alternative CS activation ( Figure 2 ). It is critical to note that the alternative CS signaling pathway is evolutionarily older and that the classical CS signaling pathway evolved from it (20, 21). Complement component C3 activation is common to all three CS pathways, or all these pathways converge at C3 to form the end product, called the membrane attack complex (MAC), which is composed of C5bC6-9 ( Figure 2 ). A brief description of all three CS signaling pathways forming the MAC has been discussed below and is shown in Figure 2 .

Figure 2

Schematic representation of the CS signaling pathways. (A) Classical CS signaling pathway. The C1 component [comprising C1q (serves as a PRR) and 2C1r and 2C1s components, which are serine proteases] initiates the classical CS signaling pathway by recognizing IgG and/or IgM bound to the pathogen, cell surfaces, or other immune complexes. The C1q binding to the pathogen/antigen/IC-IgM/IgG complex activates two serine proteases (C1r and C1s). The activated C1s recognizes C4 and generates C4a and C4b components. C4b recruits C2 and C1s to generate C2a and C2b. The C4bC2b complex serves as C3 convertase of the classical CS signaling pathway. C3 convertase cleaves C3 into C3a (an anaphylatoxin; alters immune response via C3a/C3aR axis on different immune cells) and C3b (opsonin). The remaining C3b attached to C4bC2b forms C4bC2bC3b complex called C5 convertase, which cleaves C5 into C5a (an anaphylatoxin; alters immune response via C3a/C3aR axis on different immune cells) and C5b, which forms MAC by activating the terminal pathway. (B) The lectin or MBL pathway. The MBL pathway does not require C1 but instead depends on ficolin-, MBL-, and collectin-mediated pathogen recognition. MASP-1 and MASP-2 of these molecules upon pathogen recognition become active. For example, MASP-1 activation stimulates MASP-2 enzymatic activity for C4 and C2 molecules to generate C4bC2b or lectin pathway C3 convertase to generate C3a and C3b. This pathway also generates C5a and C5b, like classical CS signaling pathway, to generate MAC. (C) The alternative CS signaling pathway. The alternative CS signaling pathway involves hydroxylation of C3 to form C3(H₂O) complex, which recognizes circulating pathogens. The bound C3b on the pathogen surface is recognized by FB. The MASP-3 of the MBL pathway cleaves pro-factor D to mature factor D that serves as a serine protease to cleave factor B (FB) and generate the C3 convertases C3(H₂O)Bb and C3bBb. Thus, the C3(H₂O)/C3bFB complex generates C3(H₂O)/C3bBb as a C3 convertase of the alternative CS signaling pathway that cleaves C3 into C3a and C3b. The fast production of C3bBbC3b (C4b2b3b) serves as a C5 convertase of the alternative CS signaling pathway to generate C5a and C5b. (D) The terminal pathway of the CS. C5b, generated due to the activation of all three CS pathways, forms a complex with C6, C7, C8, and C9 components called MAC. MAC kills invading pathogens by forming pores on their cell membranes. Kindly see the text for details. CS, complement system; PRR, pattern recognition receptor; MAC, membrane attack complex; MBL, mannan-binding lectin; FB, factor B.

Diagram of complement system pathways including the classical, lectin, alternative, and terminal pathways. Each pathway is detailed with involved proteins and processes. The classical pathway starts with C1 complex activation, the lectin pathway involves MBL and MASP proteins, and the alternative pathway activates via C3 hydrolysis. All converge on the terminal pathway forming the membrane attack complex. Annotations highlight anaphylatoxin effects mediated by C3a and C5a.

Classical CS activation starts from the C1 component, which is composed of three components: C1q, C1r, and C1s ( Figure 2A ). C1q serves as a pattern recognition molecule (PRM) or PRR. It recognizes structural changes induced by IgM and/or IgG1, IgG2, and IgG3 Abs binding to pathogens, cell surfaces, or immune complexes (ICs) ( Figure 2A ). This recognition, or the C1q–pathogen/antigen/IC-IgM/IgG complex, activates two serine proteases (C1r and C1s) of C1. The enzymatically activated C1s recognizes complement component C4 and cleaves it into C4a (smaller fraction) and C4b (larger fraction) ( Figure 2A ). The biological role of C4a is not yet clear, whereas C4b within or near the Ig–C1 complex recruits fluid phase C2 and C1s, which process C2 to C2a (biological function unknown) and C2b (which is an active serine protease) ( Figure 2A ). The C4bC2b complex serves as a classical CS pathway C3 convertase, a central player for all three CS pathways ( Figure 2A ). C3 convertase promotes C3 activation, a central component of CS signaling pathways. C3 cleavage produces C3a (serves as an anaphylatoxin and induces C3a–C3aR interaction-mediated immune response) ( Figure 2A ), and C3b serves as an opsonin to aid in phagocytosis through its exposed thioester group that recognizes amino or hydroxyl groups on the target (15, 22, 23). The remaining C3b within C4bC2b forms a complex called C4bC2bC3b or C5 convertase ( Figure 2A ). The C2b component of C5 convertase cleaves C5 into C5a (serves as anaphylatoxin and inflammogen and induces C5aR1- and C5aR2-mediated immune functions) and C5b (mediates the activation of terminal pathway or MAC formation) ( Figure 2A ).

The lectin or MBL pathway is independent of Abs and shares many characteristics of classical and alternative CS signaling pathways ( Figure 2B ). The MBL or lectin pathway does not require C1 for its activation; instead, it depends on the recognition of PAMPs by MBL, three ficolins (Ficolins 1–3), and two collectins (Collectin-10 and Collectin-11), which have serine protease activity ( Figure 2B ). MBL and collectins (Collectin-10 and Collectin-11), due to their carbohydrate recognition domain, are part of the superfamily of fibrinogen-like proteins, whereas ficolins have a fibrinogen-like recognition domain and belong to the superfamily of fibrinogen-like proteins. Thus, MBL, ficolins, and collectins can recognize different carbohydrate entities, such as mannose of bacterial pathogens by MBL, N-acetylglucosamine (GlcNAc) of injured and dying cells by MBL and ficolins, and altered l-fucose and D-galactose patterns of cells under severe stress by ficolins and Collectin-10 and Collectin-11. Furthermore, the lectin pathway can also recognize the host DNA exposed on apoptotic cells, and Collectin-12 may activate the alternative CS signaling pathway in its soluble form in conjunction with properdin. MBL-associated serine protease-1 (MASP-1), MASP-2, and MASP-3 are MBL or lectin pathway serine proteases. MASP-1 and MASP-2 are associated with common collagen regions within MBL, ficolins, and collectins ( Figure 2B ), whereas MASP-3 activity is connected to the alternative CS pathway activation via the proteolytic cleavage of pro-Factor D (FD) to enzymatically active mature FD ( Figure 2C ). FD is a serine protease that is critical for activating the alternative CS signaling pathway by cleaving factor B (FB) and generating the C3 convertases C3(H₂O)Bb and C3bBb (discussed later in the alternative CS signaling pathway section) (24, 25). Adipocytes are the main producers of circulating FD (24, 25). The MASP-3-mediated cleavage of FD to its mature form prepares it for its initiation and amplification function of the alternative CS signaling pathway (25). The details of FD in the CS signaling pathway and complement-mediated inflammatory diseases have been discussed elsewhere (24, 25).

The MBL or lectin pathway recognizes the target molecule and autoactivates MASP-1, cleaving MASP-2 for its enzymatic activity toward C4 and C2 bound to initiating MBL, ficolins, and collectin–MASP-1/2 complexes. This is followed by classical CS signaling, such as forming a C4bC2b complex and a C3 convertase, activating C3 and C5 ( Figure 2B ). The C3 and C5 convertases of the lectin pathway are also known as lectin pathway convertases.

The alternative CS signaling pathway has been considered a separate CS activation pathway ( Figure 2C ). However, it can activate the CS itself and may account for approximately 80%–90% of the total complement activation, even in conditions triggered by classical or lectin/MBL pathways (26). For example, it idles in the serum constantly at low levels of activation, as 3%–5% of circulating C3 constantly exists in a hydrolyzed [C3(H₂O)] form, and its exposed thioester can spontaneously interact with complement targets, such as microbes in the peripheral circulation (blood, lymph, and interstitial fluids). Thus, C3(H₂O) is bound to the circulating pathogen, and C3b is deposited on the target surface during the classical or lectin/MBL pathway, recognized by the inactive serine protease, FB ( Figure 2C ). The C3(H₂O)/C3bFB complex interacts with another serine protease, FC, that cleaves FB into Ba and Bb (enzymatically active) units ( Figure 2C ). The smaller Ba subunit detaches itself from the C3(H₂O)/C3bFB complex, generating C3(H₂O)/C3bBb, the C3 convertase of the alternative CS signaling pathway ( Figure 2C ). The Bb component of the alternative CS signaling pathway’s C3 convertase cleaves C3 into C3a and C3b, as occurs during classical or lectin/MBL pathways ( Figure 2C ). The rapid production of C3bBbC3b (C4b2b3b) complexes during the alternative CS signaling pathway forms its C5 convertase, cleaving C5 into C5a and C5b ( Figure 2C ) (27). Properdin, a complement protein, along with stabilizing the C3 convertase complexes (C3bBbP) of the alternative CS signaling pathway, may also serve as an initiator or focus point for the subsequent C3b deposition during different conditions, such as apoptotic immune cell death as seen during acute infections, such as sepsis (27, 28). For example, properdin targets specific proteoglycans of apoptotic immune cells, serving as DAMPs and microbial PAMPs, and recruits C3b, which promotes phagocytic clearance of these pathogens and apoptotic cells (27).

The terminal pathway of CS signaling involves the convergence of all three CS signaling pathways that form the final and lytic component of the CS called the MAC, which forms pores in the targeted microbial surface ( Figure 2D ) (27). The MAC is composed C5b, C6, C7, C8, and C9 components of the CS ( Figure 2D ) (27, 29, 30). The complement components C6 to C9 are members of the MAC/perforin/cholesterol-dependent cytolysin (MACPF/CDC) protein superfamily. Thus, the MAC is the CS signaling end product that kills the target by forming pores. However, continuous CS activation is governed by several circulating or surface-bound regulators to prevent host damage, as described in Table 1 .

Table 1

Circulating and cell surface/membrane-bound complement regulators.

Soluble/circulating complement regulators	Organ-specific expression	Cell-specific expression	Functions	Deficiency or overexpression diseases
C1 inhibitor (C1-INH) or C1 esterase inhibitor belongs to the serine protease inhibitor (Serpin) superfamily, also known as Serpin family G member 1 (SERPING1)	Highly expressed in the lungs, liver, female reproductive tract (FRT), and placenta (31, 32).	Platelet alpha granules and parenchymal cells of the liver, including hepatocytes, Kupffer cells (KCs), blood monocytes, microglial cells, skin fibroblasts, and endothelial cells (31, 33–36).	C1-INH binds to the active sites on both C1r and C1s to form a complex C1-INH-C1r-C1s-C1-INH for inhibiting activated C1 (37). It also inhibits C1 autoactivation by removing the intact C1qrs complex (38, 39).C1-INH also inhibits kallikrein, plasmin (fibrinolytic), and contact activation (intrinsic) coagulation cascade (40, 41).C1-INH also regulates alternative CS pathway (42).CI-INH also inhibits endothelial cell and leukocyte interaction by interacting with P- and E-selectin during inflammation (43).	C1 inhibitor deficiency is associated with hereditary angioedema or hereditary angioneurotic edema (HAE), causing severe swelling in the body/specific body parts due to leakage of fluids in the connective tissues from blood vessels as result of mild trauma (44).
Complement Factor I (CFI) or C3b/C4b inactivator	Mainly (90%) synthesized in the liver and circulates as a zymogen till the engagement of C3b/cofactor complex; eyes (in aqueous and vitreous fluid) (45).	Hepatocytes, retinal pigment epithelial cells (RPECs), monocytes, endothelial cells, keratinocytes, myoblasts, and hepatoma cells (45).	CFI inhibits activated C3b and C4b in the presence of cofactors, like Factor H, C4b binding protein, complement receptor 1 (CR1 or CD35), and membrane cofactor protein (MCP or CD46) (45, 46).CFI also inhibits the alternative CS signaling pathway at cellular surfaces expressing CD46 and CR1 (47).	Genetic CFI deficiency is associated with recurrent infections with encapsulated bacteria (i.e., Neisseria meningitidis, Haemophilus influenzae, and Streptococcus pneumoniae), renal autoimmune diseases, such as C3 glomerulopathy (C3G), atypical hemolytic uremic syndrome (aHUS), and age-related macular degeneration (AMD) (45, 46).
Complement Factor H (CFH) or Factor H (FH)	Mainly synthesized by the liver.	Hepatocytes, monocytes, dendritic cells (DCs), endothelial cells, fibroblasts, RPECs, and keratinocytes (48).	Mainly inhibit alternative CS signaling pathway systemically and cellular level (48–51). FH serves as an alternative CS signaling pathway convertase decay accelerator by binding to the C3b via its N-terminal four domains and FI cofactor to inactivate C3b (52). Thus, FH prevents the formation of C3bBb convertase and accelerates its decay (48). FH also inhibits classical CS signaling pathway activation in response to the fibrin clot (53).	Quantitative FH deficiency is associated with C3G and mutations in the FH complement regulatory N-terminal domains, also associated with C3G, whereas C-terminal mutations are associated with defective surface recognition and aHUS (48). Some FH genetic variants are also associated with AMD (48, 54, 55).
Factor H-related protein (CFHR) family has five family members (CFHR1–CFHR5). CFHRs are exclusively composed of complement control protein (CCP) domains, which are also called Sushi domains or short consensus repeats (CSRs) (48, 56)	Liver	Hepatocytes, monocytes, dendritic cells (DCs), endothelial cells, fibroblasts, RPECs, and keratinocytes (48).	Their function is less characterized and controversial (57). However, all five CFHRs (CFHR1–CFHR5) bind to C3b and compete with FH in the process. For example, CFHR1, CFHR4, and CFHR5 interact with C3b, enhancing alternative CS signaling pathway activation as CFHR4–C3b complex binds to factor B and properdin, forming an alternative convertase to cleave C3 into C3a and C3b (48, 57, 58).	CFHR variants are associated with increased risk for aHUS (59). Malondialdehyde (MDA)-bound CFHR1 increases pro-inflammatory cytokine release from immune cells, such as macrophages, without involving CS (60). However, CFHR1 deficiency increases TNF-α, IL-1β, and IL-6 release from lipopolysaccharide (LPS) and R484-stimulated monocytes (60).
C4b-binding protein (C4BPA and C4BPB), the only complement inhibitor with a polymorphic structure (61)	Mainly by liver and to some extent by the lungs and cells of islets of pancreas (62).	Hepatocytes, granulocytes, and monocytes	CRBP prevents uncontrolled activation of classical and MBL/lectin CS signaling pathways by serving as a cofactor for CFI during C4b inactivation and prevents the classical C3 convertase (C4bC2a) formation, also promoting the C3 convertase decay by preventing C3 convertase binding to the nascent C4b (61, 62). C4BP also inhibits alternative CS signaling pathway in the fluid phase by serving as a cofactor for CFI without inhibiting alternative C3 convertase (63–65). C-reactive protein (CRP)–C4BP complex also inhibits classic CS activation (66).C4BP also promotes apoptotic cell death (ACD) (62). CRBP also serves as an acute-phase reactant, and it increases several-fold during inflammatory conditions (61). C4BP binding to pathogens helps them to escape from complement-dependent clearance. However, C4BP inhibits target cell entry of H1N1 influenza A virus (IAV) and provides protection against infection (67). C4BP also inhibits silica and/or monosodium urate (MSU)-induced NLRP3 inflammasome activation in macrophages (68).	Confirmed cases of C4BP deficiency have not yet been reported in humans. Only one human case has been reported of the primary C4BP deficiency in a patient with disease clinically resembling Behçet’s disease with angioedema (69), but it is not clear whether the complete disease was associated with C4BP deficiency or just the angioedema.
Properdin is a plasma glycoprotein and the only known positive regulator of the CS, especially alternative CS signaling pathway (70, 71).	Liver immune cells, but not by hepatocytes (72).	Synthesized mainly by monocytes–macrophages, DCs, T cells, and granulocytes, including mast cells (70). Adipocytes and stimulated endothelial cells are secondary properdin producers (72).	Properdin stabilizes alternative CS signaling pathway C3 convertase (C3bBb) by promoting C3b–factor B interaction and providing a focal point for the assembly of C3bBb on a target surface and immune complexes (28, 73). It also binds and stabilizes the preformed alternative CS signaling pathway C3 convertase (28).Properdin also inhibits Factor H-mediated cleavage of C3b by FI. Additionally, properdin also stabilizes C5 convertase without changing its substrate specificity (74).	Humans with genetic deficiency of properdin are more prone to develop lethal pyogenic infections, especially caused by Neisseria spp (75–78).. Interestingly, human properdin deficiency is the only X-linked complement deficiency (72, 79).
Clusterin, also called complement lysis inhibitor (CLI), SP-40, 40, and apolipoprotein J	Expressed in variety of tissues and organs (80).	Versatile cells (80)	Inhibits MAC formation by binding to C5b-7 complex in fluid phase (80). It also binds C7, C8β, and domain b of C9 to inhibit MAC formation (80, 81). Furthermore, together with vitronectin, clusterin binds to the nascent amphiphilic C5b-9 complex, rendering it water-soluble and inactive (80).	Systemic lupus erythematosus (SLE) patients with high circulating clusterin and vitronectin greatly demonstrate renal involvement (82). Increased clusterin and vitronectin levels have also been reported in lenses of patients with exfoliation glaucoma (83). Thus, clusterin may not be physiological complement regulator, as it has failed to protect against complement attack under normal or pathological conditions (84).
Vitronectin, also called S-protein and epibolin, was identified as a serum spreading factor and is highly present in plasma (85).	It is also expressed in different human tissues and organs, such as liver, tonsils, duodenum, heart, skeletal muscles, and lung tissues (85).	Hepatocytes	It binds C5b-7 complex to inhibit MAC formation (85). It also inhibits C9 polymerization (86).	No genetic deficiency of vitronectin has been reported in humans (87). Vitronectin levels impact severity of bacterial infections by different mechanisms, including affecting CS (88). In mice, systemic vitronectin deficiency delays dermal wound healing, increases areas of delayed hemorrhage, and attenuates hepatic fibrosis in non-alcoholic steatohepatitis mouse model (89, 90).
Surface-bound complement regulators	Organ-specific expression	Cell-specific expression	Functions	Deficiency or overexpression diseases
Complement receptor type 1 (CR1 or CD35 or CD3b/CD4b receptor)	Wide tissue/organ distribution.	Nucleated cells, immune cells, and red blood cells (RBCs) (91, 92).	It serves as a classical and alternative CS signaling pathway convertase decay accelerator and a cofactor for FI by binding to C3b, iC3b, C4b, and C1q. Hence, CD35 helps in clearance of immune complexes, enhances phagocytosis, and regulates C3 cleavage. CR1 serves as a high-avidity receptor for polyvalent binding to clustered ligands on immune complexes (92).	CD35 genetic deficiency is rare in humans and increases their chances of getting bacterial infections and autoimmunity, such as SLE (93).
CR2 or CD21	Organs with B cells and thymus and secondary lymphoid organs (SLOs) expressing follicular DC (FDCs), such as lymph nodes, human palatine tonsils, spleen, and mucosa-associated lymphoid tissue (MALT) (94).	CR2 expression is restricted to B cells and FDCs (93), but subsets of peripheral and thymic T cells also express CR2 (95).	It binds iC3b/C3dg/C3d (96), serves as a B-cell receptor (BCR) co-stimulator, and regulates B-cell function.It also serves as an Epstein–Barr virus (EBV) receptor and binds to different forms of DNAs derived from bacteria, viruses, and mammals with moderate affinity to elicit immune response (95, 97). In humans, B cells’ co-engagement of BCR and CR2 inhibits their proliferation and cytokine and antibody production (98).	SLE patients show reduced CR2 expression, and complete CR1 and CR2 deficiency in mice promotes anti-DNA antibody development in mouse models of SLE (95).
CR3 or CD11b/CD18 or macrophage antigen-1 (Mac1)	Not applicable	Expressed exclusively on myeloid immune cells (MICs, such as macrophages, neutrophils, and DCs), NK cells, T cells, and B cells (99–103).	CR3 binds C3d and iC3b fragments of the C3 and promotes phagocytosis of complement-opsonized antigens/cells/molecules by macrophages (92, 104, 105). However, CR3 also involves complement-independent Ab-dependent phagocytosis of fungi, such as Cryptococcus neoformans (106). Talin is required for CR3-mediated phagocytosis (107). CR3 expressed on NK cells is responsible for complement-mediated NK cell cytotoxicity toward Ab-coated cancer cells (99, 102).	Genetic CR3 deficiency in humans is associated with severe MIC, such as neutrophils and macrophages, and lymphocyte defects and recurrent bacterial infections (92, 108).
CR4 or CD11c/CD18 or αXβ2 integrin	Not applicable	Expressed on MICs, platelets, T cells, and NK cells (103).	CR4 binds iC3b and regulates iC3b-mediated phagocytosis. CR4 on human DCs is critical for inducing early antiviral immune response against complement-opsonized HIV-1 (109).
Complement receptor immunoglobulin-like (CR1g) or V-set and Ig domain–containing 4 (VSIG4)	Liver and peritoneal macrophages	Kupffer cells, monocytes and macrophages, and T cells	CR1g negatively regulates complement activation by the alternative CS pathway by blocking the interaction of C3b in its C3 convertase with C5 (92, 110). CRIg enhances phagocytosis of complement-opsonized particles by phagocytes or macrophages (110, 111). CRIg also serves as a direct pattern recognition receptor (PRR) to clear circulating Gram-positive bacteria (112). In T cells, CRIg also serves as an immune checkpoint inhibitor (ICI) like programmed cell death-1 (PD-1) or cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) and inhibits T-cell proliferation and IL-2 secretion (113).	The genetic deficiency of CR4 is associated with recurrent bacterial infections, and patients die during childhood unless they receive allogenic bone marrow transplantation (92). It is common in patients with primary immunodeficiency, with leukocyte adhesion deficiency type 1 (LAD1), lacking four integrins, including CR3 and CR4 (114).
CD46 or membrane cofactor protein (MCP)	Expressed ubiquitously	Expressed on every cell type except RBCs (115).	CD46 is a transmembrane complement regulatory protein, which binds C3b and C4b, and acts as a cofactor for serine protease factor I (FI)-mediated breakdown of C3b and C4b to prevent their immunological function (115). It is expressed by most cells in four isoforms generated due to alternative splicing, and its gene is located in the regulators of complement activation (RCA) gene cluster of the long arm of chromosome 1 (115, 116).	Currently, more than 60 disease-associated CD46 mutations are known; most are linked to aHUS and other diseases, such as SLE, glomerulonephritis, and pregnancy-associated disorders (115–118).
CD55 or decay accelerator factor (DAF), a glycosylphosphatidylinositol (GPI)-linked membrane protein	Present ubiquitously, including blood and stroma. It is also present in tears, saliva, urine, and synovial fluids (119, 120).	Epithelial cells, endothelial cells, and RBCs (120).	Recognizes complement component C3b and C4b and inhibits CS signaling pathways (classical, lectin, and alternative).CD55 also serves as receptor for Coxsackieviruses, other enteroviruses, and malaria parasite. CD55 binding to the HIV-1 and hepatitis-C virus (HCV) surface as result of their replication in the infected cells protects them from CS-mediated lysis (121, 122). CD55-CD97 (expressed on macrophages and granulocytes) interaction promotes T- and B-cell proliferation and secretion of IL-10 and GM-CSF (123). CD55 also inhibits NK cell cytotoxic function (124).	Genetic CD55 deficiency is associated with paroxysmal nocturnal hemoglobinuria (PNH) (125). Additionally, genetic CD55 deficiency is also associated with hyperactivation of complement and angiopathic thrombosis, and PLE (the CHAPLE syndrome) has been identified as a monogenic form of primary intestinal lymphangiectasia or Waldmann’s disease (WD) (126). The acquired CD59 deficiency is also associated with autoimmune hemolytic anemia (AHA), autoimmune thrombocytopenia (ATP), and systemic lupus lymphopenia (SLL) (127)
CD59 or membrane inhibitor of reactive lysis (MIRL) or protectin, single chain, GPI-linked membrane protein	Ubiquitous expression, also present in tears and saliva (119, 128).	Widely expressed in cells from all tissues (128). Also expressed on RBCs (128).	CD59 binds C8 and C9 and prevents MAC formation (129). Its binding to HIV-1 also prevents the complement-dependent virus lysis (130).	Genetic CD59 deficiency is associated with PNH (125). The acquired CD59 deficiency is also associated with AHA, ATP, and SLL (127).
C1qRp or CD93	Widely expressed.	Prominently expressed by endothelial cells and the MIC, such as monocytes, macrophages, and neutrophils. However, C1qRp expression on monocyte/macrophage is target organ-dependent (131, 132). Platelets and B cells also express C1qRp. C1qRp is critical for Ab secretion and plasma cell maintenance in the bone marrow (133). Naïve T lymphocytes of human neonatal cord blood also express C1qRp (134). CD93 maintains endothelial barrier function or vascular integrity and limits metastasis (135). C1q, MBL, and surfactant protein A (SPA) are C1qRp ligands (132).	C1qRp is not a critical receptor for complement component C1q (131). It is important for phagocytosis of apoptotic cells but not critical for C1q-dependent phagocytosis (136). However, C1qRP enhances phagocytosis of molecules coated with C1q, SPA, and MBL by macrophages (137).	CD93 single-nucleotide polymorphisms (SNPs) and mutations have been found to be associated with autoimmune diseases (AIDs), such as psoriasis and AMD (138).
C1qRO2− (139)	Not clear.	Polymorphonuclear leukocytes (PMNLs) or neutrophils and monocytes (132). The C1qRO2− expression on smooth muscle cells is questionable (132, 140).	Triggers reactive oxygen species (ROS), such as superoxide generation in response to C1q binding (132). Inhibits C1 activation (140).	Unknown.
cC1qR or cell-surface calreticulin (CALR) or collectin receptor (141)	Wide tissue distribution (141).	Expressed in many cell types intracellularly (endoplasmic reticulum and nucleus) and extracellularly. Human B cells, monocytes, neutrophils, tonsil lymphocytes, vascular endothelial cells, fibroblasts, mesenchymal stem cells (MSCs), and amniotic and pulmonary epithelial cells (141, 142). Not expressed in RBCs.	Binds to C1q-collagen region, and collectins and induces phagocytosis and IL-12 production in antigen-presenting cells (APCs). It also inactivates C3 and C5 convertases (140).	AutoAbs in patients with SLE and Sjögren syndrome (140).
Megalin, an α₂-macroglobulin receptor family or low-density lipoprotein (LDL) gene family, also called epithelial glycoprotein gp330 (141)	Expression is restrictive to absorptive epithelia, such as renal proximal tubules, lung (type II pneumocytes), yolk sac, thyroid, choroid plexus, mammary gland, retina, and inner ear (141).	Epithelial cells.	Binds to C1q and other proteins, such as clusterin, plasminogen activators (free or in complex with their type-1 inhibitor), lipoprotein lipase, apolipoprotein E, and the receptor-associated protein (RAP). It is concentrated in coated pits and performs endocytosis of many proteins (141). Thus, it can endocytose immune complexes by binding to C1q and also clear extra C1q produced during inflammatory conditions seen in organs/tissues expressing megalin to prevent excessive inflammation (141). N-Glycosylation of megalin can modify its ligand-binding activity (143).	Unknown.
gC1qr (139)	Widely expressed.	Expressed intracellularly in mitochondria in all mammalian cells except RBCs (140).	Binds to the globular heads of C1q under physiological conditions, inhibits C1 activation but does not interact with collectin (140, 141), serves as a phagocytosis receptor, and modulates mitochondrial function.	Unknown.
CD305 or leukocyte-associated Ig receptor-1 (LAIR-1) (16)	Lungs, central nervous system, or CNS.	Immune cells, such as macrophages and DCs, cytotoxic T cells, and type 1 innate lymphoid cells (ILC2s) (144).	Binds C1q and collagens and inhibits DC differentiation and activation and macrophage activation (16, 145–148). Binding of C1q to the LAIR-1 of ILC2s inhibits their pro-inflammatory activity in airway hyperactivity (AHR) seen during type 2 asthma (149, 150).	LAIR deficiency increases neutrophil infiltration in the lungs and lung resistance and permeability (145, 151).
Specific intercellular adhesion molecule (ICAM)-3-grabbing nonintegrin-related 1 (SIGN-R1 or CD209b, a 325-amino acid C-type lectin), which recognizes bacterial dextrans and capsular pneumococcal polysaccharide (CPS) of S. pneumoniae (152, 153).	Spleen, lymph nodes, peritoneal macrophages, immature DCs, and microglia (154–156).	Splenic marginal zone macrophages (MZMs) and lymph node macrophages (LNMs) (153, 157, 158).	Binds C1q and activates unusual C3 activation-dependent classical CS pathway (independent of Ag–Ab complex-mediated C1q activation) upon recognizing circulating endogenous and microbial (S. pneumoniae) polysaccharides (157, 159, 160).SIGN-R1 also cooperates with macrophage CR3 in the phagocytic uptake of oligomannose-coated liposomes (OMLs) (154). MZMs’ SIGN-R1 also mediates complement C1q-dependent clearance of circulating apoptotic cells in the spleen marginal zone (161, 162). Microglia SIGN-R1 also recognize S. pneumoniae capsular polysaccharide and activate C1q-dependent classical CS pathway to protect against pneumococcal meningitis (156). SIGN-R1⁺ MZMs are also critical for the maturation of germinal center B cells in the spleen (163).	SIGN-R1 deficiency in mice is associated with defective C3 catabolism and increased susceptibility to bacterial infections (157, 164).

2.1 CS in immunoregulation and immune homeostasis

The CS was first described as a critical antimicrobial defense component of innate immunity in circulation between 1888 and 1894 (165, 166). As discussed earlier, the activation of three components of the CS in response to different stimuli, such as Ag–Ab complexes, pathogens (PAMPs/MAMPs), and DAMPs, induces the release of different complement proteins, such as C3a, C3b, C5a, and C5b, and the formation of terminal MAC to clear the exo- or endogenous threat. C3a and C5a are critical immunomodulators that, in addition to serving as anaphylatoxins, also function as potent immunomodulatory agents through their cognate receptors (C3aR, C5aR1, and C5aR2 or C5L2), which are expressed on various innate and adaptive immune cells. Therefore, this section discusses the impact of C3a and C5a on immune cells expressing their cognate receptors.

2.1.1 Impact of C3a on various immune cells via direct interaction with C3aR

In addition to the CS signaling events, C3a can also be generated by different systemic proteases, such as thrombin and immune cell-derived cathepsin G and L (a lysosomal protease) (167–169). However, the cathepsin L (CTSL)-mediated cleavage of the C3 into C3a and C3b has been reported intracellularly in T cells, which maintains their survival through intracellular C3a–C3aR interaction-mediated downstream mammalian target of rapamycin complex 1 (mTORC1), Raptor, and p56 signaling, and extracellular C3a–C3aR promotes the generation of pro-inflammatory Th1 cells as indicated by the generation of pro-inflammatory cytokines, such as interferon-γ (IFN-γ) (170, 171). Resting T-cell lysosomes and endosomes contain C3, and its cleavage by the CTSL to generate “tonic” intracellular C3a is critical in maintaining homeostatic T-cell survival. The transfer of this intracellular C3a to the T-cell surface induces the autocrine pro-inflammatory cytokine production of the Th1 phenotype, which has been seen in T cells isolated from patients with autoimmune arthritis (170). The T cells of patients with autoimmune arthritis exhibit overactivated intracellular CS and IFN-γ production that can be blocked by targeting the intracellular CTSL. Furthermore, intracellular C3–C3aR signaling in intestinal Paneth cells [intestinal secretory epithelial cells with innate immune functions, such as the production and secretion of antimicrobial peptides (AMPs) and other immunomodulatory molecules] also regulates their mTORC1 signaling to enhance their intestinal protective function by supporting the expansion of intestinal stem cells (ISCs) in the intestinal crypts during acute inflammatory intestinal injury (172–174).

Interestingly, in contrast to the extracellular/secreted C3, the intracellular C3 generated via alternative translation in the cytosol is non-glycosylated and present in the reduced state. Intracellular non-glycosylated C3 is turned over by the ubiquitin–proteasome system (UPS) (175). Furthermore, C3 can also be retranslocated from the endoplasmic reticulum (ER) to the cytosol and structurally resembles extracellular/secreted C3. Notably, cytosolic C3 also exerts antimicrobial action in epithelial cells by opsonizing invasive pathogens, such as Staphylococcus aureus, decreasing the vacuolar escape, and impacting the bacterial survival by presenting the pathogen to phagocytes, such as macrophages (175). Furthermore, the cytosolic C3 in the β cells of the pancreas protects them from IL-1β-induced inflammatory cell death by interacting with and inhibiting the downstream Fyn-related kinase (FRK) (176, 177). Another study has indicated that the C3-mediated protective effect on pancreatic islet β cells involves AKT activation and c-Jun N-terminal kinase (JNK) inhibition upon treatment with pro-inflammatory cytokines, such as IL-1β and IFN-γ (178). Thus, in different cell types, such as T cells, Paneth cells, and pancreatic β cells, the cytosolic C3 supports their survival and division. Additionally, C3 present in the breast milk protects suckling mouse pups from Citrobacter rodentium-mediated enteric infection by shaping the evolving pup gut microbiota (killing of commensal Gram-positive Staphylococcus lentus B3) but without affecting the production of secretory antibodies in the breast milk (179, 180). A more detailed review of C3a–C3aR interactions on different immune cells would be too cumbersome for the main text and is summarized in Table 2 .

Table 2

C3aR expression (cell surface and cytosolic) on different immune cells and the impact of C3 fragments on their immune functions.

Immune cells	Extracellular C3aR	Immunological impact	Intracellular/cytosolic C3aR	Immunological impact
Monocytes and macrophages (181, 182)	Yes, human monocytes express C3aR but not murine monocytes (183). Human and murine macrophages express C3aR, but murine alveolar macrophages do not (184).	C3a–C3aR interaction in monocytes and macrophages may exert pro- and anti-inflammatory action (23, 185). During human macrophage differentiation, C3a induces defective M2 macrophage production as indicated by the lower expression of different M2-associated genes, such as CD206, CCL22, IL1Rα, and PPARγ, but increased expression of TNF-α and IL-6 (186). Furthermore, C3a does not alter human M1 macrophage polarization but decreases TLR4 expression and thus the LPS-induced inflammatory response (186). However, in murine peritoneal macrophages, C3a–C3aR interaction induces anti-inflammatory M2 macrophage polarization (187).	Murine brain and lamina propria macrophages express intracellular C3aR (188).	Unknown.
Neutrophils (181, 182)	Human neutrophils express C3aR, but the expression of C3aR on normal murine neutrophils is controversial, and its expression increases during inflammatory conditions (183, 189, 190).	Immunomodulatory action in different inflammatory and infectious diseases (23, 191–193). C3a–C3aR-induced NETosis increases coagulation and N2 polarization to promote tumorigenesis in humans, such as small intestine cancer (189).	Human neutrophils express intracellular C3aR.	Unknown.
DCs (194)	Yes, human and mouse DCs express C3aR depending on their origin and tissue location (183, 195). For example, murine splenic DCs lack cell surface C3aR (183, 188). Human immature pDCs express C3aR, but murine pDCs in different target organs lack C3aR, except pDCs isolated from lamina propria (LP) of the small intestine (183, 188).	C3a–C3aR interaction in DCs regulates T-cell response to alloantigens by regulating major histocompatibility complex (MHC) and co-stimulatory molecule expression and decreasing their cytosolic cAMP levels (196, 197). C3a–C3aR interaction on DCs also promotes DC recruitment at the site of inflammation with higher levels of interferons (IFNs) and prostaglandin E2 (PGE2) (198).	Unknown.	Unknown.
Eosinophils (181, 182)	Yes, in humans only.	C3a–C3aR axis induces eosinophil chemotaxis, degranulation, oxidative burst, and calcium (Ca²⁺) mobilization in humans (199–202).	Mouse blood, lung, and vascular adipose tissue-derived eosinophils express intracellular C3aR only (183, 188).	Unknown.
Basophils (182, 203)	Yes, in normal human basophils and tumor-derived basophils, but not in murine basophils (181, 182, 204).	C3a via C3aR does not induce basophil degranulation and IL-13, IL-4, histamine, and leukotriene C₄ (LTC₄) release (205).	Unknown.	Unknown.
Mast cells	Both murine and human mast cells express C3aR depending on their location, which further increases inflammatory stimuli (183). For example, naïve human bone marrow-derived mast cells (hBMMCs) do not express C3aR, which is also true for murine BMMCs and peritoneal mast cells (183, 206).	C3a via C3aR stimulation on mast cells induces their degranulation and histamine release (205, 207–209).	Unknown.	Unknown.
Platelets	Both mouse and human platelets express C3aR (210, 211).	C3a–C3aR axis on platelets regulates different steps of thrombus formation, such as platelet aggregation, spreading, Ca²⁺ influx, and bleeding time (210, 212). Therefore, C3a–C3aR axis activation on platelets increases the risk of thrombus formation, myocardial infarction, and stroke.	Unknown.	Unknown.
Natural killer (NK) cells	Human circulating NK cells express extracellular C3aR (213). Only activated mouse NK cells express C3aR (214).	C3a via C3aR also inhibits NK cell cytotoxicity (213). C3aR activation also blocks NK cell migration to the tumor microenvironment by altering localization and confirmation of lymphocyte function-associated antigen-1 (LFA-1) (214, 215).	Unknown.	Unknown.
T cells [CD4⁺ , CD8⁺ , and regulatory T cells (T_regs)]	C3aR expression of mouse T cells is controversial (188, 216), but human activated Th1 and CD8⁺ T cells express extracellular C3aR, but not expressed by naïve T cells (217, 218).	Exogenous C3a via cell surface C3aR is critical for T-cell proliferation and differentiation (216).The cell surface C3a–C3aR interaction diminishes their immunoregulatory function (219). The cytosolic C3a and C3b generated during T-cell receptor (TCR) activation translocate to the cell surface and bind to cell surface C3aR and CD46, driving IFN-γ secretion from human CD4⁺ T cells (170, 220).	Yes, human CD4⁺ T cells in the peripheral blood also express C3aR on their lysosomes under normal conditions, which further increases during inflammatory conditions (170).	Intracellular C3a–C3aR signaling on lysosomes is critical for sustaining homeostatic survival of human CD4⁺ T cells (170, 220).
Astrocytes, microglia, and neurons (cortical and hippocampal neurons and Purkinje cells). However, C3aR expression on neurons does not alter with inflammatory brain conditions, such as experimental autoimmune encephalitis or EAE, but its expression increases on microglia and astrocytes (221–223)	Yes.	Pro-inflammatory, immune cell infiltration, or chemotaxis.	Intracellular C3aR expression in microglia and astrocytes is an intriguing question (224).	Unknown.
Endothelial cells	No data available for murine endothelial cells expressing C3aR, but human microvascular endothelial cells (HMECs) and primary endothelial cells express C3aR (225–227).	Immunomodulatory action depending on the stimulus/disease and target organ, as these factors are critical due to their intensity of expression and function (226–229).	Unknown.	Unknown.
Epithelial cells	Extracellular C3aR has not been observed in lung parenchymal, epithelial, and smooth muscle cells (SMCs) (184).	Extracellular C3a–C3aR axis synergizes with TGF-β to activate NLRP3 inflammasome for epithelial–mesenchymal transition of renal tubular epithelial cells (RTECs) during carcinogenesis (230).	Yes, retinal pigment epithelial cell (RPEC) mitochondria express C3aR, which increases during cellular stress due to the endocytic trafficking of the extracellular membrane-bound C3aR via endosomal-to-mitochondrial cargo transfer (231).	Increased mitochondrial C3aR expression and its stimulation with cytosolic C3a in stressed epithelial cells decrease ATP production by inhibiting state III ADP-driven respiration and maximal respiratory capacity (231). This may alter their metabolism, regulating survival, proliferation, and innate immune functions.
Hematopoietic stem cells (HSCs)	Yes (232).	Enhances effect of stem cell-derived factor-1 (SDF-1) and improves bone marrow engraftment.	Unknown.	Unknown.
Peripheral and tonsillar B cells (182)	No.	Unknown.	Unknown.	Unknown.
Germinal center (GC) B cells	Yes (233, 234).	C3a–C3aR axis is critical for normal GC function by controlling affinity maturation, plasma cell and memory B cell formation through mTOR, and Myc-dependent metabolic regulation (233, 234).	Yes.	Intracellular C3a–C3aR axis activates mammalian target of rapamycin (mTOR)-dependent metabolic reprogramming in GC B cells (233, 234).

2.1.2 Impact of C5a on various immune cells via direct interaction with C5aRs (C5aR1 and C5aR2 or C5L2)

The C5a generated during CS pathways due to the breakdown of C5 into C5a and C5b exerts immunomodulatory actions by interacting with C5aR1 (CD88) and C5aR2/C5L2. For example, C5a–C5aR1 interaction mediates potent leukocyte chemoattraction at the site of inflammation. It induces pro-inflammatory phenotype and functions on different immune cells during sterile and infectious inflammatory conditions, such as autoimmune diseases [rheumatoid arthritis (RA) and Crohn’s disease (CD)], allergies (asthma), ischemia–reperfusion injuries, and sepsis (235–239). However, the discovery of the second C5a receptor called C5L2 [a seven-transmembrane domain G protein-coupled receptor (GPCR)] or C5aR2 in 2000 has generated controversies in the previously established pro-inflammatory functions of C5a, as C5L2 has now been considered an anti-inflammatory C5aR (240, 241). C5L2 is also considered an active metabolic receptor, and its ligand C5a and C5a_desArg or acylation-stimulating protein (ASP) [the degraded/desarginated C5a fragment generated via enzymatic (carboxypeptidase) degradation-dependent endocytosis], is time-, clathrin-, and cholesterol-dependent (241, 242).

Circulating ASP levels increase in people with obesity, insulin resistance or Type 2 Diabetes Mellitus (T2DM), and metabolic syndrome, which increases monocyte chemoattractant protein-1 (MCP-1) and keratinocyte-derived chemokine (KC or IL-8) from their adipocytes through C5L2 or C5aR2 interaction without impacting IL-6 and adiponectin production (243, 244). The MCP-1 and KC production from adipocytes in response to ASP/C5L2 interaction involves phosphatidylinositol-3 kinase (PI3K) and nuclear factor-kappa B (NF-κB) activation (244). However, ASP via C5L2 interaction in macrophages does not induce MCP-1 and KC production. In contrast, the adipocyte-mediated production of these cytokines in the adipose tissue (AT) increases monocyte/macrophage chemotaxis and their inflammatory function (243). For example, C5a_desArg-induced C5L2 activation in adipocytes induces triglyceride synthesis and glucose and fatty acid (FA) uptake, which is absent in the adipocytes of C5L2 knockout mice (243–245).

C5L2 ligand binding induces their internalization and degradation, which decreases their extracellular expression level, which is a step to decrease the generation of profound or tissue-damaging complement-mediated inflammatory immune response (241). In contrast, C5aR1 internalizes ligands at a slow rate, which are further expelled back into the extracellular environment without undergoing degradation, which further aggravates the inflammatory cascade (241). Furthermore, Thr196Asn mutations in the C5L2 gene were associated with hyperlipidemia and retinitis pigmentosa (RP) in a Chinese family (246).

In humans, the GPR77 gene on chromosome 19, q13.33-13.34, is located downstream of the C5aR1 gene encoding C5aR2 or C5L2 (247). Interestingly, C5L2, belonging to C3a, C5a, and formyl Met-Leu-Ph (fMLP) receptors related to the chemokine receptor family, also binds to C3a with a moderate affinity (247, 248). However, the C3a binding to C5L2 can be easily displaced by C4a, indicating that C3a has a lower affinity to C5L2 than C5a. Moreover, the binding of anaphylatoxins (C3a and C5a) to C5L2 only increases the immune cell degranulation potential upon cross-linking high-affinity immunoglobulin E (IgE) receptor by a pertussis toxin-sensitive mechanism. C5L2 binding affinity to C5a is similar to that of C5aR1. C5L2 binds to C5a_desArg with a higher affinity than C5aR1 (242, 247). The C5L2 transcripts have been widely expressed in different organs, such as the spleen, testis, brain (frontal cortex, hippocampus, and hypothalamus), heart, lung, liver, kidney, adrenal gland, thyroid gland, spinal cord, ovary, and colon, and in immune and non-immune cells, like granulocytes, immature DCs, adipocytes, and skin fibroblasts, but not in monocyte-derived macrophages (MDMs) (248–253). Table 3 shows the impact of C5a and C5aR1/C5L2 or C5aR2 interaction on different immune cells.

Table 3

C5aR1 and C5L2 expression (cell surface and cytosolic) on different immune cells and the impact of C5a on their immune functions.

Immune cells	Extracellular/intracellular C5aR1	Immunological impact	Extra-/intracellular C5aR2 or C5L2	Immunological impact
Monocytes and macrophages (both murine and human) (182)	Yes, both mouse and human macrophages express C5aR1, but the intensity of the receptor expression is organ-specific (183).	Pro-inflammatory function.	Both mouse and human macrophages express C5L2 (183).	Immunomodulatory action.
Neutrophils (182, 254)	Yes, both murine and human neutrophils express extracellular C5aR1 (183, 255).	C5a–C5aR1 interaction regulates their phagocytic and pro-inflammatory functions (183, 255).	Yes, both mouse and human neutrophils express C5L2 (248, 256).	C5L2 stimulation in neutrophils controls their immunological function by regulating the expression of Fcγ receptors and CD11b, thus regulating their phagocytic and inflammatory function (256).
DCs	Yes, murine DCs, except intestinal and pulmonary CD103⁺ DCs and plasmacytoid DCs (pDCs) (194, 255). Only activated human DCs express C5aR1, and its expression on pDCs depends on their activation status. However, human moDCs express both C5aR1 and C5aR2 (257).	DC maturation increases co-stimulatory molecule expression and IL-12 and TNF-α production and supports the generation of pro-inflammatory Th1 immune response in mice (257). However, C5a treatment of prior activated (TLR-mediated) DCs suppresses their pro-inflammatory function in both mice and humans (257, 258)	Modest expression in murine lung monocyte-derived DCs (moDCs) (60–65%) and lung CD11b⁺CD103⁻ DCs (15–20%); low C5aR2 expression is observed in intestinal CD11b⁺ and CD103⁺ DC subsets (257). C5L2 is highly expressed in immature DCs (248).	Activation of immature DCs and leukocyte recruitment (248).
Eosinophils (182)	Both mouse and human eosinophils express C5aR1 (259–261).	C5a–C5aR1 interaction promotes transendothelial migration of eosinophils.	Both human and mouse eosinophils express C5L2 (183, 262).	Critical role in experimental allergic asthma (EAA) (263).
Basophils (182)	Human basophils express C5aR1 (264, 265).	C5a–C5aR1 interaction on basophils induces their degranulation and histamine, leukotriene C₄ (LTC₄), IL-4, and IL-13 release (264, 266).	Unknown.	Unknown.
Mast cells	Murine BMMCs and peritoneal mast cells do not significantly express C5aR1 but increase with allergen/antigen/inflammogen stimuli (206). Human mast cells express C5aR1 (267).	C5a–C5aR1 interaction promotes their inflammatory function, including mast cell degranulation and histamine release, and chemotaxis to inflammatory site (267–269).	Human mast cells express C5L2 (270).	C5L2 activation in human mast cells induces the release of pro-inflammatory cytokines and chemokines (271, 272).
Platelets	Both human and mouse platelets express C5aR1 (211, 273).	C5a–C5aR1 interaction on platelets activates their pro-inflammatory functions, such as their degranulation and aggregation, but also negatively regulates neovascularization by releasing CXCL4 or platelet factor 4 (PF4), an antiangiogenic factor, which also induces NETosis (273–277).	Unknown.	Unknown.
NK cells	Human NK cells express C5aR1 extra- and intracellularly; however, intracellular C5aR1 further increases in preterm infants (213, 278). In mice, naïve NK and NKT cells do not express active extracellular C5aR1, which is seen only during inflammatory conditions, like sepsis (279, 280).	Pro-inflammatory action.	Murine splenic and circulating NK cells express C5aR2 (254). Human circulating NK cells express C5aR1 and C5aR2 intracellularly (213).	NK cell C5aR2 activation suppresses IL-12/IL-18-induced interferon (IFN-γ) production (254).
γδT cells	Mouse γδT cells express C5aR1 on their surface (281, 282).	C5aR1 activation on γδT cells increases IL-17 expression and, thus, their pro-inflammatory function (281, 282).	Murine γδT cells do not express C5L2.	Not applicable.
CD4⁺ T cells	Murine CD4⁺ T cells express C5aR1 (216, 283). Murine naïve or activated CD4⁺ T cells do not express C5aR1 (255).Human CD4⁺ T cells express intracellular C5aR1.	The locally produced C5a via cell surface C5aR1 increases the effector T-cell (T_eff) proliferation and prevents their apoptosis by increasing Bcl-2 and decreasing Fas expression during antigen challenge (216, 283).	Central memory T cells express C5L2 (262).	Unknown.
CD8⁺ T cells	Human CD8⁺ T cells express C5aR1 (284).	C5a–C5aR1 axis is critical for optimal CD8⁺ T-cell response during viral infections, such as influenza A virus infection (IAV), but suppresses antitumor CD8⁺ T cells (285, 286).	Not clear.
Thymus-derived (natural) CD4⁺ FoxP3⁺ regulatory T cells (T_regs)	Murine T_regs express C5aR1 (219).	T_reg C5aR1 activation via C5a diminishes their immune regulatory function (219).	Not clear.
B cells	Murine and human germinal center (GC) B cells express C5aR1 (234).	C5a–C5aR1 axis is required for optimum GC formation, effective GC B-cell activation, antibody affinity maturation, and somatic maturation (234).	Murine and human GC B cells express C5aR2/C5L2 (234).	C5L2 serves as “decoy” C5a receptor (234).
Astrocytes, microglia, and neurons (221, 287, 288). In contrast to C3aR, the C5aR expression on neurons increases during CNS inflammation (222)	Yes.	Activation of astrocyte and microglia C5aR1 by C5a binding is pro-inflammatory and induces their proliferation and astrogliosis and microgliosis (289–291)	Astrocytes and microglia.	C5a–C5aR2/C5L2 interaction in astrocytes plays a role in astrocyte-mediated neuroinflammation (289). However, C5L2 exerts neuroprotection in traumatic brain injury (TBI) and chronic neurodegenerative diseases, such as Alzheimer’s disease (AD) (292, 293).
Endothelial cells	HMECs and primary endothelial cells express C5aR (225–227). Mouse dermal microvascular endothelial cells (MDMECs) and capillary endothelium of their lungs also express C5aR (294)	Immunomodulatory action depending on the stimulus/disease and target organ, as these factors are critical for their intensity of expression and function (225, 226).	C5L2 expression in endothelial cells of atherosclerotic plaques (295).	C5a–C5L2 axis exerts pro-inflammatory action (increased levels of IL-1β and TNF-α) in atherosclerotic plaques (295).
Epithelial cells (296)	Human colonic epithelial cells express intracellular C5aR1 (297).Malignant epithelial cells, such as colorectal cancer epithelial cells, overexpress C5aR1 (298).	The intracellular C5a generated through cathepsin-D (CTSD) binds and activates intracellular C5aR1, which, via downstream C5a/C5aR1/KCTD5/cullin3/Roc-1 complex, aggravates β-catenin stability to promote colorectal tumorigenesis (297). Human retinal epithelial cells also express C5aR1 in their mitochondria, which, upon C5a binding, increase mitochondria-endoplasmic reticulum (ER) contact frequency and mitochondrial fusion, sensitizing cells to oxidative stress, promoting mitochondrial fragmentation and cell death (299).	Epithelial HeLa cells constitutively express C5L2, and its expression decreases upon treatment with IFN-γ and TNF-α (300). Keratinocytes also express C5L2 (300).	Not clear.
Hematopoietic stem cells (HSCs)	No (232).		No.

3 CS in human pregnancy 3.1 CS in human fertilization

The CS is critical for women’s reproductive health and successful pregnancy (fertilization to childbirth). For example, the human female reproductive tract (FRT), comprising the ovaries, fallopian tubes, uterine endometrium, myometrium, and cervix, expresses complement regulatory proteins (CRPs), such as CD55 and CD59 (protectin), and CD46 [membrane cofactor protein (MCP)] ( Figure 3 ) (301). The CRPs (CD55, CD59, and CD46) are overexpressed in stressed endometrial cells, indicating that their endometrial cells develop a complement-mediated lysis process, modifying their inflammatory outcome in different immune-mediated inflammatory diseases (IMIDs) (302). However, all CS components/proteins of classical and alternative pathways are present in the uterine, tubal, and follicular fluids (303).

Figure 3

The CS signaling pathway in establishing human pregnancy. The complement components are present in human male and female reproductive tracts, and their gametes (eggs and sperms) also express different CS components. For example, CD55, C59, and C46 are present in the human uterus, ovaries, fallopian tubes, and cervix. Furthermore, the uterine, tubal, and follicular fluids have all the components of classical and alternative CS signaling pathways. Human unfertilized eggs also express CD55, CD59, factor H, C5, CR1, and CR3. Human sperms also express CD55, CD59, CD46, C3b, and C1-INH. The C3b interaction with CR1 and CR3 between sperm and ovum is critical for fertilization. Different complement components are expressed on developing embryo depending on the developmental stage. For example, CD46 appears at six-to-eight embryonic stage, which also expresses C1q. C5aR1, CD18, CR2, and C3d are also expressed by the developing embryo to check the complement activity for healthy pregnancy. Kindly see the text for details. CS, complement system.

Diagram illustrating the human reproductive process, highlighting the female and male systems. It shows ovulation, fertilization, and the stages from a human unfertilized egg to an eight-cell embryo, with labels for proteins like CD55, CD59, and others. The bottom section provides a key for the symbols used, such as CD55, CD46, CD59, C5, and more.

Moreover, human unfertilized eggs (plasma membrane and zona pellucida) and pre-implantation embryos express CD55/DAF and CD59, preventing them from complement attack ( Figure 3 ) (304–306). Unfertilized oocytes do not express CD46, but it appears at the six-to-eight cell embryonic stage on their cell membrane as the first embryonic human gene expression begins ( Figure 3 ) (304, 305). Interestingly, oocytes and pre-implantation embryos do not express complement receptor 1 (CR1 or CD35)/C3b/C4b receptor and major histocompatibility complex 1 (MHC-1) proteins (303, 304). Of note, mRNA transcripts of soluble complement inhibitors, including C4b-binding protein (C4BP beta chain), factor I, and clusterin, are present in oocytes through their eight-cell stage embryo blastomeres (306).

The mRNA transcripts of central complement activating components, such as C3 and C5, along with their activators (factor B and D, C3 activators in the alternative pathway) and other complement cascade proteins (C1s and C2) of the classical and MBL CS pathways are also present in oocytes and embryos, indicating that their transcripts remain after fertilization (306). Human embryos also express C5aR1, CR2, and CD18 ( Figure 3 ). CD18/CD11b serves as CR3, and CD18/CD11c comprises CR4. C1q is present at all embryonic developmental stages ( Figure 3 ) (306). The C3b/iC3b complex on the cell surface of different early embryonic developmental stages indicates targeting of the embryo by the activated complement. The inactivated C3, known as C3d, is present on the cell surface of the developing embryo, indicating that a complement activation check is crucial for embryo development ( Figure 3 ) (306). However, C5 is expressed on the zona pellucida surface of the oocyte but not on the surface of blastomeres ( Figure 3 ). Interestingly, oocytes and blastomeres do not have intracellular C3 and C5 but express C4bp and factor H on their cell surface (306). Factor H is also present in the zona pellucida of oocytes ( Figure 3 ).

In addition to the expression of complement proteins in the human female ovum, the sperm also expresses different complement components. For example, human sperms express C1 inhibitor (C1-INH), C1qR (cC1qR and gC1qR/p33), CD46, CD55, and CD59, which may be critical for their survival and motility ( Figure 3 ) (307–309). CD46, CD55, and CD59 are expressed on the inner acrosomal membrane of a human sperm, which are critical for the fertilization process but do not protect sperm from anti-sperm antibodies and complement-mediated immune attack (310). Furthermore, C1q promotes the agglutination of capacitated sperms, and C1qR (cC1qR and gC1qR) expression increases in this process (311, 312). The cleaved complement component C3b on sperm acrosome (formed during acrosome reaction) binds with CR1 and CR3 of the oocyte to facilitate the fertilization process ( Figure 3 ) (313). Factor H, but not CD46, serves as a cofactor in C3b cleavage, which contributes to the fertilization process (314). Human sperm CD46 also contributes to the survival of acrosome-reacted spermatozoa in the FRT by modulating CS activation (308). The complement activation critical for the fertilization process is initiated by the C-reactive protein (CRP) and is dependent on other complement components, such as C1q, C2, and factor B (314). Hence, complement components (expressed in ovum and sperm) are critical for mammalian/human fertilization to create a new life.

3.2 CS in embryo implantation and spiral artery formation

The trophoblast is a local producer of complement components in the maternal decidua, serving as a primary source of complement components C3 and C4 at the maternal–fetal interface (315). Local IFN-γ at the maternal–fetal interface positively impacts trophoblast C3 and C4 production. Uterine or decidual NK (dNK) cells comprise the majority of immune cells at the time of blastocyst implantation, are the primary source of local IFN-γ during the early stages of human pregnancy, and are critical mediators of spiral artery formation (1, 316–319). Human circulating NK cells express C3aR, which migrate to the uterine microenvironment during pregnancy to serve as dNK or uNK cells, comprising 70% of the decidual lymphocyte population. The C3a–C3aR interaction on NK cells inhibits their cytotoxic action (320, 321). Additionally, C3b deposition on target cells also inhibits NK cell cytotoxicity (322). It is well known that human dNK cells exhibit lower cytotoxic activity and secrete high levels of immunoregulatory cytokines and molecules to support a healthy pregnancy (323–325). Therefore, it would be interesting to explore how homeostatic complement activation during embryo implantation influences dNK cell functions (decreasing cytotoxic function but increasing their secretory function to release immunoregulatory cytokines) to support their pregnancy functions.

Human decidual stroma widely expresses and secretes complement component C1q, which interacts with proteins expressed on decidual extracellular matrix (DEM) and promotes trophoblast adhesion and migration by activating ERK1/2 mitogen-activated protein kinases (MAPKs) to promote trophoblast invasion of decidua and placental development (326, 327). Furthermore, epithelial–mesenchymal transition (EMT) is critical for trophoblast differentiation and maternal–fetal interface establishment, as indicated by the differentiation of trophoblast [extravillous trophoblast (EVT)] cells from proximal epithelial phenotype to a distal invasive mesenchymal phenotype called interstitial trophoblast penetrating the maternal decidua basalis and into the maternal myometrium (328). Complement components, such as the C3a–C3aR axis, promote EMT during fibrosis and cancer metastasis (230, 329–331). Trophoblast cells also exhibit characteristics of cancer cells and pseudotumorigenesis to nourish the developing embryo (332–334). Thus, CS components are critical for embryo implantation and placental development to maintain a healthy human pregnancy.

4 Impact of pregnancy on maternal circulating CS components

The circulating levels of C3a, C4a, and C5a increase in normal pregnant women and remain elevated throughout pregnancy, from 20 weeks post-gestation to the newborn’s delivery (335–337). However, some studies have indicated a decrease in circulating C5a with no alteration in C3a and C4a levels in women with healthy pregnancies than non-pregnant women (338). Moreover, an early (first trimester of pregnancy) increase in circulating C3a levels is associated with adverse pregnancy outcomes (336, 339). Nevertheless, a study from China has indicated that the circulating C1q, C5a, and C5b-9 (MAC) levels in the first and second trimesters are similar to those of non-pregnant healthy women (340). In contrast, increased levels of C3, properdin, C1q, factors H and B, C4, and adipsin and decreased levels of circulating C2 and C5a have been associated with successful implantation as indicated by a study comprising Middle Eastern (Qatar) women with obesity undergoing in vitro fertilization (IVF)-assisted conception (341). The maternal circulating C1-INH level decreases during this period (336). Thus, in a healthy pregnancy, maternal circulating complement components, such as C3a, adipsin (FD), and C5a, increase above baseline during the second and third trimesters and remain stable afterward (340, 342). However, women with preeclampsia develop higher circulating adipsin levels later in their pregnancy (343). In addition, catalyzing the rate-limiting step of alternative CS signaling pathway activation, adipsin (FD) is also involved in MAC formation and C3a and C5a anaphylatoxin generation (27, 344, 345). Thus, increased circulating adipsin levels during pregnancy and preeclampsia indicate associated metabolic and cardiovascular changes, as circulating adipsin levels are directly associated with the metabolic and cardiovascular health of an individual (346–348).

The MBL–MASP2 activity also increases during normal pregnancy (349). Any alteration in circulating complement components beyond their regulatory/protective function at the early stages of pregnancy (first trimester) causes an abnormal pregnancy outcome (337, 350–352). Preeclampsia is one of the conditions that affect the fetus and mother, which is discussed in the following section, specifically in the context of the complement system to maintain the article’s specificity. Moreover, preeclampsia predisposes surviving women to develop hypertension, cardiovascular diseases (CVDs), and metabolic syndrome later in life (353, 354).

5 CS in preeclampsia

Clinically, preeclampsia is characterized by the new onset of hypertension and proteinuria in pregnant women or any other maternal signs of maternal vascular dysfunction, such as edema or dysfunction of any other organ (liver, kidney, pulmonary, cerebral, or visual) or restricted fetal growth after 20 weeks of gestation (355, 356). A comparative preeclampsia study based on American College of Obstetricians and Gynecologists (ACOG) and International Society for the Study of Hypertension in Pregnancy (ISSHP) definitions of preeclampsia at term gestational age (≥37 0/7 weeks) to identify adverse maternal and perinatal outcomes has indicated the inclusion of broad definition for preeclampsia, as it can better identify women and babies at risk of adverse outcomes (357). For example, the more inclusive ISSHP definition of maternal end-organ dysfunction seemed to be more sensitive in identifying adverse maternal and perinatal outcomes associated with preeclampsia than following the less inclusive ACOG definition (357). Moreover, the inclusion of uteroplacental dysfunction (particularly when angiogenic factors are included) to diagnose preeclampsia on its broad definition optimizes preeclampsia identification in pregnant women and babies at risk (357). In contrast, eclampsia represents severe convulsions/seizures in women with gestational hypertension or preeclampsia (355, 358). The etiology of preeclampsia, including placentation’s impact, has been described elsewhere and will not be discussed in the current article (359, 360).

It is interesting to note that preeclampsia was described in the early 20th century, while eclampsia was recognized much earlier, with descriptions dating back thousands of years (355, 361). Immunology, including the study of the innate immune system, is also a new branch of modern medicine. For example, the field of the innate immune system was revolutionized after the discovery of macrophages/phagocytosis by Elia Metchnikoff in 1882 (362). Furthermore, the functional studies associated with the CS were first described between 1888 and 1894, although evolutionarily, the CS is the most ancient component of the innate immune system, as a complement component called C3-like protein has existed a billion years ago (BYA) (12, 13, 166). Although immunological advances in preeclampsia immunopathogenesis have been made, information about the CS in preeclampsia is scarce (363–369). Furthermore, inflammation (local and systemic) also plays a critical role in preeclampsia immunopathogenesis, and the CS is a key mediator of the inflammatory process (370–373). Therefore, understanding the role of this (CS) evolutionarily ancient innate immune component in preeclampsia pathogenesis is critical to understanding its immunology.

5.1 Maternal circulating CS components during preeclampsia

Recent studies have indicated the alteration of CS (classical, lectin, and alternative complement activation pathways) proteins in maternal and fetal circulation and placental tissues (342, 374–376). Nevertheless, data are not equivocal for some maternal circulating complement proteins, which may be due to race, ethnicity, comorbidity, and geographical locations, as race and ethnicity also play a crucial role in the origin, pathophysiology, and outcomes of preeclampsia (377). For example, women with preeclampsia have significantly lower circulating properdin and C4 levels but higher factor B (Ba and Bb) than women with normal pregnancy, which starts to increase during early pregnancy (first trimester) (350, 374, 375, 378, 379). The decreased circulating C1q and factor H levels in patients with early- and late-onset severe preeclampsia have also been observed (379). However, another study has indicated a significant increase in circulating C1q and C4d levels in late-onset severe preeclampsia (LOSPE). C3a, C5a, and MAC levels also increase in maternal circulation with early-onset severe preeclampsia (EOSPE) and LOSPE (380–382). The placentae of pregnant women with preeclampsia express lower C3aR and C5aR levels than those of women with normal pregnancy (381, 383). Nevertheless, a positive correlation between higher serum C3a and C5a levels in women with preeclampsia with circulating angiotensin II type 1 (AT1) receptor agonistic autoantibody (AT1-AA) has been observed (381). AT1-AA is one of several mediators of hypertension during pregnancy, along with increasing soluble fms-like tyrosine kinase-1 (sFlt1) and soluble endoglin (CD105) (sEng), and endothelin-1, which are elevated in women with preeclampsia (384–386). Increased sEng and sFlt1 in EOSPE directly correlate with MAC levels and, inversely, with circulating C3a levels (382). Thus, increased AT1-AA in circulation during pregnancy may activate the CS signaling pathway to generate potent anaphylatoxins, such as C3a and C5a, to induce EOSPE. Increased circulating sFlt1 during pregnancy induces hypertension, proteinuria, and glomerular endotheliosis, which are associated with preeclampsia (387). In addition to the circulating complement component alteration during preeclampsia, the cell surface component, such as CD93 (C1qRp or C1qR1 expressed on endothelial cells), level decreases in the circulation, whereas its level increases in the serum during the first trimester of normal pregnancy (388). Therefore, further studies are needed in this direction.

A study of women with singleton pregnancies in Colombia has indicated the association between decreased maternal circulating factor H in the first trimester and spontaneous preterm birth (389). Recently, a genome-wide association study (GWAS) in Finland has identified five rare heterozygous factor H variants (L3V, R127H, R166Q, C1077S, and N1176K) only in women with severe preeclampsia (390, 391). Of these five factor H variants in women with severe preeclampsia, variants R127H and C1077S are associated with normal factor H synthesis without its release in the circulation. In contrast, variants R166Q and N1176K are associated with normal factor H secretion with reduced binding to C3b, causing dysregulated CS activation associated with severe preeclampsia (390). However, the authors could not find any defect in patients with severe preeclampsia exhibiting the L3V factor H variant. Thus, CS-associated genetic mutations can also determine women’s susceptibility or resistance to developing preeclampsia during pregnancy. The decreased maternal circulating factor H levels have also been associated with preeclampsia in women from European countries, such as the Netherlands, Finland, Norway, Italy, and the United Kingdom, without any increase in circulating anti-factor H autoantibodies (392, 393). Furthermore, the placentae [decidual stromal cells (DSCs), decidual endothelial cells (DECs), and EVTs] of women with preeclampsia express lower factor H levels (mRNA and protein) than those of women with normal pregnancy (393). In addition to factor H, other C3b regulators, such as MCP and Complement Factor I (CFI) genetic mutants [typically associated with atypical hemolytic uremic syndrome (aHUS)], in pregnant women with systemic lupus erythematosus (SLE) or antiphospholipid antibodies (APL Ab) have been identified, indicating their higher susceptibility to develop preeclampsia than normal women (394). Moreover, normal pregnant women (without SLE and APL Ab) with hypomorphic MCP and CFI genetic variants are more susceptible to developing preeclampsia than those without these variants.

Nevertheless, despite inconsistencies in different circulating CS components, a systematic meta-analysis of selected 41 studies out of a total of 456 studies has retrieved results consistently reporting reduction of C4, C3, and factor H and increase of C4d, Bb, factor D, C3a, C5a, and MAC or C5b-9 in maternal circulation during preeclampsia than in women with normal pregnancies (395). In addition to altered circulating CS components/proteins, the CR variants, such as CR3 (CD11b/18, Mac-1, or integrin αMβ2) variant M441K, display a trend toward an increased adhesion to iC3b, which is most significantly associated with preeclampsia in the Finnish Genetics of Pre-eclampsia Consortium (FINNPEC) cohort (396). The CR4 variant A251T increases C4 adhesion to iC3b, and the W48R CR4 variant decreases CR4 binding to iC3b, which may have functional consequences on the CS signaling pathway to impact preeclampsia susceptibility/resistance and severity in the population (396, 397). Even 14 variants within nine genes coding for components of the MAC or C5b-9 have a strong association with preeclampsia (398). For example, two missense variants (rs200674959 and rs147430470) of C5 are strongly associated with preeclampsia predisposition among pregnant women. Moreover, the C6 variant rs41271067 predisposes women to preeclampsia, whereas its rs114609505 variant protects against preeclampsia (398).

In addition to the classical and alternative CS components, the circulating MBL pathway components are critical for pregnancy and preeclampsia (399); for example, H-ficolin and MASP-3 of the MBL pathway of the CS decrease in women with preeclampsia (399). Ficolin-2 and ficolin-3 are also lower in pregnant women with preeclampsia than in those with normal pregnancy (400). The decreased plasma ficolin-2 level of women with preeclampsia positively correlates with circulating placental growth factor (PIGF) and inversely correlates with circulating sFlt1. However, pregnant women with preeclampsia have higher plasma MBL concentration than women with normal pregnancy (376). Women with MBL codon 54 gene polymorphism are protected from preeclampsia development (401). The protective effect of the MBL codon 54 gene against preeclampsia may be due to low MBL production, as low-MBL production genotypes are considered disease (preeclampsia) modifiers (402). Therefore, further studies are needed to establish preeclampsia’s genetic and immunological mechanisms with MBL pathway dysregulation.

Additionally, second-trimester amniotic fluids of pregnant (singleton) women have shown upregulated C3a and factor Bb before the onset of preeclampsia, indicating that CS activation during early pregnancy is associated with early-onset preeclampsia (403). Elevated C5a levels in the amniotic fluid of pregnant women developing preeclampsia have also been observed (404). Women with preeclampsia exhibit urinary excretion of the MAC because of an antiangiogenic state (high circulating sFlt1 and low PIGF and VEGF levels) associated with severe preeclampsia (405–407). Hence, altered maternal complement components during pregnancy are critical for the onset and severity of preeclampsia.

5.2 Placental CS components and preeclampsia

The complement proteins expressed on placental tissues are also critical for a healthy pregnancy, and their alteration plays a critical role in inducing preeclampsia (408). For example, a term placenta obtained after a healthy delivery expresses complement inhibitor C4b-binding protein (C4bBP) on its outer layer (syncytial knots of syncytiotrophoblast) that facilitates material exchange between the mother and the developing fetus (409). C4d is rarely present in the placentae of normal pregnant women, but its expression increases in syncytiotrophoblasts of women with preeclampsia (408, 410). In contrast, factor H is abundant in the placental tissue stroma of normal pregnancy, which is decreased in the placentae obtained from women with preeclampsia (409). EVTs express CD46, CD55, and CD59 in all three trimesters of normal pregnancy (411, 412). The placentae obtained from women with preeclampsia overexpress CD55 and CD59 (408). The C1q, MBL, and properdin expression in the placenta do not change between a healthy pregnancy and preeclampsia (408). However, despite no difference between control and preeclampsia in control and EOSPE patients, C1q expression decreases in LOSPE patients, which needs further investigation (408, 409). Moreover, the placental macrophages of women with preeclampsia overexpress C5a, and their trophoblasts overexpress C5aR (413). The C5a–C5aR interaction on trophoblast cells polarizes them toward an anti-angiogenic phenotype by balancing their angiogenic factors, such as sFlt1 or soluble vascular endothelial growth factor receptor-1 (sVEGFR-1) and PIGF (410, 413). Another study has indicated an increase in placental sFlt1 and PIGF in women with preeclampsia, which increases maternal circulating sFlt1 and falls post-delivery (387). The upregulated C4d, sFlt1, and MAC in the placentae of women with preeclampsia correlate well, indicating the aberrant CS activation. C5a–C5aR axis inhibition has prevented aberrant placental development by decreasing sFlt1 levels and rescued pregnancies (413, 414). Furthermore, C3a also induces the upregulation of cellular sFlt1 in human syncytiotrophoblast cells, and upregulated MAC induces its release (415). Increased sFlt1 and decreased PIGF-mediated angiogenic imbalance suppress the expression and secretion of factor H from placental endothelial cells, further activating the CS to cause endothelial cell damage and systemic vascular dysfunction, hypertension, and proteinuria during preeclampsia (416). Fetal cord blood factor B levels do not vary during healthy pregnancy and preeclampsia, and other complement components (C1q, C3, C4, and C3d) are much lower than those in healthy maternal circulation (375, 417). Nevertheless, C3d levels increase in fetal cord blood with the degree of placental inflammation, indicating their increase during preeclampsia (418).

It is interesting to mention that the placentae of women with SLE and APL syndrome show higher classical CS pathway activation, including higher C4d (a most important classical CS pathway activation marker) expression at the feto-maternal interface, leading to fetal loss and preeclampsia development, than normal healthy pregnant women (408, 419, 420). However, a very recent case–control study from Finland comprising pregnancies from 2000 to 2018 has indicated no statistical difference between pregnant women with SLE and normal pregnant women in the occurrence of preeclampsia or any other congenital malformation despite a significantly shorter duration of pregnancies and a more urgent need for cesarean section among pregnant women with SLE (421). A retrospective study comprising all SLE pregnancies during a period of 10 years (2006–2015) from a single center in Malaysia has indicated the development of complicated pregnancies, including preeclampsia, fetal losses, and the need for cesarean deliveries (422). Another retrospective study by a different group in Malaysia comprising pregnant SLE women for the period January 2008 to 2020 indicated the development of complicated pregnancies, such as SLE flares, preeclampsia, and eclampsia (423). Another retrospective study from Beijing, China, comprising 105 SLE-associated pregnancies for the period from January 1990 to December 2008, has also indicated complicated pregnancies, fetal loss, and preeclampsia development in active SLE pregnant women (424). A retrospective cohort study of 149 pregnancies in 98 women with SLE conducted over 10 years in Oman has also indicated the development of preeclampsia and eclampsia in these women along with an increase in SLE-associated pathologies, such as lupus nephritis and flares (425). The data from four retrospective studies performed in Sub-Saharan African pregnant women with SLE (137 pregnancies in 102 women) over a 26-year period have indicated a higher incidence of preeclampsia and aggravation of SLE symptoms, such as lupus nephritis and SLE flares, which further increased adverse pregnancy outcomes, including preeclampsia (426). This difference [geographical and ethnic origin (Europe, Asia, and Africa)] indicates the genetic and environmental impact on SLE and other autoimmune conditions affecting pregnancy outcomes, including preeclampsia, which must be explored. SLE and APL syndrome-mediated immune alteration, including CS pathway association with pregnancy loss and preeclampsia discussion, is beyond the scope of the current article and has been discussed elsewhere (427–429).

5.3 Mechanisms of CS pathway activation during preeclampsia

We have discussed earlier that altered CS signaling pathways are critical players in the onset and severity of preeclampsia. However, we do not know the triggers activating the CS pathway to induce inflammatory consequences that support and aggravate preeclampsia pathogenesis and outcome. For example, maternal hypertension and proteinuria (endothelial dysfunction) after 20 weeks of gestation are significant characteristics of preeclampsia, along with increased platelet aggregation and the hyperactivation of the coagulation system (430, 431). The pathogenesis of preeclampsia varies in nulliparous women compared with women with pre-existing vascular diseases, metabolic syndrome, multifetal gestation, and/or previous preeclampsia. However, some pregnant women with HELLP (hemolysis, elevated liver enzymes, or low platelet counts) syndrome (10%–15%) or eclampsia (38%) may not exhibit hypertension or proteinuria, which are associated with higher rates of maternal and fetal morbidities than in mild preeclampsia (432, 433). Interestingly, HELLP syndrome exhibits elevated maternal CS pathway activation as indicated by the increased systemic levels of different complement components, such as C5a, MAC, CFH, and CFH-related 1 and 3 (CFHR1 and 3), which are comparable to preeclampsia systemic values of complement components (434–437).

Furthermore, HELLP syndrome patients with complement gene variants exhibit poorer clinical outcomes than those with no complement gene variants. These patients have higher complement mutation frequency, including rare germline mutations in the alternative CS pathway (CFHR1, CFHR3, CFI, CFB, and CD46) than women with preeclampsia, having similar rates of variants as the control population (438, 439). Thus, pregnant women with complement gene variants are more likely to progress from preeclampsia to HELLP syndrome, where gene variants and pregnancy provide first and second hits, like other complement disorders, such as aHUS and paroxysmal nocturnal hemoglobinuria (PNH). Furthermore, a clinical trial with eculizumab, a long-acting human monoclonal antibody targeting C5 to block its cleavage to C5a and C5b, has shown positive results in phase 1 clinical trials of pregnant women with early-onset HELLP syndrome (440). Hence, CS activation is critical for the pathogenesis and severity of preeclampsia and HELLP syndrome. Therefore, it is critical to identify factors that dysregulate the CS activation during preeclampsia and its severe forms.

5.3.1 Maternal factors associated with increased risk of preeclampsia and their association with complement dysregulation

Women facing infertility associated with polycystic ovary syndrome (PCOS) and recurrent pregnancy loss (RPL; defined as ≥3 consecutive embryonic losses before 10 weeks’ gestation or ≥2 fetal losses after 10 weeks’ gestation) are more prone to develop preeclampsia (441). The immune system plays a critical role in the pathogenesis of PCOS and RPL, and the CS is a critical component of the immune system. Studies have shown that high maternal circulating C3 and C4 levels via CS signaling pathway activation before conception are associated with RPL independent of MBL CS pathways and other components of immunity, such as B cells and antibodies (442–445). Furthermore, women with specific mutations in C4BP carrying C4BP gene polymorphism R120H also suffer from RPL due to decreased C3b degradation that elevates their circulating C3b level (446). Another study has indicated several C3 gene variants associated with defective secretion/function of C3 in European women (n = 192) who suffered from RPL (447). Thus, dysregulated CS activation, such as the alternative CS signaling pathway in women who suffered RPL previously, predisposes them to develop preeclampsia during a successful pregnancy due to their altered CS signaling pathway, even in the presence of healthy placental development. Furthermore, fasting circulating complement components, such as C3 and C3a (desArg), are higher in PCOS women with insulin resistance, which increases to a similar extent in the control and PCOS groups (448). However, higher factor H levels are present in the circulation in PCOS women with obesity (448, 449).

Non-obese, non-insulin-resistant women with PCOS have higher systemic alternative and classical CS signaling pathway components, such as C3, iC3b, properdin, and C4 levels (450). Further study has indicated that upregulated alternative CS pathway components, such as C3, properdin, factor B, and factor I, are elevated in non-obese patients with PCOS, which further increases with obesity (449, 450). Systemic C5a levels are also increased in normal-weight women and women with obesity suffering from PCOS (449). Hence, activation and terminal CS pathway components are altered in PCOS women, which increases their propensity to develop RPL. Thus, we can speculate that infertile women (due to RPL and PCOS) with otherwise normal sexual function and immune components may have altered CS components, which increases their propensity to develop preeclampsia.

Elevated body mass index (BMI) and obesity are other definite preeclampsia risk factors (431, 451–454). AT comprises adipocytes and stromal vascular fraction (SVF), containing different cell types, such as preadipocytes, fibroblasts, and immune cells (macrophages and T cells). Adipocytes are the primary source of FD, a critical player in the alternative CS signaling pathway activation (455). Along with FD, other alternative CS components, such as C3, factor B, factor H, factor I, and properdin, are overexpressed in ATs, which increase with BMI and obesity status (455). Furthermore, adipocytes express C3aR and C5aRs (C5aR1 and C5aR2), which, via their corresponding ligands (C3a and C5a), increase the local and systemic inflammation along with increasing insulin resistance (244, 456, 457). Women with obesity with elevated circulating Bb (active protease, generated during the alternative CS signaling pathway) and C3a levels compared with the control group are more likely to develop preeclampsia (458, 459). Thus, women with obesity, high BMI, and insulin resistance or glucose tolerance have hyperactivated alternative CS signaling, which predisposes them to develop preeclampsia during their pregnancy. Hence, pre-pregnancy CS component dysregulation due to the above-mentioned factors in women increases their chances of facing preeclampsia during their pregnancy.

6 Future perspective and conclusion

Preeclampsia is a disease that specifically occurs during pregnancy; therefore, the placenta and dysregulated maternal immune response are key factors for its pathogenesis. However, immunological advances in pregnancy and preeclampsia have now clarified that poor placentation is not the only driving force behind preeclampsia pathogenesis but rather serves as a critical factor for preeclampsia predisposition (431). The degree of maternal physiological reaction, including the immune response severity, determines the predisposition to preeclampsia and its severity. For example, the immune system governs the effective allotransplantation of the fetus in the uterus of the pregnant woman by modifying the maternal local (uterine) and systemic immune response, vascular, and coagulatory functions, which are further governed by the hormonal and psychogenic changes taking place in a pregnant woman (460–465). Hence, any pre-pregnancy immune dysfunction can be lethal to the future mother and developing fetus, as the CS is the first and rapid immune component of innate immunity; therefore, its homeostatic levels during pregnancy are critical for a healthy outcome.

Hypertension development during pregnancy is a critical factor in the development of preeclampsia. A study has indicated systemic elevation of the clusterin (a complement regulatory protein) in pregnant women during pre-hypertension disorder of pregnancy (pre-HDP) development, which proved to be the critical factor for HDP development (466). Further studies have indicated increased clusterin systemic levels before the onset of preeclampsia clinical symptoms in pregnant women that increase with preeclampsia severity (467–469). Moreover, clusterin plays a critical role in the decidualization process by interacting with the triggering receptor expressed on myeloid cells 2 (TREM-2) receptor expressed on decidual cells, and its alteration may impact placental development, including trophoblast invasion (467, 470). The higher clusterin levels in the placenta inhibit MAC formation; therefore, it will be interesting to investigate the systemic clusterin and MAC levels during normal human pregnancy and preeclampsia.

Furthermore, aberrant and persistent CS activation (local and systemic) elevates systemic MAC or C5b-9 and C1q, causing systemic vasculitis or thromboinflammation that impairs endothelial function, which may cause hypertension (471–476). Thus, aberrant CS activation in pregnant women and their placentae may induce endothelial damage that may cause hypertension and elevate circulating endothelial cells, further aggravating the CS, predisposing them to preeclampsia, and increasing its severity (476, 477). For example, fetal endothelial cell damage and CS dysregulation (elevated MAC and C3a levels but decreased factor H and Bb) have been observed in pregnancies complicated by preeclampsia (478).

C3 is a critical component in hypertension pathogenesis due to its maintenance effect on undifferentiated mesenchymal stem cells (MSCs), and maternal and placental C3a levels are upregulated in women with preeclampsia, indicating aberrant CS activation (479). Furthermore, increased maternal circulating C5a in women with preeclampsia is positively correlated with maternal blood pressure and arterial stiffness (413). Targeting the CS during preeclampsia may prevent associated organ damage, such as renal manifestations, as the kidneys are among the most affected organs in preeclampsia (480). Hence, CS proteins must be checked for a healthy pregnancy.

Women with preeclampsia also exhibit a hypercoagulable state than women with normal pregnancy at an early stage of the disease (481). Women with preeclampsia have elevated circulating levels of factor VIII, von Willebrand factor (vWF; due to endothelial cell damage/inflammation), the thrombin–antithrombin complex (TAT), D dimers, soluble fibrin, and thrombomodulin levels than women with normal pregnancy (481–483). Increased fibrin deposition in women with preeclampsia occurs in the glomerulus sub-endothelium, spiral arteries, decidual components, and occlusive lesions of placental vasculature (484, 485). Fibrin deposition activates the classical CS signaling pathway by interacting with C1q by covalent interaction mediated by FXIIIa (53). However, this fibrin–C1q interaction is antagonized by factor H, which is downregulated in women with preeclampsia.

The activated CS signaling pathway in patients with preeclampsia can stimulate the extrinsic coagulation system pathway to form thrombin by increasing the tissue factor (TF) activity on different cells, such as endothelial cells, as evolutionarily the CS and coagulation system have a common origin and interact to maintain homeostasis and hemostasis (486–489). Moreover, overproduced plasmin, a protease generated in response to thrombin production and fibrin deposition, also serves as C5 convertase and cleaves C5 into C5a and C5b to induce the inflammatory cascade and the assembly of procoagulant C5b-9 or the MAC (490). In addition to C5 cleavage, plasmin also cleaves C3 into C3a, which is upregulated in women with preeclampsia (491). Furthermore, inflammatory events, including organ injuries, complement (increase in C5a levels), coagulation (thrombin–antithrombin complexes), activation, and cross-talk, are very early events, which have also been reported in patients with preeclampsia (491). Several other coagulation pathway components, such as Factor Xa, thrombin, FIXa, and FXIa, also cleave C3 and C5 into biologically active C3a and C5a capable of exerting their pro-inflammatory effects (491, 492). Further maternal proteomics-based study has indicated the increased deposition of C5b-9 or the MAC and vWF in the endothelial cells of women with early-onset severe preeclampsia, indicating that the complement and coagulation systems are the critical pathways for early-onset severe preeclampsia (493). Thus, aberrant complement activation not only dysregulates immune homeostasis but also affects the coagulation system, hypertension, and metabolism to initiate and increase the severity of preeclampsia.

Moreover, increased circulating C3a levels have been observed in women with depression; therefore, it may be interesting to investigate whether increased circulating C3a levels predispose women to develop preeclampsia upon getting pregnant (494). Increased circulating C3a levels during pregnancy are a critical biomarker not only for preeclampsia prediction but also for depression during pregnancy, as the Edinburgh postnatal depression scale (EPDS) alone is not perfectly sufficient to detect major depressive disorder during pregnancy (495). Interestingly, more than 10% of pregnant women in high-income countries, such as the United States, have depression during pregnancy (496).

6.1 Conclusion

Measuring different circulating complement proteins in pregnant women may serve as a biomarker for early preeclampsia detection. Targeting the CS in pregnant women with preeclampsia will complement normal pregnancy and associated organ damage. Understanding CS signaling during preeclampsia will further help to track future maternal health issues, such as metabolic, cardiovascular, and neurologic disorders in survivors. Complementing helps in a healthy pregnancy, but decomplementing will equip us to fight against preeclampsia and other future health issues in preeclampsia survivors. Therefore, future studies are warranted to understand the CS signaling pathways’ alteration and their mechanism of action in human pregnancy and preeclampsia.

Author contributions

VK: Writing – original draft, Conceptualization, Software, Writing – review & editing. JS: Writing – review & editing.

Funding

The author(s) declare that no financial support was received for the research, and/or publication of this article.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

Generative AI statement

The author(s) declare that no Generative AI was used in the creation of this manuscript.

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References 1 Kumar

Medhi

. Emerging role of uterine natural killer cells in establishing pregnancy. Iranian J Immunol. (2008) 5:71–81. doi: 10.22034/iji.2008.48555, PMID: 18523352 2 Feyaerts

Joosten

van der Molen

. A pregnancy to remember: trained immunity of the uterine mucosae. Mucosal Immunol. (2021) 14:539–41. doi: 10.1038/s41385-020-00362-7, PMID: 33299087 3 Zhou

Way

Chen

. Immunology of uterine and vaginal mucosae: (Trends in immunology 39, 302-314, 2018). Trends Immunol. (2018) 39:355. doi: 10.1016/j.it.2018.02.006, PMID: 29530651 4 Solano

. Decidual immune cells: Guardians of human pregnancies. Best Pract Res Clin Obstetrics Gynaecology. (2019) 60:3–16. doi: 10.1016/j.bpobgyn.2019.05.009, PMID: 31285174 5 Wegmann

Lin

Guilbert

Mosmann

. Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon? Immunol Today. (1993) 14:353–6. doi: 10.1016/0167-5699(93)90235-D, PMID: 8363725 6 Vince

Johnson

. Is there a Th2 bias in human pregnancy? J Reprod Immunol. (1996) 32:101–4. doi: 10.1016/S0165-0378(96)00995-3, PMID: 9023814 7 Male

Moffett

. Natural killer cells in the human uterine mucosa. Annu Rev Immunol. (2023) 41:127–51. doi: 10.1146/annurev-immunol-102119-075119, PMID: 36630598 8 Sacks

Sargent

Redman

. An innate view of human pregnancy. Immunol Today. (1999) 20:114–8. doi: 10.1016/S0167-5699(98)01393-0, PMID: 10203701 9 Colamatteo

Fusco

Micillo

D’Hooghe

de Candia

Alviggi

. Immunobiology of pregnancy: from basic science to translational medicine. Trends Mol Med. (2023) 29:711–25. doi: 10.1016/j.molmed.2023.05.009, PMID: 37331882 10 Orefice

. Immunology and the immunological response in pregnancy. Best Pract Res Clin Obstetrics Gynaecology. (2021) 76:3–12. doi: 10.1016/j.bpobgyn.2020.07.013, PMID: 33191116 11 Kolev

Le Friec

Kemper

. Complement–tapping into new sites and effector systems. Nat Rev Immunol. (2014) 14:811–20. doi: 10.1038/nri3761, PMID: 25394942 12 Kumar

. The complement system, toll-like receptors and inflammasomes in host defense: three musketeers’ one target. Int Rev Immunol. (2019) 38:131–56. doi: 10.1080/08830185.2019.1609962, PMID: 31066339 13 Nonaka

Kimura

. Genomic view of the evolution of the complement system. Immunogenetics. (2006) 58:701–13. doi: 10.1007/s00251-006-0142-1, PMID: 16896831 14 Lynch

Nnamani

Kapusta

Brayer

Plaza

Mazur

. Ancient transposable elements transformed the uterine regulatory landscape and transcriptome during the evolution of mammalian pregnancy. Cell Rep. (2015) 10:551–61. doi: 10.1016/j.celrep.2014.12.052, PMID: 25640180 15 Mastellos

Hajishengallis

Lambris

. A guide to complement biology, pathology and therapeutic opportunity. Nat Rev Immunol. (2024) 24:118–41. doi: 10.1038/s41577-023-00926-1, PMID: 37670180 16 Son

. Understanding the contextual functions of C1q and LAIR-1 and their applications. Exp Mol Med. (2022) 54:567–72. doi: 10.1038/s12276-022-00774-4, PMID: 35562585 17 Qin

Gao

. The complement system in liver diseases. Cell Mol Immunol. (2006) 3:333–40. 18 Thorgersen

Barratt-Due

Haugaa

Harboe

Pischke

Nilsson

. The role of complement in liver injury, regeneration, and transplantation. Hepatology. (2019) 70:725–36. doi: 10.1002/hep.30508, PMID: 30653682 19 Lubbers

van Essen

van Kooten

Trouw

. Production of complement components by cells of the immune system. Clin Exp Immunol. (2017) 188:183–94. doi: 10.1111/cei.12952, PMID: 28249350 20 Farries

Steuer

Atkinson

. Evolutionary implications of a new bypass activation pathway of the complement system. Immunol Today. (1990) 11:78–80. doi: 10.1016/0167-5699(90)90031-4, PMID: 2186743 21 Farries

Atkinson

. Evolution of the complement system. Immunol Today. (1991) 12:295–300. doi: 10.1016/0167-5699(91)90002-B, PMID: 1755941 22 Ricklin

Reis

Mastellos

Gros

Lambris

. Complement component C3 - The “Swiss Army Knife” of innate immunity and host defense. Immunol Rev. (2016) 274:33–58. doi: 10.1111/imr.12500, PMID: 27782325 23 Coulthard

Woodruff

. Is the complement activation product C3a a proinflammatory molecule? Re-evaluating the evidence and the myth. J Immunol. (2015) 194:3542–8. doi: 10.4049/jimmunol.1403068, PMID: 25848071 24 Sekine

Machida

Fujita

. Factor D. Immunol Rev. (2023) 313:15–24. doi: 10.1111/imr.13155, PMID: 36316810 25 Barratt

Weitz

. Complement factor D as a strategic target for regulating the alternative complement pathway. Front Immunol. (2021) 12. doi: 10.3389/fimmu.2021.712572, PMID: 34566967 26 Harboe

Mollnes

. The alternative complement pathway revisited. J Cell Mol Med. (2008) 12:1074–84. doi: 10.1111/j.1582-4934.2008.00350.x, PMID: 18419792 27 Ricklin

Hajishengallis

Yang

Lambris

. Complement: a key system for immune surveillance and homeostasis. Nat Immunol. (2010) 11:785–97. doi: 10.1038/ni.1923, PMID: 20720586 28 Fearon

Austen

. Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase. J Exp Med. (1975) 142:856–63. doi: 10.1084/jem.142.4.856, PMID: 1185108 29 Müller-Eberhard

. The killer molecule of complement. J Invest Dermatol. (1985) 85:47s–52s. doi: 10.1111/1523-1747.ep12275445, PMID: 3891882 30 Podack

Tschopp

. Membrane attack by complement. Mol Immunol. (1984) 21:589–603. doi: 10.1016/0161-5890(84)90044-0, PMID: 6379417 31 Prada

Zahedi

Davis

. 3rd, Regulation of C1 inhibitor synthesis. Immunobiology. (1998) 199:377–88. doi: 10.1016/S0171-2985(98)80042-9, PMID: 9777421 32 Gitlin

Biasucci

. Development of γG, γA, γM, β 1C/β 1A, C′ 1 esterase inhibitor, ceruloplasmin, transferrin, hemopexin, haptoglobin, fibrinogen, plasminogen, α 1-antitrypsin, orosomucoid, β-lipoprotein, α 2-macroglobulin, and prealbumin in the human conceptus. J Clin Invest. (1969) 48:1433–46. doi: 10.1172/JCI106109, PMID: 5796355 33 Schmaier

Smith

Colman

. Platelet C1- inhibitor. A secreted alpha-granule protein. J Clin Invest. (1985) 75:242–50. doi: 10.1172/JCI111680, PMID: 3965505 34 Schmaier

Amenta

Xiong

Heda

Gewirtz

. Expression of platelet C1 inhibitor. Blood. (1993) 82:465–74. doi: 10.1182/blood.V82.2.465.465 35 Armbrust

Schwögler

Zöhrens

Ramadori

. C1 esterase inhibitor gene expression in rat Kupffer cells, peritoneal macrophages and blood monocytes: modulation by interferon gamma. J Exp Med. (1993) 178:373–80. doi: 10.1084/jem.178.2.373, PMID: 8340749 36 Katz

Strunk

. Synthesis and regulation of C1 inhibitor in human skin fibroblasts. J Immunol. (1989) 142:2041–5. doi: 10.4049/jimmunol.142.6.2041, PMID: 2537870 37 Harpel

Cooper

. Studies on human plasma C1 inactivator-enzyme interactions. I. Mechanisms of interaction with C1s, plasmin, and trypsin. J Clin Invest. (1975) 55:593–604. doi: 10.1172/JCI107967, PMID: 123251 38 Chen

Boackle

. A newly discovered function for C1 inhibitor, removal of the entire C1qr2s2 complex from immobilized human IgG subclasses. Clin Immunol Immunopathol. (1998) 87:68–74. doi: 10.1006/clin.1997.4515, PMID: 9576012 39 Chen

Lam

Boackle

. C1 inhibitor removes the entire C1qr2s2 complex from anti-C1Q monoclonal antibodies with low binding affinities. Immunology. (1998) 95:648–54. doi: 10.1046/j.1365-2567.1998.00635.x, PMID: 9893058 40 Schreiber

Kaplan

Austen

. Inhibition by C1INH of Hagemann factor fragment activation of coagulation, fibrinolysis, and kinin generation. J Clin Invest. (1973) 52:1402–9. doi: 10.1172/JCI107313, PMID: 4703226 41 Ratnoff

Pensky

Ogston

Naff

. The inhibition of plasmin, plasma kallikrein, plasma permeability factor, and the C’1r subcomponent of the first component of complement by serum C’1 esterase inhibitor. J Exp Med. (1969) 129:315–31. doi: 10.1084/jem.129.2.315, PMID: 4178758 42 Jiang

Wagner

Zhang

Frank

. Complement 1 inhibitor is a regulator of the alternative complement pathway. J Exp Med. (2001) 194:1609–16. doi: 10.1084/jem.194.11.1609, PMID: 11733575 43 Cai

Davis

. III, complement regulatory protein C1 inhibitor binds to selectins and interferes with endothelial-leukocyte adhesion 1. J Immunol. (2003) 171:4786–91. doi: 10.4049/jimmunol.171.9.4786, PMID: 14568956 44 Gompels

Lock

Abinun

Bethune

Davies

Grattan

. C1 inhibitor deficiency: consensus document. Clin Exp Immunol. (2005) 139:379–94. doi: 10.1111/j.1365-2249.2005.02726.x, PMID: 15730382 45 Hallam

Sharp

Andreadi

Kavanagh

. Complement factor I: Regulatory nexus, driver of immunopathology, and therapeutic. Immunobiology. (2023) 228:152410. doi: 10.1016/j.imbio.2023.152410, PMID: 37478687 46 Nilsson

Sim

Lea

Fremeaux-Bacchi

Blom

. Complement factor I in health and disease. Mol Immunol. (2011) 48:1611–20. doi: 10.1016/j.molimm.2011.04.004, PMID: 21529951 47 Cole

Housley

Jr. Dykman

MacDermott

Atkinson

. Identification of an additional class of C3-binding membrane proteins of human peripheral blood leukocytes and cell lines. Proc Natl Acad Sci U.S.A. (1985) 82:859–63. 48 Cserhalmi

Papp

Brandus

Uzonyi

Józsi

. Regulation of regulators: Role of the complement factor H-related proteins. Semin Immunol. (2019) 45:101341. doi: 10.1016/j.smim.2019.101341, PMID: 31757608 49 Kiss

Papac-Miličević

Porsch

Tsiantoulas

Hendrikx

Takaoka

. Cell-autonomous regulation of complement C3 by factor H limits macrophage efferocytosis and exacerbates atherosclerosis. Immunity. (2023) 56:1809–1824.e1810. doi: 10.1016/j.immuni.2023.06.026, PMID: 37499656 50 Pouw

Brouwer

de Gast

van Beek

van den Heuvel

Schmidt

. Potentiation of complement regulator factor H protects human endothelial cells from complement attack in aHUS sera. Blood Adv. (2019) 3:621–32. doi: 10.1182/bloodadvances.2018025692, PMID: 30804016 51 Mahajan

Jacob

Kelkar

Chang

McSkimming

Neelamegham

. Local complement factor H protects kidney endothelial cell structure and function. Kidney Int. (2021) 100:824–36. doi: 10.1016/j.kint.2021.05.033, PMID: 34139209 52 Wu

Y-Q

Ricklin

Janssen

BJC

Lambris

Gros

. Structure of complement fragment C3b–factor H and implications for host protection by complement regulators. Nat Immunol. (2009) 10:728–33. doi: 10.1038/ni.1755, PMID: 19503104 53 Kang

Varghese

Aiyan

Pondman

Kishore

Sim

. Complement-Coagulation Cross-talk: Factor H-mediated regulation of the Complement Classical Pathway activation by fibrin clots. Front Immunol. (2024) 15:1368852. doi: 10.3389/fimmu.2024.1368852, PMID: 38933264 54 Cipriani

Tierney

Griffiths

Zuber

Sergouniotis

Yates

JRW

. Beyond factor H: The impact of genetic-risk variants for age-related macular degeneration on circulating factor-H-like 1 and factor-H-related protein concentrations. Am J Hum Genet. (2021) 108:1385–400. doi: 10.1016/j.ajhg.2021.05.015, PMID: 34260948 55 Lorés-Motta

van Beek

Willems

Zandstra

van Mierlo

Einhaus

. Common haplotypes at the CFH locus and low-frequency variants in CFHR2 and CFHR5 associate with systemic FHR concentrations and age-related macular degeneration. Am J Hum Genet. (2021) 108:1367–84. doi: 10.1016/j.ajhg.2021.06.002, PMID: 34260947 56 Sándor

Schneider

Matola

Barbai

Bencze

Hammad

. The human factor H protein family – an update. Front Immunol. (2024) 15. doi: 10.3389/fimmu.2024.1135490, PMID: 38410512 57 Józsi

Tortajada

Uzonyi

Goicoechea de Jorge

Rodríguez de Córdoba

. Factor H-related proteins determine complement-activating surfaces. Trends Immunol. (2015) 36:374–84. doi: 10.1016/j.it.2015.04.008, PMID: 25979655 58 Hebecker

Józsi

. Factor H-related protein 4 activates complement by serving as a platform for the assembly of alternative pathway C3 convertase via its interaction with C3b protein. J Biol Chem. (2012) 287:19528–36. doi: 10.1074/jbc.M112.364471, PMID: 22518841 59 Bernabéu-Herrero

Jiménez-Alcázar

Anter

Pinto

Sánchez Chinchilla

Garrido

. FHR-3 and FHR-1 variants associate in an extended haplotype conferring increased risk of atypical hemolytic uremic syndrome. Mol Immunol. (2015) 67:276–86. doi: 10.1016/j.molimm.2015.06.021, PMID: 26163426 60 Li

Zong

. Complement Factor H related protein 1 and immune inflammatory disorders. Mol Immunol. (2022) 145:43–9. doi: 10.1016/j.molimm.2022.03.117, PMID: 35279539 61 Blom

Villoutreix

Dahlbäck

. Complement inhibitor C4b-binding protein—friend or foe in the innate immune system? Mol Immunol. (2004) 40:1333–46. doi: 10.1016/j.molimm.2003.12.002, PMID: 15072852 62 Werner

Criss

. Diverse functions of C4b-binding protein in health and disease. J Immunol. (2023) 211:1443–9. doi: 10.4049/jimmunol.2300333, PMID: 37931209 63 Seya

Holers

Atkinson

. Purification and functional analysis of the polymorphic variants of the C3b/C4b receptor (CR1) and comparison with H, C4b-binding protein (C4bp), and decay accelerating factor (DAF). J Immunol (Baltimore Md.: 1950). (1985) 135:2661–7. doi: 10.4049/jimmunol.135.4.2661, PMID: 3161944 64 Seya

Nakamura

Masaki

Ichihara-Itoh

Matsumoto

Nagasawa

. and C4b-binding protein serve as factor I-cofactors both encompassing inactivation of C3b and C4b. Mol Immunol. (1995) 32:355–60. doi: 10.1016/0161-5890(94)00157-V, PMID: 7739573 65 Blom

Kask

Dahlbäck

. Structural requirements for the complement regulatory activities of C4BP*. J Biol Chem. (2001) 276:27136–44. doi: 10.1074/jbc.M102445200, PMID: 11369776 66 Sjöberg

Trouw

McGrath

FDG

Hack

Blom

. Regulation of complement activation by C-reactive protein: targeting of the inhibitory activity of C4b-binding protein1. J Immunol. (2006) 176:7612–20. doi: 10.4049/jimmunol.176.12.7612, PMID: 16751408 67 Varghese

Murugaiah

Beirag

Temperton

Khan

Alrokayan

. C4b binding protein acts as an innate immune effector against influenza A virus. Front Immunol. (2021) 11. doi: 10.3389/fimmu.2020.585361, PMID: 33488586 68 Bierschenk

Papac-Milicevic

Bresch

Kovacic

Bettoni

Dziedzic

. C4b-binding protein inhibits particulate- and crystalline-induced NLRP3 inflammasome activation. Front Immunol. (2023) 14:1149822. doi: 10.3389/fimmu.2023.1149822, PMID: 37283747 69 Trapp

Fletcher

Forristal

West

. C4 binding protein deficiency in a patient with atypical Behçet’s disease. J Rheumatol. (1987) 14:135–8., PMID: 3572915 70 Schwaeble

Reid

KBM

. Does properdin crosslink the cellular and the humoral immune response? Immunol Today. (1999) 20:17–21. doi: 10.1016/s0167-5699(98)01376-0, PMID: 10081225 71 Pillemer

Blum

Lepow

Ross

Todd

Wardlaw

. The properdin system and immunity: I. Demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena. Science. (1954) 120:279–85. doi: 10.1126/science.120.3112.279, PMID: 13186838 72 Ferreira

. Chapter 27 - properdin. In: Barnum

Schein

, editors. The Complement FactsBook, 2nd ed. USA: Academic Press (2018). p. pp 283–293. 73 Hourcade

. The role of properdin in the assembly of the alternative pathway C3 convertases of complement*. J Biol Chem. (2006) 281:2128–32. doi: 10.1074/jbc.M508928200, PMID: 16301317 74 Medicus

Götze

Müller-Eberhard

. Alternative pathway of complement: recruitment of precursor properdin by the labile C3/C5 convertase and the potentiation of the pathway. J Exp Med. (1976) 144:1076–93. doi: 10.1084/jem.144.4.1076, PMID: 978134 75 Densen

Weiler

Griffiss

Hoffmann

. Familial properdin deficiency and fatal meningococcemia. Correction of the bactericidal defect by vaccination. N Engl J Med. (1987) 316:922–6. doi: 10.1056/NEJM198704093161506, PMID: 3102964 76 Schlesinger

Nave

Levy

Slater

Fishelson

. Prevalence of hereditary properdin, C7 and C8 deficiencies in patients with meningococcal infections. Clin Exp Immunol. (1990) 81:423–7. doi: 10.1111/j.1365-2249.1990.tb05350.x, PMID: 2397612 77 Linton

Morgan

. Properdin deficiency and meningococcal disease–identifying those most at risk. Clin Exp Immunol. (1999) 118:189–91. doi: 10.1046/j.1365-2249.1999.01057.x, PMID: 10540177 78 Fijen

van den Bogaard

Schipper

Mannens

Schlesinger

Nordin

. Properdin deficiency: molecular basis and disease association. Mol Immunol. (1999) 36:863–7. doi: 10.1016/S0161-5890(99)00107-8, PMID: 10698340 79 Sullivan

. Chapter 81 - inherited complement deficiencies. In: Rimoin

Pyeritz

Korf

, editors. Emery and Rimoin’s Principles and Practice of Medical Genetics, Sixth Edition. Academic Press, Oxford (2013). p. pp 1–13. doi: 10.1016/B978-0-12-383834-6.00085-9 80 Tschopp

Chonn

Hertig

French

. Clusterin, the human apolipoprotein and complement inhibitor, binds to complement C7, C8 beta, and the b domain of C9. J Immunol. (1993) 151:2159–65. doi: 10.4049/jimmunol.151.4.2159, PMID: 8345200 81 Massri

Toonen

EJM

Sarg

Kremser

Grasse

Fleischer

. Complement C7 and clusterin form a complex in circulation. Front Immunol. (2024) 15. doi: 10.3389/fimmu.2024.1330095, PMID: 38333209 82 Chauhan

Moore

. Presence of plasma complement regulatory proteins clusterin (Apo J) and vitronectin (S40) on circulating immune complexes (CIC). Clin Exp Immunol. (2006) 145:398–406. doi: 10.1111/j.1365-2249.2006.03135.x, PMID: 16907906 83 Doudevski

Rostagno

Cowman

Liebmann

Ritch

Ghiso

. Clusterin and complement activation in exfoliation glaucoma. Invest Ophthalmol Visual Sci. (2014) 55:2491–9. doi: 10.1167/iovs.13-12941, PMID: 24550356 84 Hochgrebe

Humphreys

Wilson

Easterbrook-Smith

. A reexamination of the role of clusterin as a complement regulator. Exp Cell Res. (1999) 249:13–21. doi: 10.1006/excr.1999.4459, PMID: 10328949 85 Schvartz

Seger

Shaltiel

. Vitronectin. Int J Biochem Cell Biol. (1999) 31:539–44. doi: 10.1016/S1357-2725(99)00005-9, PMID: 10399314 86 Milis

Morris

Sheehan

Charlesworth

Pussell

. Vitronectin-mediated inhibition of complement: evidence for different binding sites for C5b-7 and C9. Clin Exp Immunol. (1993) 92:114–9. doi: 10.1111/j.1365-2249.1993.tb05956.x, PMID: 7682159 87 Zheng

Saunders

Camper

Samuelson

Ginsburg

. Vitronectin is not essential for normal mammalian development and fertility. Proc Natl Acad Sci U.S.A. (1995) 92:12426–30. doi: 10.1073/pnas.92.26.12426, PMID: 8618914 88 Singh

Y-C

Riesbeck

. Vitronectin in bacterial pathogenesis: a host protein used in complement escape and cellular invasion. Mol Microbiol. (2010) 78:545–60. doi: 10.1111/j.1365-2958.2010.07373.x, PMID: 20807208 89 Jang

Y-C

Tsou

Gibran

Isik

. Vitronectin deficiency is associated with increased wound fibrinolysis and decreased microvascular angiogenesis in mice. Surgery. (2000) 127:696–704. doi: 10.1067/msy.2000.105858, PMID: 10840366 90 Hayashida

Hashimoto

Ishikawa

Miyamoto

. Vitronectin deficiency attenuates hepatic fibrosis in a non-alcoholic steatohepatitis-induced mouse model. Int J Exp Pathol. (2019) 100:72–82. doi: 10.1111/iep.12306, PMID: 30887659 91 Fearon

. Identification of the membrane glycoprotein that is the C3b receptor of the human erythrocyte, polymorphonuclear leukocyte, B lymphocyte, and monocyte. J Exp Med. (1980) 152:20–30. doi: 10.1084/jem.152.1.20, PMID: 6967510 92 Dustin

. Complement receptors in myeloid cell adhesion and phagocytosis. Microbiol Spectr. (2016) 4. doi: 10.1128/microbiolspec.mchd-0034-2016, PMID: 27809953 93 Kazatchkine

Fearon

. Deficiencies of human C3 complement receptors type 1 (CR1, CD35) and type 2 (CR2, CD21). Immunodefic Rev. (1990) 2:17–41., PMID: 2164822 94 Steiniger

Trabandt

Barth

. The follicular dendritic cell network in secondary follicles of human palatine tonsils and spleens. Histochem Cell Biol. (2011) 135:327–36. doi: 10.1007/s00418-011-0799-x, PMID: 21394653 95 Asokan

Banda

Szakonyi

Chen

Holers

. Human complement receptor 2 (CR2/CD21) as a receptor for DNA: implications for its roles in the immune response and the pathogenesis of systemic lupus erythematosus (SLE). Mol Immunol. (2013) 53:99–110. doi: 10.1016/j.molimm.2012.07.002, PMID: 22885687 96 Iida

Nadler

Nussenzweig

. Identification of the membrane receptor for the complement fragment C3d by means of a monoclonal antibody. J Exp Med. (1983) 158:1021–33. doi: 10.1084/jem.158.4.1021, PMID: 6225820 97 Wagner

Ochmann

Schoels

Giese

Stegmaier

Richter

. The complement receptor 1, CR1 (CD35), mediates inhibitory signals in human T-lymphocytes. Mol Immunol. (2006) 43:643–51. doi: 10.1016/j.molimm.2005.04.006, PMID: 16360013 98 Kovács

Mácsik-Valent

Matkó

Bajtay

Erdei

. Revisiting the coreceptor function of complement receptor type 2 (CR2, CD21); coengagement with the B-cell receptor inhibits the activation, proliferation, and antibody production of human B cells. Front Immunol. (2021) 12. doi: 10.3389/fimmu.2021.620427, PMID: 33868238 99 Vorup-Jensen

Jensen

. Structural immunology of complement receptors 3 and 4. Front Immunol. (2018) 9:2716. doi: 10.3389/fimmu.2018.02716, PMID: 30534123 100 Sándor

Kristóf

Paréj

Pap

Erdei

Bajtay

. CR3 is the dominant phagocytotic complement receptor on human dendritic cells. Immunobiology. (2013) 218:652–63. doi: 10.1016/j.imbio.2012.07.031, PMID: 22906751 101 Wagner

Hänsch

Stegmaier

Denefleh

Hug

Schoels

. The complement receptor 3, CR3 (CD11b/CD18), on T lymphocytes: activation-dependent up-regulation and regulatory function. Eur J Immunol. (2001) 31:1173–80. doi: 10.1002/1521-4141(200104)31:4<1173::AID-IMMU1173>3.0.CO;2-9, PMID: 11298342 102 Klein

Di Renzo

Yefenof

. Contribution of CR3, CD11b/CD18 to cytolysis by human NK cells. Mol Immunol. (1990) 27:1343–7. doi: 10.1016/0161-5890(90)90041-W, PMID: 1980339 103 Vik

Fearon

. Cellular distribution of complement receptor type 4 (CR4): expression on human platelets. J Immunol. (1987) 138:254–8. doi: 10.4049/jimmunol.138.1.254, PMID: 2946777 104 Walbaum

Ambrosy

Schütz

Bachg

Horsthemke

Leusen

JHW

. Complement receptor 3 mediates both sinking phagocytosis and phagocytic cup formation via distinct mechanisms. J Biol Chem. (2021) 296. doi: 10.1016/j.jbc.2021.100256, PMID: 33839682 105 Lukácsi

Nagy-Baló

Erdei

Sándor

Bajtay

. The role of CR3 (CD11b/CD18) and CR4 (CD11c/CD18) in complement-mediated phagocytosis and podosome formation by human phagocytes. Immunol Lett. (2017) 189:64–72. doi: 10.1016/j.imlet.2017.05.014, PMID: 28554712 106 Taborda

Casadevall

. CR3 (CD11b/CD18) and CR4 (CD11c/CD18) are involved in complement-independent antibody-mediated phagocytosis of Cryptococcus neoformans. Immunity. (2002) 16:791–802. doi: 10.1016/S1074-7613(02)00328-X, PMID: 12121661 107 Lim

Wiedemann

Tzircotis

Monkley

Critchley

Caron

. An essential role for talin during αMβ2-mediated phagocytosis. Mol Biol Cell. (2007) 18:976–85. doi: 10.1091/mbc.e06-09-0813, PMID: 17202407 108 Kazatchkine

Jouvin

Wilson

Fischer

. Human diseases associated with C3 receptor deficiencies. Immunol Lett. (1987) 14:191–5. doi: 10.1016/0165-2478(87)90100-3, PMID: 3552968 109 Bermejo-Jambrina

Blatzer

Jauregui-Onieva

Yordanov

Hörtnagl

Valovka

. CR4 signaling contributes to a DC-driven enhanced immune response against complement-opsonized HIV-1. Front Immunol. (2020) 11. doi: 10.3389/fimmu.2020.02010, PMID: 32922405 110 Wiesmann

Katschke

Yin

Helmy

Steffek

Fairbrother

. Structure of C3b in complex with CRIg gives insights into regulation of complement activation. Nature. (2006) 444:217–20. doi: 10.1038/nature05263, PMID: 17051150 111 Gorgani

Katschke

Helmy

Steffek

. Complement receptor of the Ig superfamily enhances complement-mediated phagocytosis in a subpopulation of tissue resident macrophages. J Immunol. (2008) 181:7902–8. doi: 10.4049/jimmunol.181.11.7902, PMID: 19017980 112 Zeng

Surewaard

BGJ

Wong

CHY

Geoghegan

Jenne

Kubes

. CRIg functions as a macrophage pattern recognition receptor to directly bind and capture blood-borne gram-positive bacteria. Cell Host Microbe. (2016) 20:99–106. doi: 10.1016/j.chom.2016.06.002, PMID: 27345697 113 Vogt

Schmitz

Kurrer

Bauer

Hinton

Behnke

. VSIG4, a B7 family–related protein, is a negative regulator of T cell activation. J Clin Invest. (2006) 116:2817–26. doi: 10.1172/JCI25673, PMID: 17016562 114 Anderson

Springer

. Leukocyte adhesion deficiency: an inherited defect in the Mac-1, LFA-1, and p 150, 95 glycoproteins. Annu Rev Med. (1987) 38:175–94. doi: 10.1146/annurev.me.38.020187.001135, PMID: 3555290 115 Liszewski

Atkinson

. Membrane cofactor protein (MCP; CD46): deficiency states and pathogen connections. Curr Opin Immunol. (2021) 72:126–34. doi: 10.1016/j.coi.2021.04.005, PMID: 34004375 116 Liszewski

Kemper

. Complement in motion: the evolution of CD46 from a complement regulator to an orchestrator of normal cell physiology. J Immunol. (2019) 203:3–5. doi: 10.4049/jimmunol.1900527, PMID: 31209141 117 Liszewski

Atkinson

. Complement regulator CD46: genetic variants and disease associations. Hum Genomics. (2015) 9:7. doi: 10.1186/s40246-015-0029-z, PMID: 26054645 118 Richards

Kemp

Liszewski

Goodship

Lampe

Decorte

. Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc Natl Acad Sci. (2003) 100:12966–71. doi: 10.1073/pnas.2135497100, PMID: 14566051 119 Cocuzzi

Szczotka

Brodbeck

Bardenstein

Wei

Medof

. Tears contain the complement regulator CD59 as well as decay-accelerating factor (DAF). Clin Exp Immunol. (2001) 123:188–95. doi: 10.1046/j.1365-2249.2001.01408.x, PMID: 11207647 120 Dho

Lim

Kim

. Beyond the role of CD55 as a complement component. Immune Netw. (2018) 18:e11. doi: 10.4110/in.2018.18.e11, PMID: 29503741 121 Marschang

Sodroski

Würzner

Dierich

. Decay-accelerating factor (CD55) protects human immunodeficiency virus type 1 from inactivation by human complement. Eur J Immunol. (1995) 25:285–90. doi: 10.1002/eji.1830250147, PMID: 7531147 122 Kwon

Y-C

Kim

Meyer

Di Bisceglie

Ray

. Distinct CD55 isoform synthesis and inhibition of complement-dependent cytolysis by hepatitis C virus. J Immunol. (2016) 197:1127–36. doi: 10.4049/jimmunol.1600631, PMID: 27357152 123 Capasso

Durrant

Stacey

Gordon

Ramage

Spendlove

. Costimulation via CD55 on human CD4+ T cells mediated by CD97. J Immunol. (2006) 177:1070–7. doi: 10.4049/jimmunol.177.2.1070, PMID: 16818763 124 Finberg

White

Nicholson-Weller

. Decay-accelerating factor expression on either effector or target cells inhibits cytotoxicity by human natural killer cells. J Immunol (Baltimore Md.: 1950). (1992) 149:2055–60. doi: 10.4049/jimmunol.149.6.2055 125 Parker

Omine

Richards

Nishimura

J-I

Bessler

Ware

. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood. (2005) 106:3699–709. doi: 10.1182/blood-2005-04-1717, PMID: 16051736 126 Ozen

. CHAPLE syndrome uncovers the primary role of complement in a familial form of Waldmann’s disease. Immunol Rev. (2019) 287:20–32. doi: 10.1111/imr.12715, PMID: 30565236 127 Ruiz-Argüelles

Llorente

. The role of complement regulatory proteins (CD55 and CD59) in the pathogenesis of autoimmune hemocytopenias. Autoimmun Rev. (2007) 6:155–61. doi: 10.1016/j.autrev.2006.09.008, PMID: 17289551 128 Meri

Waldmann

Lachmann

. Distribution of protectin (CD59), a complement membrane attack inhibitor, in normal human tissues. Lab Invest. (1991) 65:532–7., PMID: 1721667 129 Couves

Gardner

Voisin

Bickel

Stansfeld

Tate

. Structural basis for membrane attack complex inhibition by CD59. Nat Commun. (2023) 14:890. doi: 10.1038/s41467-023-36441-z, PMID: 36797260 130 Spear

Lurain

Parker

Ghassemi

Payne

Saifuddin

. Host cell-derived complement control proteins CD55 and CD59 are incorporated into the virions of two unrelated enveloped viruses. Human T cell leukemia/lymphoma virus type I (HTLV-I) and human cytomegalovirus (HCMV). J Immunol (Baltimore Md.: 1950). (1995) 155:4376–81. doi: 10.4049/jimmunol.155.9.4376, PMID: 7594597 131 McGreal

Ikewaki

Akatsu

Morgan

Gasque

. Human C1qRp is identical with CD93 and the mNI-11 antigen but does not bind C1q. J Immunol. (2002) 168:5222–32. doi: 10.4049/jimmunol.168.10.5222, PMID: 11994479 132 Tenner

. C1q receptors: regulating specific functions of phagocytic cells. Immunobiology. (1998) 199:250–64. doi: 10.1016/S0171-2985(98)80031-4, PMID: 9777410 133 Chevrier

Genton

Kallies

Karnowski

Otten

Malissen

. CD93 is required for maintenance of antibody secretion and persistence of plasma cells in the bone marrow niche. Proc Natl Acad Sci U.S.A. (2009) 106:3895–900. doi: 10.1073/pnas.0809736106, PMID: 19228948 134 Ikewaki

Yamao

Kulski

Inoko

. Flow cytometric identification of CD93 expression on naive T lymphocytes (CD4(+)CD45RA (+) cells) in human neonatal umbilical cord blood. J Clin Immunol. (2010) 30:723–33. doi: 10.1007/s10875-010-9426-1, PMID: 20512406 135 Vemuri

de Alves Pereira

Fuenzalida

Subashi

Barbera

van Hooren

. CD93 maintains endothelial barrier function and limits metastatic dissemination. JCI Insight. (2024) 9. doi: 10.1172/jci.insight.169830, PMID: 38441970 136 Norsworthy

Fossati-Jimack

Cortes-Hernandez

Taylor

Bygrave

Thompson

. Murine CD93 (C1qRp) contributes to the removal of apoptotic cells in vivo but is not required for C1q-mediated enhancement of phagocytosis. J Immunol. (2004) 172:3406–14. doi: 10.4049/jimmunol.172.6.3406, PMID: 15004139 137 Nepomuceno

Ruiz

Park

Tenner

. C1qRP is a heavily O-glycosylated cell surface protein involved in the regulation of phagocytic activity. J Immunol. (1999) 162:3583–9. doi: 10.4049/jimmunol.162.6.3583, PMID: 10092817 138 Tossetta

Piani

Borghi

Marzioni

. Role of CD93 in health and disease. Cells. (2023) 12. doi: 10.3390/cells12131778, PMID: 37443812 139 Kishore

Reid

. C1q: structure, function, and receptors. Immunopharmacology. (2000) 49:159–70. doi: 10.1016/S0162-3109(00)80301-X, PMID: 10904115 140 Eggleton

Tenner

Reid

. C1q receptors. Clin Exp Immunol. (2000) 120:406–12. doi: 10.1046/j.1365-2249.2000.01218.x, PMID: 10844516 141 Sim

Moestrup

Stuart

Lynch

Schwaeble

. Interaction of C1q and the collectins with the potential receptors calreticulin (cClqR/collectin receptor) and megalin. Immunobiology. (1998) 199:208–24. doi: 10.1016/S0171-2985(98)80028-4, PMID: 9777407 142 Qiu

Marquez-Curtis

Janowska-Wieczorek

. Mesenchymal stem cells express the surface receptor calreticulin (cC1qR) and complement C1q chemoattracts them. Blood. (2010) 116:3855–5. doi: 10.1182/blood.V116.21.3855.3855 143 Hirano

Totani

Fukuda

Suzuki

. N-Glycoform-dependent interactions of megalin with its ligands. Biochim Biophys Acta (BBA) - Gen Subj. (2017) 1861:3106–18. doi: 10.1016/j.bbagen.2016.10.015, PMID: 27773703 144 Hammad

Aglan

Mohammed

Awad

Elsaid

Bedair

. Cytotoxic T cell expression of leukocyte-associated immunoglobulin-like receptor-1 (LAIR-1) in viral hepatitis C-mediated hepatocellular carcinoma. Int J Mol Sci. (2022) 23. doi: 10.3390/ijms232012541, PMID: 36293412 145 Helou

Quach

Hurrell

Akbari

. LAIR-1 limits macrophage activation in acute inflammatory lung injury. Mucosal Immunol. (2023) 16:788–800. doi: 10.1016/j.mucimm.2023.08.003, PMID: 37634572 146 Son

Santiago-Schwarz

Al-Abed

Diamond

. C1q limits dendritic cell differentiation and activation by engaging LAIR-1. Proc Natl Acad Sci U.S.A. (2012) 109:E3160–3167. doi: 10.1073/pnas.1212753109, PMID: 23093673 147 Son

Diamond

Volpe

Aranow

Mackay

Santiago-Schwarz

. Evidence for C1q-mediated crosslinking of CD33/LAIR-1 inhibitory immunoreceptors and biological control of CD33/LAIR-1 expression. Sci Rep. (2017) 7:270. doi: 10.1038/s41598-017-00290-w, PMID: 28325905 148 Carvalheiro

Garcia

Pascoal Ramos

Giovannone

Radstake

Marut

. Leukocyte associated immunoglobulin like receptor 1 regulation and function on monocytes and dendritic cells during inflammation. Front Immunol. (2020) 11:1793. doi: 10.3389/fimmu.2020.01793, PMID: 32973751 149 Helou

Shafiei-Jahani

Hurrell

Painter

Quach

Howard

. LAIR-1 acts as an immune checkpoint on activated ILC2s and regulates the induction of airway hyperreactivity. J Allergy Clin Immunol. (2022) 149:223–236.e226. doi: 10.1016/j.jaci.2021.05.042, PMID: 34144112 150 Morita

Saito

Matsumoto

. Immune checkpoint molecules on ILC2s as potential therapeutic targets for allergic diseases. J Allergy Clin Immunol. (2022) 149:60–2. doi: 10.1016/j.jaci.2021.10.021, PMID: 34718042 151 Kumawat

Geerdink

Hennus

Roda

van Ark

Leusink-Muis

. LAIR-1 limits neutrophilic airway inflammation. Front Immunol. (2019) 10:842. doi: 10.3389/fimmu.2019.00842, PMID: 31080449 152 Park

Takahara

Umemoto

Yashima

Matsubara

Matsuda

. Five mouse homologues of the human dendritic cell C-type lectin, DC-SIGN. Int Immunol. (2001) 13:1283–90. doi: 10.1093/intimm/13.10.1283, PMID: 11581173 153 Kang

Y-S

Kim

Bruening

Pack

Charalambous

Pritsker

. The C-type lectin SIGN-R1 mediates uptake of the capsular polysaccharide of Streptococcus pneumoniae in the marginal zone of mouse spleen. Proc Natl Acad Sci. (2004) 101:215–20. doi: 10.1073/pnas.0307124101, PMID: 14694198 154 Takagi

Numazaki

Kajiwara

Abe

Ishii

Kato

. Cooperation of specific ICAM-3 grabbing nonintegrin-related 1 (SIGNR1) and complement receptor type 3 (CR3) in the uptake of oligomannose-coated liposomes by macrophages. Glycobiology. (2009) 19:258–66. doi: 10.1093/glycob/cwn128, PMID: 19029201 155 Kawauchi

Igarashi

Kojima

. C-type lectin receptor SIGNR1 expressed on peritoneal phagocytic cells with an immature dendritic cell-like phenotype is involved in uptake of oligomannose-coated liposomes and subsequent cell maturation. Cell Immunol. (2014) 287:121–8. doi: 10.1016/j.cellimm.2014.01.004, PMID: 24491912 156 Park

Choi

Prabagar

Choi

Kim

Cheong

. The C-type lectin CD209b is expressed on microglia and it mediates the uptake of capsular polysaccharides of Streptococcus pneumoniae. Neurosci Lett. (2009) 450:246–51. doi: 10.1016/j.neulet.2008.11.070, PMID: 19095040 157 Kang

Y-S

Lee

H-K

Park

Cheong

Lynch

. A dominant complement fixation pathway for pneumococcal polysaccharides initiated by SIGN-R1 interacting with C1q. Cell. (2006) 125:47–58. doi: 10.1016/j.cell.2006.01.046, PMID: 16615889 158 Geijtenbeek

Groot

Nolte

van Vliet

Gangaram-Panday

van Duijnhoven

. Marginal zone macrophages express a murine homologue of DC-SIGN that captures blood-borne antigens. vivo. Blood. (2002) 100:2908–16. doi: 10.1182/blood-2002-04-1044, PMID: 12351402 159 Roozendaal

Carroll

. Emerging patterns in complement-mediated pathogen recognition. Cell. (2006) 125:29–32. doi: 10.1016/j.cell.2006.03.018, PMID: 16615887 160 Silva-Martín

Bartual

Ramírez-Aportela

Chacón

Park

Hermoso

. Structural basis for selective recognition of endogenous and microbial polysaccharides by macrophage receptor SIGN-R1. Structure. (2014) 22:1595–606. doi: 10.1016/j.str.2014.09.001, PMID: 25450767 161 Prabagar

Ryu

Park

Choi

. SIGN-R1, a C-type lectin, enhances apoptotic cell clearance through the complement deposition pathway by interacting with C1q in the spleen. Cell Death Differentiation. (2013) 20:535–45. doi: 10.1038/cdd.2012.160, PMID: 23238564 162 Park

Loh

Cho

Choi

Nemeno

. SIGN-R1 and complement factors are involved in the systemic clearance of radiation-induced apoptotic cells in whole-body irradiated mice. Biochem Biophys Res Commun. (2015) 463:1064–70. doi: 10.1016/j.bbrc.2015.06.059, PMID: 26079881 163 Pirgova

Chauveau

MacLean

Cyster

Arnon

. Marginal zone SIGN-R1⁺ macrophages are essential for the maturation of germinal center B cells in the spleen. Proc Natl Acad Sci. (2020) 117:12295–305. doi: 10.1073/pnas.1921673117, PMID: 32424104 164 Koppel

Litjens

van den Berg

van Kooyk

Geijtenbeek

. Interaction of SIGNR1 expressed by marginal zone macrophages with marginal zone B cells is essential to early IgM responses against Streptococcus pneumoniae. Mol Immunol. (2008) 45:2881–7. doi: 10.1016/j.molimm.2008.01.032, PMID: 18343501 165 Figueroa

Densen

. Infectious diseases associated with complement deficiencies. Clin Microbiol Rev. (1991) 4:359–95. doi: 10.1128/CMR.4.3.359, PMID: 1889047 166 Ross

. Introduction and history of complement research. In: Ross

, editor. Immunobiology of the Complement System. USA: Academic Press (1986). p. pp 1–19. 167 Markiewski

Nilsson

Nilsson Ekdahl

Mollnes

Lambris

. Complement and coagulation: strangers or partners in crime? Trends Immunol. (2007) 28:184–92. doi: 10.1016/j.it.2007.02.006, PMID: 17336159 168 Maison

Villiers

Colomb

. Proteolysis of C3 on U937 cell plasma membranes. Purification cathepsin G. J Immunol. (1991) 147:921–6. doi: 10.4049/jimmunol.147.3.921 169 Matsuda

Nagasawa

Koide

Koyama

. Limited proteolysis of a chemically modified third component of human complement, C3, by cathepsin G of human leukocytes. J Biochem. (1985) 98:229–36. doi: 10.1093/oxfordjournals.jbchem.a135262, PMID: 4044552 170 Liszewski

Kolev

Le Friec

Leung

Bertram

Fara

. Intracellular complement activation sustains T cell homeostasis and mediates effector differentiation. Immunity. (2013) 39:1143–57. doi: 10.1016/j.immuni.2013.10.018, PMID: 24315997 171 Lajoie

Wills-Karp

. New twist on an ancient innate immune pathway. Immunity. (2013) 39:1000–2. doi: 10.1016/j.immuni.2013.11.015, PMID: 24332028 172 Ye

Yuan

Dai

Sun

Tan

. The mTORC1 signaling modulated by intracellular C3 activation in Paneth cells promotes intestinal epithelial regeneration during acute injury. Int Immunopharmacol. (2019) 67:54–61. doi: 10.1016/j.intimp.2018.12.002, PMID: 30530169 173 Lueschow

McElroy

. The paneth cell: the curator and defender of the immature small intestine. Front Immunol. (2020) 11:587. doi: 10.3389/fimmu.2020.00587, PMID: 32308658 174 Ouellette

. Paneth cell alpha-defensins: peptide mediators of innate immunity in the small intestine. Springer Semin Immunopathol. (2005) 27:133–46. doi: 10.1007/s00281-005-0202-x, PMID: 15931529 175 Kremlitzka

Colineau

Nowacka

Mohlin

Wozniak

Blom

. Alternative translation and retrotranslocation of cytosolic C3 that detects cytoinvasive bacteria. Cell Mol Life Sci. (2022) 79:291. doi: 10.1007/s00018-022-04308-z, PMID: 35546365 176 Kulak

Kuska

Colineau

McKay

Maziarz

Slaby

. Intracellular C3 protects β-cells from IL-1β-driven cytotoxicity via interaction with Fyn-related kinase. Proc Natl Acad Sci U.S.A. (2024) 121:e2312621121. doi: 10.1073/pnas.2312621121, PMID: 38346191 177 Welsh

Welsh

Ekman

Dixelius

Hägerkvist

Annerén

. The tyrosine kinase FRK/RAK participates in cytokine-induced islet cell cytotoxicity. Biochem J. (2004) 382:261–8. doi: 10.1042/BJ20040285, PMID: 15186217 178 Dos Santos

Marroqui

Grieco

Marselli

Suleiman

Henz

. Protective role of complement C3 against cytokine-mediated β-cell apoptosis. Endocrinology. (2017) 158:2503–21. doi: 10.1210/en.2017-00104, PMID: 28582497 179 Xu

Zhou

Liu

Scott

Yang

Wan

. Complement in breast milk modifies offspring gut microbiota to promote infant health. Cell. (2024) 187:750–763.e720. doi: 10.1016/j.cell.2023.12.019, PMID: 38242132 180 Papatriantafyllou

. Complement in maternal milk shapes the infant microbiome. Nat Rev Immunol. (2024) 24:159–9. doi: 10.1038/s41577-024-01006-8, PMID: 38351196 181 Martin

Bock

Arseniev

Tornetta

Ames

Bautsch

. The human C3a receptor is expressed on neutrophils and monocytes, but not on B or T lymphocytes. J Exp Med. (1997) 186:199–207. doi: 10.1084/jem.186.2.199, PMID: 9221749 182 Zwirner

Götze

Begemann

Kapp

Kirchhoff

Werfel

. Evaluation of C3a receptor expression on human leucocytes by the use of novel monoclonal antibodies. Immunology. (1999) 97:166–72. doi: 10.1046/j.1365-2567.1999.00764.x, PMID: 10447728 183 Laumonnier

Karsten

Köhl

. Novel insights into the expression pattern of anaphylatoxin receptors in mice and men. Mol Immunol. (2017) 89:44–58. doi: 10.1016/j.molimm.2017.05.019, PMID: 28600003 184 Tschernig

Kiafard

Dibbert

Neumann

Zwirner

. Use of monoclonal antibodies to assess expression of anaphylatoxin receptors in rat and murine models of lung inflammation. Exp Toxicologic Pathol. (2007) 58:419–25. doi: 10.1016/j.etp.2007.03.004, PMID: 17544263 185 Asgari

Le Friec

Yamamoto

Perucha

Sacks

Köhl

. C3a modulates IL-1β secretion in human monocytes by regulating ATP efflux and subsequent NLRP3 inflammasome activation. Blood. (2013) 122:3473–81. doi: 10.1182/blood-2013-05-502229, PMID: 23878142 186 Mogilenko

Danko

Larionova

Shavva

Kudriavtsev

Nekrasova

. Differentiation of human macrophages with anaphylatoxin C3a impairs alternative M2 polarization and decreases lipopolysaccharide-induced cytokine secretion. Immunol Cell Biol. (2022) 100:186–204. doi: 10.1111/imcb.12534, PMID: 35148436 187 Wei

L-L

K-Y

Wang

J-X

Diao

T-Y

Zhao

S-J

. Protective role of C3aR (C3a anaphylatoxin receptor) against atherosclerosis in atherosclerosis-prone mice. Arteriosclerosis Thrombosis Vasc Biol. (2020) 40:2070–83. doi: 10.1161/ATVBAHA.120.314150, PMID: 32762445 188 Quell

Karsten

Kordowski

Almeida

Briukhovetska

Wiese

. Monitoring C3aR expression using a floxed tdTomato-C3aR reporter knock-in mouse. J Immunol. (2017) 199:688–706. doi: 10.4049/jimmunol.1700318, PMID: 28626064 189 Guglietta

Chiavelli

Zagato

Krieg

Gandini

Ravenda

. Coagulation induced by C3aR-dependent NETosis drives protumorigenic neutrophils during small intestinal tumorigenesis. Nat Commun. (2016) 7:11037. doi: 10.1038/ncomms11037, PMID: 26996437 190 Gasque

Singhrao

Neal

Wang

Sayah

Fontaine

. The receptor for complement anaphylatoxin C3a is expressed by myeloid cells and nonmyeloid cells in inflamed human central nervous system: analysis in multiple sclerosis and bacterial meningitis. J Immunol. (1998) 160:3543–54. doi: 10.4049/jimmunol.160.7.3543, PMID: 9531317 191 Corcoran

Napier

. C3aR plays both sides in regulating resistance to bacterial infections. PLoS Pathog. (2022) 18:e1010657. doi: 10.1371/journal.ppat.1010657, PMID: 35925892 192 Brennan

Jogia

Gillespie

Blomster

Nowlan

. Complement receptor C3aR1 controls neutrophil mobilization following spinal cord injury through physiological antagonism of CXCR2. JCI Insight. (2019) 4. doi: 10.1172/jci.insight.98254, PMID: 31045582 193 Wu

MCL

Brennan

Lynch

JPL

Mantovani

Phipps

Wetsel

. The receptor for complement component C3a mediates protection from intestinal ischemia-reperfusion injuries by inhibiting neutrophil mobilization. Proc Natl Acad Sci. (2013) 110:9439–44. doi: 10.1073/pnas.1218815110, PMID: 23696668 194 Kirchhoff

Weinmann

Zwirner

Begemann

Götze

Kapp

. Detection of anaphylatoxin receptors on CD83+ dendritic cells derived from human skin. Immunology. (2001) 103:210–7. doi: 10.1046/j.1365-2567.2001.01197.x, PMID: 11412308 195 Li

Fazekasova

Wang

Sagoo

Peng

Khamri

. Expression of complement components, receptors and regulators by human dendritic cells. Mol Immunol. (2011) 48:1121–7. doi: 10.1016/j.molimm.2011.02.003, PMID: 21397947 196 Peng

Anderson

Farrar

Smith

RAG

. Local production and activation of complement up-regulates the allostimulatory function of dendritic cells through C3a–C3aR interaction. Blood. (2008) 111:2452–61. doi: 10.1182/blood-2007-06-095018, PMID: 18056835 197 Li

Anderson

Peng

Noble

Kelly

. Cyclic AMP plays a critical role in C3a-receptor–mediated regulation of dendritic cells in antigen uptake and T-cell stimulation. Blood. (2008) 112:5084–94. doi: 10.1182/blood-2008-05-156646, PMID: 18812470 198 Gutzmer

Lisewski

Zwirner

Mommert

Diesel

Wittmann

. Human monocyte-derived dendritic cells are chemoattracted to C3a after up-regulation of the C3a receptor with interferons. Immunology. (2004) 111:435–43. doi: 10.1111/j.1365-2567.2004.01829.x, PMID: 15056381 199 Petering

Köhl

Weyergraf

Dulkys

Kimmig

Smolarski

. Characterization of synthetic C3a analog peptides on human eosinophils in comparison to the native complement component C3a1. J Immunol. (2000) 164:3783–9. doi: 10.4049/jimmunol.164.7.3783, PMID: 10725738 200 Takafuji

Tadokoro

Ito

Dahinden

. Degranulation from human eosinophils stimulated with C3a and C5a. Int Arch Allergy Immunol. (1994) 104 Suppl 1:27–9. doi: 10.1159/000236743, PMID: 8156000 201 Daffern

Pfeifer

Ember

Hugli

. C3a is a chemotaxin for human eosinophils but not for neutrophils. I. C3a stimulation of neutrophils is secondary to eosinophil activation. J Exp Med. (1995) 181:2119–27. doi: 10.1084/jem.181.6.2119, PMID: 7760001 202 Elsner

Oppermann

Czech

Dobos

Schöpf

Norgauer

. C3a activates reactive oxygen radical species production and intracellular calcium transients in human eosinophils. Eur J Immunol. (1994) 24:518–22. doi: 10.1002/eji.1830240304, PMID: 8125125 203 Dahinden

Bischoff

Brunner

Krieger

Takafuji

de Weck

. Regulation of mediator release by human basophils: importance of the sequence and time of addition in the combined action of different agonists. Int Arch Allergy Appl Immunol. (1991) 94:161–4. doi: 10.1159/000235350, PMID: 1718886 204 Kretzschmar

Jeromin

Gietz

Bautsch

Klos

Köhl

. Chronic myelogenous leukemia-derived basophilic granulocytes express a functional active receptor for the anaphylatoxin C3a. Eur J Immunol. (1993) 23:558–61. doi: 10.1002/eji.1830230239, PMID: 7679650 205 Ali

. Regulation of human mast cell and basophil function by anaphylatoxins C3a and C5a. Immunol Lett. (2010) 128:36–45. doi: 10.1016/j.imlet.2009.10.007, PMID: 19895849 206 Soruri

Grigat

Kiafard

Zwirner

. Mast cell activation is characterized by upregulation of a functional anaphylatoxin C5a receptor. BMC Immunol. (2008) 9:29. doi: 10.1186/1471-2172-9-29, PMID: 18559098 207 Guo

Subramanian

Gupta

Ali

. Regulation of C3a receptor signaling in human mast cells by G protein coupled receptor kinases. PLoS One. (2011) 6:e22559. doi: 10.1371/journal.pone.0022559, PMID: 21799898 208 Elieh Ali Komi

Shafaghat

Kovanen

Meri

. Mast cells and complement system: Ancient interactions between components of innate immunity. Allergy. (2020) 75:2818–28. doi: 10.1111/all.14413, PMID: 32446274 209 Lohman

R-J

Hamidon

Reid

Rowley

Yau

M-K

Halili

. Exploiting a novel conformational switch to control innate immunity mediated by complement protein C3a. Nat Commun. (2017) 8:351. doi: 10.1038/s41467-017-00414-w, PMID: 28839129 210 Sauter

Sauter

Reis

Emschermann

Nording

Ebenhöch

. Functional relevance of the anaphylatoxin receptor C3aR for platelet function and arterial thrombus formation marks an intersection point between innate immunity and thrombosis. Circulation. (2018) 138:1720–35. doi: 10.1161/CIRCULATIONAHA.118.034600, PMID: 29802205 211 Patzelt

Mueller

KAL

Breuning

Karathanos

Schleicher

Seizer

. Expression of anaphylatoxin receptors on platelets in patients with coronary heart disease. Atherosclerosis. (2015) 238:289–95. doi: 10.1016/j.atherosclerosis.2014.12.002, PMID: 25544179 212 Polley

Nachman

. Human platelet activation by C3a and C3a des-arg. J Exp Med. (1983) 158:603–15. doi: 10.1084/jem.158.2.603, PMID: 6604123 213 Min

Liu

Wei

Wang

Yuan

Liu

. Expression and regulation of complement receptors by human natural killer cells. Immunobiology. (2014) 219:671–9. doi: 10.1016/j.imbio.2014.03.018, PMID: 24775270 214 Nandagopal

Sodji

Graves

Giaccia

. C3aR signaling inhibits NK-cell infiltration into the tumor microenvironment in mouse models. Cancer Immunol Res. (2022) 10:245–58. doi: 10.1158/2326-6066.CIR-21-0435, PMID: 34819308 215 Sodji

Nambiar

Viswanathan

von Eyben

Colburg

Binkley

. The combination of radiotherapy and complement C3a inhibition potentiates natural killer cell functions against pancreatic cancer. Cancer Res Commun. (2022) 2:725–38. doi: 10.1158/2767-9764.CRC-22-0069, PMID: 35937458 216 Strainic

Liu

Huang

Lalli

Muqim

. Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+ T cells. Immunity. (2008) 28:425–35. doi: 10.1016/j.immuni.2008.02.001, PMID: 18328742 217 Ghannam

Fauquert

J-L

Thomas

Kemper

Drouet

. Human complement C3 deficiency: Th1 induction requires T cell-derived complement C3a and CD46 activation. Mol Immunol. (2014) 58:98–107. doi: 10.1016/j.molimm.2013.11.010, PMID: 24321396 218 Werfel

Kirchhoff

Wittmann

Begemann

Kapp

Heidenreich

. Activated human T lymphocytes express a functional C3a receptor1. J Immunol. (2000) 165:6599–605. doi: 10.4049/jimmunol.165.11.6599, PMID: 11086104 219 Kwan

van der Touw

Paz-Artal

Heeger

. Signaling through C5a receptor and C3a receptor diminishes function of murine natural regulatory T cells. J Exp Med. (2013) 210:257–68. doi: 10.1084/jem.20121525, PMID: 23382542 220 Hess

Kemper

. Complement-mediated regulation of metabolism and basic cellular processes. Immunity. (2016) 45:240–54. doi: 10.1016/j.immuni.2016.08.003, PMID: 27533012 221 Nataf

Stahel

Davoust

Barnum

. Complement anaphylatoxin receptors on neurons: new tricks for old receptors? Trends Neurosci. (1999) 22:397–402. doi: 10.1016/s0166-2236(98)01390-3, PMID: 10441300 222 Davoust

Jones

Stahel

Ames

Barnum

. Receptor for the C3a anaphylatoxin is expressed by neurons and glial cells. Glia. (1999) 26:201–11. doi: 10.1002/(SICI)1098-1136(199905)26:3<201::AID-GLIA2>3.0.CO;2-M, PMID: 10340761 223 Ischenko

Sayah

Patte

Andreev

Gasque

Schouft

. Expression of a functional anaphylatoxin C3a receptor by astrocytes. J Neurochem. (1998) 71:2487–96. doi: 10.1046/j.1471-4159.1998.71062487.x, PMID: 9832147 224 Gedam

Zheng

. Complement C3aR signaling: Immune and metabolic modulation and its impact on Alzheimer’s disease. Eur J Immunol. (2024) 54:2350815. doi: 10.1002/eji.202350815, PMID: 38778507 225 Schraufstatter

Trieu

Sikora

Sriramarao

DiScipio

. Complement C3a and C5a induce different signal transduction cascades in endothelial cells1. J Immunol. (2002) 169:2102–10. doi: 10.4049/jimmunol.169.4.2102, PMID: 12165538 226 Sartain

Turner

Moake

. Brain microvascular endothelial cells exhibit lower activation of the alternative complement pathway than glomerular microvascular endothelial cells. J Biol Chem. (2018) 293:7195–208. doi: 10.1074/jbc.RA118.002639, PMID: 29555686 227 Shivshankar

Y-D

Mueller-Ortiz

Wetsel

. In response to complement anaphylatoxin peptides C3a and C5a, human vascular endothelial cells migrate and mediate the activation of B-cells and polarization of T-cells. FASEB J. (2020) 34:7540–60. doi: 10.1096/fj.201902397R, PMID: 32301538 228 Propson

Roy

Litvinchuk

Köhl

Zheng

. Endothelial C3a receptor mediates vascular inflammation and blood-brain barrier permeability during aging. J Clin Invest. (2021) 131. doi: 10.1172/JCI140966, PMID: 32990682 229 Wolf

Guempelein

Schikora

Pauly

. C3a Mediates Endothelial Barrier Disruption in Brain-Derived, but Not Retinal, Human Endothelial Cells. Int J Mol Sci. (2024) 25. doi: 10.3390/ijms252011240, PMID: 39457022 230 You

Nie

Weng

Yang

Chen

. C3a/C3aR synergies with TGF-β to promote epithelial-mesenchymal transition of renal tubular epithelial cells via the activation of the NLRP3 inflammasome. J Transl Med. (2023) 21:904. doi: 10.1186/s12967-023-04764-6, PMID: 38082306 231 Ishii

Beeson

Rohrer

. Mitochondrial C3a receptor activation in oxidatively stressed epithelial cells reduces mitochondrial respiration and metabolism. Front Immunol. (2021) 12:628062. doi: 10.3389/fimmu.2021.628062, PMID: 33746964 232 Schraufstatter

Khaldoyanidi

DiScipio

. Complement activation in the context of stem cells and tissue repair. World J Stem Cells. (2015) 7:1090–108. doi: 10.4252/wjsc.v7.i8.1090, PMID: 26435769 233 Robinson

Quast

Tarlinton

. Complement-in’ the germinal center response. Nat Immunol. (2021) 22:673–4. doi: 10.1038/s41590-021-00946-w, PMID: 34031616 234 Cumpelik

Heja

Varano

Ordikhani

Roberto

. Dynamic regulation of B cell complement signaling is integral to germinal center responses. Nat Immunol. (2021) 22:757–68. doi: 10.1038/s41590-021-00926-0, PMID: 34031614 235 Schanzenbacher

Hendrika Kähler

Mesler

Kleingarn

Marcel Karsten

Leonard Seiler

. The role of C5a receptors in autoimmunity. Immunobiology. (2023) 228:152413. doi: 10.1016/j.imbio.2023.152413, PMID: 37598588 236 Zhang

G-Q

Q-H

Tang

Zheng

Q-Y

. C5a/C5aR pathway accelerates renal ischemia-reperfusion injury by downregulating PGRN expression. Int Immunopharmacol. (2017) 53:17–23. doi: 10.1016/j.intimp.2017.10.006, PMID: 29031143 237 Gao

Yan

. New insights for C5a and C5a receptors in sepsis. Front Immunol. (2012) 3. doi: 10.3389/fimmu.2012.00368, PMID: 23233853 238 Riedemann

Guo

Ward

. A key role of C5a/C5aR activation for the development of sepsis. J Leukoc Biol. (2003) 74:966–70. doi: 10.1189/jlb.0403137, PMID: 12960283 239 Ward

. The dark side of C5a in sepsis. Nat Rev Immunol. (2004) 4:133–42. doi: 10.1038/nri1269, PMID: 15040586 240 Li

Coulthard

Taylor

Woodruff

. C5L2: a controversial receptor of complement anaphylatoxin, C5a. FASEB J. (2013) 27:855–64. doi: 10.1096/fj.12-220509, PMID: 23239822 241 Scola

Johswich

Morgan

Klos

Monk

. The human complement fragment receptor, C5L2, is a recycling decoy receptor. Mol Immunol. (2009) 46:1149–62. doi: 10.1016/j.molimm.2008.11.001, PMID: 19100624 242 Cui

Simaan

Laporte

Lodge

Cianflone

. C5a- and ASP-mediated C5L2 activation, endocytosis and recycling are lost in S323I-C5L2 mutation. Mol Immunol. (2009) 46:3086–98. doi: 10.1016/j.molimm.2009.06.007, PMID: 19615750 243 Tom

Gauvreau

Lapointe

Poursharifi

Luo

. Differential chemoattractant response in adipocytes and macrophages to the action of acylation stimulating protein. Eur J Cell Biol. (2013) 92:61–9. doi: 10.1016/j.ejcb.2012.10.005, PMID: 23245988 244 Poursharifi

Lapointe

Fisette

Roy

Munkonda

. C5aR and C5L2 act in concert to balance immunometabolism in adipose tissue. Mol Cell Endocrinol. (2014) 382:325–33. doi: 10.1016/j.mce.2013.10.019, PMID: 24397921 245 Cui

Lapointe

Gauvreau

Kalant

Cianflone

. Recombinant C3adesArg/acylation stimulating protein (ASP) is highly bioactive: a critical evaluation of C5L2 binding and 3T3-L1 adipocyte activation. Mol Immunol. (2009) 46:3207–17. doi: 10.1016/j.molimm.2009.08.013, PMID: 19767107 246 Qu

Jin

Xie

. A novel mutation in C5L2 gene was associated with hyperlipidemia and retinitis pigmentosa in a Chinese family. Lipids Health Dis. (2014) 13:75. doi: 10.1186/1476-511X-13-75, PMID: 24885523 247 Cain

Monk

. The orphan receptor C5L2 has high affinity binding sites for complement fragments C5a and C5a des-arg⁷⁴*. J Biol Chem. (2002) 277:7165–9. doi: 10.1074/jbc.C100714200, PMID: 11773063 248 Ohno

Hirata

Enomoto

Araki

Ishimaru

Takahashi

. A putative chemoattractant receptor, C5L2, is expressed in granulocyte and immature dendritic cells, but not in mature dendritic cells. Mol Immunol. (2000) 37:407–12. doi: 10.1016/S0161-5890(00)00067-5, PMID: 11090875 249 Lee

George

Cheng

Nguyen

Liu

Brown

. Identification of four novel human G protein-coupled receptors expressed in the brain. Brain Res Mol Brain Res. (2001) 86:13–22. doi: 10.1016/S0169-328X(00)00242-4, PMID: 11165367 250 Gao

Neff

Guo

Speyer

Sarma

Tomlins

. Evidence for a functional role of the second C5a receptor C5L2. FASEB J. (2005) 19:1003–5. doi: 10.1096/fj.04-3424fje, PMID: 15784721 251 Chen

Mirtsos

Suh

Lin

McKerlie

. C5L2 is critical for the biological activities of the anaphylatoxins C5a and C3a. Nature. (2007) 446:203–7. doi: 10.1038/nature05559, PMID: 17322907 252 Kalant

MacLaren

Cui

Samanta

Monk

Laporte

. C5L2 is a functional receptor for acylation-stimulating protein. J Biol Chem. (2005) 280:23936–44. doi: 10.1074/jbc.M406921200, PMID: 15833747 253 Lee

Whitfeld

Mackay

. Receptors for complement C5a. The importance of C5aR and the enigmatic role of C5L2. Immunol Cell Biol. (2008) 86:153–60. doi: 10.1038/sj.icb.7100166, PMID: 18227853 254 Karsten

Wiese

Mey

Figge

Woodruff

Reuter

. Monitoring C5aR2 expression using a floxed tdTomato-C5aR2 knock-in mouse. J Immunol. (2017) 199:3234–48. doi: 10.4049/jimmunol.1700710, PMID: 28864475 255 Karsten

Laumonnier

Eurich

Ender

Bröker

Roy

. Monitoring and cell-specific deletion of C5aR1 using a novel floxed GFP-C5aR1 reporter knock-in mouse. J Immunol. (2015) 194:1841–55. doi: 10.4049/jimmunol.1401401, PMID: 25589074 256 Seiler

Kähler

Kleingarn

Sadik

Bieber

Köhl

. The complement receptor C5aR2 regulates neutrophil activation and function contributing to neutrophil-driven epidermolysis bullosa acquisita. Front Immunol. (2023) 14:1197709. doi: 10.3389/fimmu.2023.1197709, PMID: 37275893 257 Zaal

van Ham

Ten Brinke

. Differential effects of anaphylatoxin C5a on antigen presenting cells, roles for C5aR1 and C5aR2. Immunol Lett. (2019) 209:45–52. doi: 10.1016/j.imlet.2019.03.014, PMID: 30959077 258 Zaal

Dieker

Oudenampsen

Turksma

Lissenberg-Thunnissen

Wouters

. Anaphylatoxin C5a regulates 6-sulfo-lacNAc dendritic cell function in human through crosstalk with toll-like receptor-induced CREB signaling. Front Immunol. (2017) 8. doi: 10.3389/fimmu.2017.00818, PMID: 28769928 259 Gerard

Hodges

Drazen

Weller

Gerard

. Characterization of a receptor for C5a anaphylatoxin on human eosinophils. J Biol Chem. (1989) 264:1760–6. doi: 10.1016/S0021-9258(18)94252-3 260 DiScipio

Daffern

Jagels

Broide

Sriramarao

. A comparison of C3a and C5a-mediated stable adhesion of rolling eosinophils in postcapillary venules and transendothelial migration in vitro and in vivo1. J Immunol. (1999) 162:1127–36. doi: 10.4049/jimmunol.162.2.1127, PMID: 9916743 261 Elsner

Oppermann

Kapp

. Detection of C5a receptors on human eosinophils and inhibition of eosinophil effector functions by anti-C5a receptor (CD88) antibodies. Eur J Immunol. (1996) 26:1560–4. doi: 10.1002/eji.1830260723, PMID: 8766561 262 Bamberg

Mackay

Lee

Zahra

Jackson

Lim

. The C5a receptor (C5aR) C5L2 is a modulator of C5aR-mediated signal transduction*. J Biol Chem. (2010) 285:7633–44. doi: 10.1074/jbc.M109.092106, PMID: 20044484 263 Zhang

Schmudde

Laumonnier

Pandey

Clark

König

. A critical role for C5L2 in the pathogenesis of experimental allergic asthma. J Immunol. (2010) 185:6741–52. doi: 10.4049/jimmunol.1000892, PMID: 20974988 264 Füreder

Agis

Willheim

Bankl

Maier

Kishi

. Differential expression of complement receptors on human basophils and mast cells. Evidence for mast cell heterogeneity and CD88/C5aR expression on skin mast cells. J Immunol. (1995) 155:3152–60. doi: 10.4049/jimmunol.155.6.3152, PMID: 7673728 265 Schulman

Post

Henson

Giclas

. Differential effects of the complement peptides, C5a and C5a des Arg on human basophil and lung mast cell histamine release. J Clin Invest. (1988) 81:918–23. doi: 10.1172/JCI113403, PMID: 2449462 266 Eglite

Plüss

Dahinden

. Requirements for C5a receptor-mediated IL-4 and IL-13 production and leukotriene C4 generation in human basophils. J Immunol. (2000) 165:2183–9. doi: 10.4049/jimmunol.165.4.2183, PMID: 10925305 267 Nilsson

Johnell

Hammer

Tiffany

Nilsson

Metcalfe

. C3a and C5a are chemotaxins for human mast cells and act through distinct receptors via a pertussis toxin-sensitive signal transduction pathway. J Immunol. (1996) 157:1693–8. doi: 10.4049/jimmunol.157.4.1693, PMID: 8759757 268 Hartmann

Henz

Krüger-Krasagakes

Köhl

Burger

Guhl

. C3a and C5a stimulate chemotaxis of human mast cells. Blood. (1997) 89:2863–70. doi: 10.1182/blood.V89.8.2863, PMID: 9108406 269 el-Lati

Dahinden

Church

. Complement peptides C3a- and C5a-induced mediator release from dissociated human skin mast cells. J Invest Dermatol. (1994) 102:803–6. doi: 10.1111/1523-1747.ep12378589, PMID: 7513741 270 Pundir

MacDonald

Kulka

. The novel receptor C5aR2 is required for C5a-mediated human mast cell adhesion, migration, and proinflammatory mediator production. J Immunol. (2015) 195:2774–87. doi: 10.4049/jimmunol.1401348, PMID: 26283482 271 Pundir

Kulka

. The seven-transmembrane receptor, C5L2, is a stimulatory receptor on human mast cells. Allergy Asthma Clin Immunol. (2010) 6:P25. doi: 10.1186/1710-1492-6-S2-P25 272 Pundir

Kulka

. Functional expression of the novel C5a receptor C5L2 in human mast cells. J Allergy Clin Immunol. (2013) 131:AB239. 273 Nording

Baron

Haberthür

Emschermann

Mezger

Sauter

. The C5a/C5a receptor 1 axis controls tissue neovascularization through CXCL4 release from platelets. Nat Commun. (2021) 12:3352. doi: 10.1038/s41467-021-23499-w, PMID: 34099640 274 Meuer

Ecker

Hadding

Bitter-Suermann

. Platelet-serotonin release by C3a and C5a: two independent pathways of activation. J Immunol. (1981) 126:1506–9. doi: 10.4049/jimmunol.126.4.1506, PMID: 7204973 275 Matsumoto

Yasuoka

Yoshimoto

Suzuki

Takeuchi

. Platelet CXCL4 mediates neutrophil extracellular traps formation in ANCA-associated vasculitis. Sci Rep. (2021) 11:222. doi: 10.1038/s41598-020-80685-4, PMID: 33420306 276 Apostolidis

Sarkar

Giannini

Goel

Mathew

Suzuki

. Signaling through fcγRIIA and the C5a-C5aR pathway mediate platelet hyperactivation in COVID-19. Front Immunol. (2022) 13:834988. doi: 10.3389/fimmu.2022.834988, PMID: 35309299 277 Aiello

Gastoldi

Galbusera

Ruggenenti

Portalupi

Rota

. C5a and C5aR1 are key drivers of microvascular platelet aggregation in clinical entities spanning from aHUS to COVID-19. Blood Adv. (2022) 6:866–81. doi: 10.1182/bloodadvances.2021005246, PMID: 34852172 278 Boeckel

Karsten

Göpel

Herting

Rupp

Härtel

. Increased expression of anaphylatoxin C5a-receptor-1 in neutrophils and natural killer cells of preterm infants. Int J Mol Sci. (2023) 24. doi: 10.3390/ijms241210321, PMID: 37373467 279 Fusakio

Mohammed

Laumonnier

Hoebe

Köhl

Mattner

. C5a regulates NKT and NK cell functions in sepsis. J Immunol. (2011) 187:5805–12. doi: 10.4049/jimmunol.1100338, PMID: 22058413 280 Qing

Koo

Salmon

. Complement regulates conventional DC-mediated NK-cell activation by inducing TGF-β1 in Gr-1+ myeloid cells. Eur J Immunol. (2012) 42:1723–34. doi: 10.1002/eji.201142290, PMID: 22535677 281 Han

Geng

Chen

Wang

. γδT-cell function in sepsis is modulated by C5a receptor signalling. Immunology. (2011) 133:340–9. doi: 10.1111/j.1365-2567.2011.03445.x, PMID: 21501163 282 Zheng

Yang

Sun

Zhong

. C5a/C5aR1 mediates IMQ-induced psoriasiform skin inflammation by promoting IL-17A production from γδ-T cells. FASEB J. (2020) 34:10590–604. doi: 10.1096/fj.202000384R, PMID: 32557852 283 Lalli

Strainic

Yang

Lin

Medof

Heeger

. Locally produced C5a binds to T cell-expressed C5aR to enhance effector T-cell expansion by limiting antigen-induced apoptosis. Blood. (2008) 112:1759–66. doi: 10.1182/blood-2008-04-151068, PMID: 18567839 284 Nataf

Davoust

Ames

Barnum

. Human T cells express the C5a receptor and are chemoattracted to C5a. J Immunol. (1999) 162:4018–23. doi: 10.4049/jimmunol.162.7.4018, PMID: 10201923 285 Kim

AHJ

Dimitriou

Holland

MCH

Mastellos

Mueller

Altman

. Complement C5a receptor is essential for the optimal generation of antiviral CD8+ T cell responses1. J Immunol. (2004) 173:2524–9. doi: 10.4049/jimmunol.173.4.2524, PMID: 15294968 286 Luan

Lei

Fang

Liu

. Blockade of C5a receptor unleashes tumor-associated macrophage antitumor response and enhances CXCL9-dependent CD8+ T cell activity. Mol Ther. (2024) 32:469–89. doi: 10.1016/j.ymthe.2023.12.010, PMID: 38098230 287 Ager

Fonseca

Chu

Sanderson

Taylor

Woodruff

. Microglial C5aR (CD88) expression correlates with amyloid-beta deposition in murine models of Alzheimer’s disease. J Neurochem. (2010) 113:389–401. doi: 10.1111/j.1471-4159.2010.06595.x, PMID: 20132482 288 Griffin

Costigan

Brenner

Scholz

Moss

. Complement induction in spinal cord microglia results in anaphylatoxin C5a-mediated pain hypersensitivity. J Neurosci. (2007) 27:8699–708. doi: 10.1523/JNEUROSCI.2018-07.2007, PMID: 17687047 289 Pekna

Pekny

. The complement system: A powerful modulator and effector of astrocyte function in the healthy and diseased central nervous system. Cells. (2021) 10. doi: 10.3390/cells10071812, PMID: 34359981 290 Brennan

Gordon

Lao

Biggins

Taylor

Franklin

. The complement receptor C5aR controls acute inflammation and astrogliosis following spinal cord injury. J Neurosci. (2015) 35:6517–31. doi: 10.1523/JNEUROSCI.5218-14.2015, PMID: 25904802 291 Schartz

Liang

Carvalho

Chu

S-H

Mendoza-Arvilla

Petrisko

. C5aR1 antagonism suppresses inflammatory glial responses and alters cellular signaling in an Alzheimer’s disease mouse model. Nat Commun. (2024) 15:7028. doi: 10.1038/s41467-024-51163-6, PMID: 39147742 292 Biggins

PJC

Brennan

Taylor

Woodruff

Ruitenberg

. The alternative receptor for complement component 5a, C5aR2, conveys neuroprotection in traumatic spinal cord injury. J Neurotrauma. (2017) 34:2075–85. doi: 10.1089/neu.2016.4701, PMID: 28173736 293 Carvalho

Schartz

Balderrama-Gutierrez

Liang

Chu

Selvan

. Modulation of C5a-C5aR1 signaling alters the dynamics of AD progression. J Neuroinflamm. (2022) 19:178. doi: 10.1186/s12974-022-02539-2, PMID: 35820938 294 Laudes

Chu

Huber-Lang

Guo

Riedemann

Sarma

. Expression and function of C5a receptor in mouse microvascular endothelial cells. J Immunol. (2002) 169:5962–70. doi: 10.4049/jimmunol.169.10.5962, PMID: 12421982 295 Vijayan

Asare

Grommes

Soehnlein

Lutgens

Shagdarsuren

. High expression of C5L2 correlates with high proinflammatory cytokine expression in advanced human atherosclerotic plaques. Am J Pathol. (2014) 184:2123–33. doi: 10.1016/j.ajpath.2014.04.004, PMID: 24819959 296 Monk

Scola

Madala

Fairlie

. Function, structure and therapeutic potential of complement C5a receptors. Br J Pharmacol. (2007) 152:429–48. doi: 10.1038/sj.bjp.0707332, PMID: 17603557 297 Ding

Chen

. Intracellular complement C5a/C5aR1 stabilizes β-catenin to promote colorectal tumorigenesis. Cell Rep. (2022) 39:110851. doi: 10.1016/j.celrep.2022.110851, PMID: 35649359 298 Beach

MacLean

Majorova

Melemenidis

Nambiar

Kim

. Innate immune receptor C5aR1 regulates cancer cell fate and can be targeted to improve radiotherapy in tumours with immunosuppressive microenvironments. bioRxiv. (2023). doi: 10.1101/2023.01.10.521547 299 Ishii

Rohrer

. Anaphylatoxin C5a receptor signaling induces mitochondrial fusion and sensitizes retinal pigment epithelial cells to oxidative stress. Biochim Biophys Acta (BBA) - Gen Subj. (2023) 1867:130374. doi: 10.1016/j.bbagen.2023.130374, PMID: 37187450 300 Johswich

Martin

Thalmann

Rheinheimer

Monk

Klos

. Ligand specificity of the anaphylatoxin C5L2 receptor and its regulation on myeloid and epithelial cell lines. J Biol Chem. (2006) 281:39088–95. doi: 10.1074/jbc.M609734200, PMID: 17068344 301 Oglesby

Longwith

Huettner

. Human complement regulator expression by the normal female reproductive tract. Anat Rec. (1996) 246:78–86. doi: 10.1002/(SICI)1097-0185(199609)246:1<78::AID-AR9>3.0.CO;2-B, PMID: 8876826 302 Iborra

Mayorga

Llobet

Martínez

. Expression of complement regulatory proteins [membrane cofactor protein (CD46), decay accelerating factor (CD55), and protectin (CD59)] in endometrial stressed cells. Cell Immunol. (2003) 223:46–51. doi: 10.1016/S0008-8749(03)00127-8, PMID: 12914757 303 Fénichel

Cervoni

Donzeau

Hsi

. Expression and role of complement regulatory proteins on human gametes and pre-implantation embryos. Contracept Fertil Sex. (1995) 23:576–80., PMID: 7496432 304 Fenichel

Donzeau

Cervoni

Menezo

Hsi

. Expression of complement regulatory proteins on human eggs and preimplantation embryos. Am J Reprod Immunol. (1995) 33:155–64. doi: 10.1111/j.1600-0897.1995.tb00879.x, PMID: 7544131 305 Taylor

Johnson

. Complement-binding proteins are strongly expressed by human preimplantation blastocysts and cumulus cells as well as gametes. Mol Hum Reprod. (1996) 2:52–9. doi: 10.1093/molehr/2.1.52, PMID: 9238658 306 Reichhardt

Lundin

Lokki

Recher

Vuoristo

Katayama

. Complement in human pre-implantation embryos: attack and defense. Front Immunol. (2019) 10:2234. doi: 10.3389/fimmu.2019.02234, PMID: 31620138 307 Jiang

Pillai

. Complement regulatory proteins on the sperm surface: relevance to sperm motility. Am J Reprod Immunol. (1998) 39:243–8. doi: 10.1111/j.1600-0897.1998.tb00360.x, PMID: 9553648 308 Cervoni

Oglesby

Adams

Milesifluet

Nickells

Fenichel

. Identification and characterization of membrane cofactor protein of human spermatozoa. J Immunol. (1992) 148:1431–7. doi: 10.4049/jimmunol.148.5.1431, PMID: 1538128 309 Cummerson

Flanagan

Spiller

Johnson

. The complement regulatory proteins CD55 (decay accelerating factor) and CD59 are expressed on the inner acrosomal membrane of human spermatozoa as well as CD46 (membrane cofactor protein). Immunology. (2006) 118:333–42. doi: 10.1111/j.1365-2567.2006.02374.x, PMID: 16827894 310 D’Cruz

Haas

Jr . The expression of the complement regulators CD46, CD55, and CD59 by human sperm does not protect them from antisperm antibody- and complement-mediated immune injury. Fertil Steril. (1993) 59:876–84. doi: 10.1016/S0015-0282(16)55875-0, PMID: 7681414 311 Bronson

Bronson

Oula

Zhang

Ghebrehiwet

. Detection of complement C1q receptors on human spermatozoa. J Reprod Immunol. (1998) 38:1–14. doi: 10.1016/S0165-0378(98)00006-0, PMID: 9616874 312 Grace

Bronson

Ghebrehiwet

. Surface Expression of Complement Receptor gC1q-R/p33 Is Increased on the Plasma Membrane of Human Spermatozoa after Capacitation1. Biol Reprod. (2002) 66:823–9. doi: 10.1095/biolreprod66.3.823, PMID: 11870091 313 Anderson

Abbott

Jack

. The role of complement component C3b and its receptors in sperm-oocyte interaction. Proc Natl Acad Sci U.S.A. (1993) 90:10051–5. doi: 10.1073/pnas.90.21.10051, PMID: 8234255 314 Riley-Vargas

Lanzendorf

Atkinson

. Targeted and restricted complement activation on acrosome-reacted spermatozoa. J Clin Invest. (2005) 115:1241–9. doi: 10.1172/JCI23213, PMID: 15849610 315 Bulla

Bossi

Agostinis

Radillo

Colombo

De Seta

. Complement production by trophoblast cells at the feto-maternal interface. J Reprod Immunol. (2009) 82:119–25. doi: 10.1016/j.jri.2009.06.124, PMID: 19665237 316 Hanna

Wald

Goldman-Wohl

Prus

Markel

Gazit

. CXCL12 expression by invasive trophoblasts induces the specific migration of CD16- human natural killer cells. Blood. (2003) 102:1569–77. doi: 10.1182/blood-2003-02-0517, PMID: 12730110 317 Drake

Gunn

Charo

Tsou

Zhou

Huang

. Human placental cytotrophoblasts attract monocytes and CD56(bright) natural killer cells via the actions of monocyte inflammatory protein 1alpha. J Exp Med. (2001) 193:1199–212. doi: 10.1084/jem.193.10.1199, PMID: 11369791 318 Koopman

Kopcow

Rybalov

Boyson

Orange

Schatz

. Human decidual natural killer cells are a unique NK cell subset with immunomodulatory potential. J Exp Med. (2003) 198:1201–12. doi: 10.1084/jem.20030305, PMID: 14568979 319 Pijnenborg

Vercruysse

Hanssens

. The uterine spiral arteries in human pregnancy: facts and controversies. Placenta. (2006) 27:939–58. doi: 10.1016/j.placenta.2005.12.006, PMID: 16490251 320 Charriaut

Senik

Kolb

Barel

Frade

. Inhibition of in vitro natural killer activity by the third component of complement: role for the C3a fragment. Proc Natl Acad Sci U.S.A. (1982) 79:6003–7., PMID: 6985269 321 Wang

Veeramani

Racila

Cagley

Fritzinger

Vogel

. Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model. Blood. (2009) 114:5322–30. doi: 10.1182/blood-2009-01-200469, PMID: 19805620 322 Wang

Racila

Taylor

Weiner

. NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement. Blood. (2008) 111:1456–63. doi: 10.1182/blood-2007-02-074716, PMID: 18024795 323 Hanna

Goldman-Wohl

Hamani

Avraham

Greenfield

Natanson-Yaron

. Decidual NK cells regulate key developmental processes at the human fetal-maternal interface. Nat Med. (2006) 12:1065–74. doi: 10.1038/nm1452, PMID: 16892062 324 Karimi

Arck

. Natural Killer cells: keepers of pregnancy in the turnstile of the environment. Brain Behav Immun. (2010) 24:339–47. doi: 10.1016/j.bbi.2009.09.015, PMID: 19800965 325 Kopcow

Allan

Chen

Rybalov

Andzelm

. Human decidual NK cells form immature activating synapses and are not cytotoxic. Proc Natl Acad Sci U.S.A. (2005) 102:15563–8. doi: 10.1073/pnas.0507835102, PMID: 16230631 326 Agostinis

Bulla

Tripodo

Gismondi

Stabile

Bossi

. An alternative role of C1q in cell migration and tissue remodeling: contribution to trophoblast invasion and placental development. J Immunol. (2010) 185:4420–9. doi: 10.4049/jimmunol.0903215, PMID: 20810993 327 Agostinis

Mangogna

Balduit

Kishore

Bulla

. A non-redundant role of complement protein C1q in normal and adverse pregnancy. Explor Immunol. (2022) 2:622–36. doi: 10.37349/ei 328 E Davies

Pollheimer

Yong

Kokkinos

Kalionis

Knöfler

. Epithelial-mesenchymal transition during extravillous trophoblast differentiation. Cell Adh Migr. (2016) 10:310–21. doi: 10.1080/19336918.2016.1170258, PMID: 27070187 329 Tang

Hatch

Sacks

Sheerin

. C3a mediates epithelial-to-mesenchymal transition in proteinuric nephropathy. J Am Soc Nephrol. (2009) 20:593–603. doi: 10.1681/ASN.2008040434, PMID: 19158354 330 Otsuki

Fukuda

Chen

Tsunemi

Abe

. Twist-related protein 1 induces epithelial-mesenchymal transition and renal fibrosis through the upregulation of complement 3. PLoS One. (2022) 17:e0272917. doi: 10.1371/journal.pone.0272917, PMID: 36018840 331 Cho

Rupaimoole

Choi

H-J

Noh

Chen

. Complement component 3 is regulated by TWIST1 and mediates epithelial–mesenchymal transition. J Immunol. (2016) 196:1412–8. doi: 10.4049/jimmunol.1501886, PMID: 26718342 332 Soundararajan

Rao

. Trophoblast ‘pseudo-tumorigenesis’: significance and contributory factors. Reprod Biol Endocrinol. (2004) 2:15. doi: 10.1186/1477-7827-2-15, PMID: 15043753 333 Carvajal

Gutiérrez

Morselli

Leiva

. Autophagy process in trophoblast cells invasion and differentiation: similitude and differences with cancer cells. Front Oncol. (2021) 11. doi: 10.3389/fonc.2021.637594, PMID: 33937039 334 Ferretti

Bruni

Dangles-Marie

Pecking

Bellet

. Molecular circuits shared by placental and cancer cells, and their implications in the proliferative, invasive and migratory capacities of trophoblasts. Hum Reprod Update. (2006) 13:121–41. doi: 10.1093/humupd/dml048, PMID: 17068222 335 Richani

Soto

Romero

Espinoza

Chaiworapongsa

Nien

. Normal pregnancy is characterized by systemic activation of the complement system. J Matern Fetal Neonatal Med. (2005) 17:239–45. doi: 10.1080/14767050500072722, PMID: 16147832 336 Derzsy

Prohászka

Rigó

Jr. Füst

Molvarec

. Activation of the complement system in normal pregnancy and preeclampsia. Mol Immunol. (2010) 47:1500–6. doi: 10.1016/j.molimm.2010.01.021, PMID: 20181396 337 Abramson

Buyon

. Activation of the complement pathway: comparison of normal pregnancy, preeclampsia, and systemic lupus erythematosus during pregnancy. Am J Reprod Immunol. (1992) 28:183–7. doi: 10.1111/j.1600-0897.1992.tb00787.x, PMID: 1285875 338 Soto

Romero

Richani

Espinoza

Nien

Chaiworapongsa

. Anaphylatoxins in preterm and term labor. J Perinat Med. (2005) 33:306–13. doi: 10.1515/JPM.2005.051, PMID: 16207115 339 Lynch

Gibbs

Murphy

Giclas

Salmon

Holers

. Early elevations of the complement activation fragment C3a and adverse pregnancy outcomes. Obstet Gynecol. (2011) 117:75–83. doi: 10.1097/AOG.0b013e3181fc3afa, PMID: 21173647 340 He

Song

Wang

Chen

. Normal range of complement components during pregnancy: A prospective study. Am J Reprod Immunol. (2020) 83:e13202. doi: 10.1111/aji.13202, PMID: 31646704 341 Ramanjaneya

Diboun

Rizwana

Dajani

Ahmed

Butler

. Elevated adipsin and reduced C5a levels in the maternal serum and follicular fluid during implantation are associated with successful pregnancy in obese women. Front Endocrinol (Lausanne). (2022) 13:918320. doi: 10.3389/fendo.2022.918320, PMID: 35909516 342 Liu

Luo

Gao

Zhou

. Adipsin of the alternative complement pathway is a potential predictor for preeclampsia in early pregnancy. Front Immunol. (2021) 12:702385. doi: 10.3389/fimmu.2021.702385, PMID: 34671343 343 Poveda

Garcés

Ruiz-Linares

Varón

Valderrama

Sanchez

. Serum adipsin levels throughout normal pregnancy and preeclampsia. Sci Rep. (2016) 6:20073. doi: 10.1038/srep20073, PMID: 26832661 344 Rosen

Cook

Yaglom

Groves

Volanakis

Damm

. Adipsin and complement factor D activity: an immune-related defect in obesity. Science. (1989) 244:1483–7. doi: 10.1126/science.2734615, PMID: 2734615 345 Xu

Ippolito

Schroeder

Jr. Carroll

Volanakis

. Complement activation in factor D-deficient mice. Proc Natl Acad Sci U.S.A. (2001) 98:14577–82. doi: 10.1073/pnas.261428398, PMID: 11724962 346 Milek

Moulla

Kern

Stroh

Dietrich

Schön

. Adipsin serum concentrations and adipose tissue expression in people with obesity and type 2 diabetes. Int J Mol Sci. (2022) 23. doi: 10.3390/ijms23042222, PMID: 35216336 347 Lo

Ljubicic

Leibiger

Kern

Leibiger

Moede

. Adipsin is an adipokine that improves β cell function in diabetes. Cell. (2014) 158:41–53. doi: 10.1016/j.cell.2014.06.005, PMID: 24995977 348 Dare

Chen

S-Y

. Adipsin in the pathogenesis of cardiovascular diseases. Vasc Pharmacol. (2024) 154:107270. doi: 10.1016/j.vph.2023.107270, PMID: 38114042 349 Csuka

Molvarec

Derzsy

Varga

Füst

Rigó

Jr. . Functional analysis of the mannose-binding lectin complement pathway in normal pregnancy and preeclampsia. J Reprod Immunol. (2010) 87:90–6. doi: 10.1016/j.jri.2010.07.004, PMID: 20952075 350 Lynch

Wagner

Giclas

West

Gibbs

Holers

. The relationship of longitudinal levels of complement bb during pregnancy with preeclampsia. Am J Reprod Immunol. (2016) 75:104–11. doi: 10.1111/aji.12439, PMID: 26510395 351 Regal

Gilbert

Burwick

. The complement system and adverse pregnancy outcomes. Mol Immunol. (2015) 67:56–70. doi: 10.1016/j.molimm.2015.02.030, PMID: 25802092 352 Denny

Woodruff

Taylor

Callaway

. Complement in pregnancy: a delicate balance. Am J Reprod Immunol. (2013) 69:3–11. doi: 10.1111/aji.12000, PMID: 22925193 353 Alonso-Ventura

Pasupuleti

Roman

Hernandez

Pérez-López

. Effects of preeclampsia and eclampsia on maternal metabolic and biochemical outcomes in later life: a systematic review and meta-analysis. Metabolism. (2020) 102:154012. doi: 10.1016/j.metabol.2019.154012, PMID: 31734276 354 Perry

Khalil

Thilaganathan

. Preeclampsia and the cardiovascular system: An update. Trends Cardiovasc Med. (2018) 28:505–13. doi: 10.1016/j.tcm.2018.04.009, PMID: 29884568 355 Robillard

Dekker

Chaouat

Scioscia

Iacobelli

Hulsey

. Historical evolution of ideas on eclampsia/preeclampsia: A proposed optimistic view of preeclampsia. J Reprod Immunol. (2017) 123:72–7. doi: 10.1016/j.jri.2017.09.006, PMID: 28941881 356 Garrido-Gómez

Castillo-Marco

Cordero

Simón

. Decidualization resistance in the origin of preeclampsia. Am J Obstet Gynecol. (2022) 226:S886–s894. doi: 10.1016/j.ajog.2020.09.039, PMID: 33007270 357 Lai

Syngelaki

Nicolaides

von Dadelszen

Magee

. Impact of new definitions of preeclampsia at term on identification of adverse maternal and perinatal outcomes. Am J Obstetrics Gynecology. (2021) 224:518.e511–518.e511. doi: 10.1016/j.ajog.2020.11.004, PMID: 33166504 358 Ghulmiyyah

Sibai

. Maternal mortality from preeclampsia/eclampsia. Semin Perinatol. (2012) 36:56–9. doi: 10.1053/j.semperi.2011.09.011, PMID: 22280867 359 Jung

Romero

Yeo

Gomez-Lopez

Chaemsaithong

Jaovisidha

. The etiology of preeclampsia. Am J Obstet Gynecol. (2022) 226:S844–s866. doi: 10.1016/j.ajog.2021.11.1356, PMID: 35177222 360 Fisher

. Why is placentation abnormal in preeclampsia? Am J Obstetrics Gynecology. (2015) 213:S115–22. doi: 10.1016/j.ajog.2015.08.042, PMID: 26428489 361 Erez

Romero

Jung

Chaemsaithong

Bosco

Suksai

. Preeclampsia and eclampsia: the conceptual evolution of a syndrome. Am J Obstet Gynecol. (2022) 226:S786–s803. doi: 10.1016/j.ajog.2021.12.001, PMID: 35177220 362 Kumar

. Introductory chapter: macrophages – more than sentinel innate immune cells. In: Kumar

, editor. Macrophages - Celebrating 140 Years of Discovery. IntechOpen, Rijeka (2022). doi: 10.5772/intechopen.109647 363 Dekker

Sibai

. The immunology of preeclampsia. Semin Perinatol. (1999) 23:24–33. doi: 10.1016/S0146-0005(99)80057-3, PMID: 10102168 364 Redman

Sargent

. Immunology of pre-eclampsia. Am J Reprod Immunol. (2010) 63:534–43. doi: 10.1111/j.1600-0897.2010.00831.x, PMID: 20331588 365 Collier

Modest

Aguayo

Bondzie

Patel

Hacker

. Altered cytokine production in human intervillous blood T cells in preeclampsia. Reprod Sci. (2023) 30:2655–64. doi: 10.1007/s43032-023-01165-4, PMID: 36749459 366 Darmochwal-Kolarz

Kludka-Sternik

Tabarkiewicz

Kolarz

Rolinski

Leszczynska-Gorzelak

. The predominance of Th17 lymphocytes and decreased number and function of Treg cells in preeclampsia. J Reprod Immunol. (2012) 93:75–81. doi: 10.1016/j.jri.2012.01.006, PMID: 22370101 367 Stefańska

Kurkowiak

Piekarska

Chruściel

Zamkowska

Jassem-Bobowicz

. High maternal-fetal HLA eplet compatibility is associated with severe manifestation of preeclampsia. Front Immunol. (2023) 14:1272021. doi: 10.3389/fimmu.2023.1272021, PMID: 38022600 368 van Bentem

Bos

van der Keur

Brand-Schaaf

Haasnoot

Roelen

. The development of preeclampsia in oocyte donation pregnancies is related to the number of fetal-maternal HLA class II mismatches. J Reprod Immunol. (2020) 137:103074. doi: 10.1016/j.jri.2019.103074, PMID: 31864034 369 Boulanger

Bounan

Mahdhi

Drouin

Ahriz-Saksi

Guimiot

. Immunologic aspects of preeclampsia. AJOG Global Rep. (2024) 4:100321. doi: 10.1016/j.xagr.2024.100321, PMID: 38586611 370 Borzychowski

Sargent

Redman

. Inflammation and pre-eclampsia. Semin Fetal Neonatal Med. (2006) 11:309–16. doi: 10.1016/j.siny.2006.04.001, PMID: 16828580 371 Ramma

Ahmed

. Is inflammation the cause of pre-eclampsia? Biochem Soc Trans. (2011) 39:1619–27. doi: 10.1042/BST20110672, PMID: 22103497 372 Markiewski

Lambris

. The role of complement in inflammatory diseases from behind the scenes into the spotlight. Am J Pathol. (2007) 171:715–27. doi: 10.2353/ajpath.2007.070166, PMID: 17640961 373 Ruan

C-C

Gao

P-J

. Role of complement-related inflammation and vascular dysfunction in hypertension. Hypertension. (2019) 73:965–71. doi: 10.1161/HYPERTENSIONAHA.118.11210, PMID: 30929519 374 Blakey

Sun

Xie

Russell

Sarween

Hodson

. Pre-eclampsia is associated with complement pathway activation in the maternal and fetal circulation, and placental tissue. Pregnancy Hypertension. (2023) 32:43–9. doi: 10.1016/j.preghy.2023.04.001, PMID: 37088032 375 Velickovic

Dalloul

Wong

Bakare

Schweis

Garala

. Complement factor B activation in patients with preeclampsia. J Reprod Immunol. (2015) 109:94–100. doi: 10.1016/j.jri.2014.12.002, PMID: 25604034 376 Than

Romero

Erez

Kusanovic

Tarca

Edwin

. A role for mannose-binding lectin, a component of the innate immune system in pre-eclampsia. Am J Reprod Immunol. (2008) 60:333–45. doi: 10.1111/j.1600-0897.2008.00631.x, PMID: 18727690 377 Johnson

Louis

. Does race or ethnicity play a role in the origin, pathophysiology, and outcomes of preeclampsia? An expert review of the literature. Am J Obstetrics Gynecology. (2022) 226:S876–85. doi: 10.1016/j.ajog.2020.07.038, PMID: 32717255 378 Lynch

Murphy

Byers

Gibbs

Neville

Giclas

. Alternative complement pathway activation fragment Bb in early pregnancy as a predictor of preeclampsia. Am J Obstet Gynecol. (2008) 198:385.e381–389. doi: 10.1016/j.ajog.2007.10.793, PMID: 18221926 379 Jia

Yang

. Serum levels of complement factors C1q, bb, and H in normal pregnancy and severe pre-eclampsia. Med Sci Monit. (2019) 25:7087–93. doi: 10.12659/MSM.915777, PMID: 31541546 380 He

Song

Chen

Zhao

. Expression of the complement system’s activation factors in plasma of patients with early/late-onset severe pre-eclampsia. Am J Reprod Immunol. (2016) 76:205–11. doi: 10.1111/aji.12541, PMID: 27461873 381 Ye

Kong

Zhang

. Complement split products C3a/C5a and receptors: are they regulated by circulating angiotensin II type 1 receptor autoantibody in severe preeclampsia? Gynecol Obstet Invest. (2016) 81:28–33. doi: 10.1159/000440651, PMID: 26485247 382 He

Song

Chen

Zhao

. Correlations between complement system’s activation factors and anti-angiogenesis factors in plasma of patients with early/late-onset severe preeclampsia. Hypertens Pregnancy. (2016) 35:499–509. doi: 10.1080/10641955.2016.1190845, PMID: 27315511 383 Lim

Lappas

. Decreased expression of complement 3a receptor (C3aR) in human placentas from severe preeclamptic pregnancies. Eur J Obstet Gynecol Reprod Biol. (2012) 165:194–8. doi: 10.1016/j.ejogrb.2012.08.003, PMID: 22901903 384 LaMarca

Wallace

Granger

. Role of angiotensin II type I receptor agonistic autoantibodies (AT1-AA) in preeclampsia. Curr Opin Pharmacol. (2011) 11:175–9. doi: 10.1016/j.coph.2011.01.003, PMID: 21317038 385 Herse

LaMarca

. Angiotensin II type 1 receptor autoantibody (AT1-AA)-mediated pregnancy hypertension. Am J Reprod Immunol. (2013) 69:413–8. doi: 10.1111/aji.12072, PMID: 23279165 386 Palmer

Tong

Kaitu’u-Lino

. Placental-specific sFLT-1: role in pre-eclamptic pathophysiology and its translational possibilities for clinical prediction and diagnosis. Mol Hum Reprod. (2017) 23:69–78. doi: 10.1093/molehr/gaw077, PMID: 27986932 387 Maynard

Min

Merchan

Lim

Mondal

. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. (2003) 111:649–58. doi: 10.1172/JCI17189, PMID: 12618519 388 Piani

Tossetta

Fantone

Agostinis

Di Simone

Mandalà

. First trimester CD93 as a novel marker of preeclampsia and its complications: A pilot study. High Blood Pressure Cardiovasc Prev. (2023) 30:591–4. doi: 10.1007/s40292-023-00608-y, PMID: 38010536 389 Becerra-Mojica

Mora-Guevara

Parra-Saavedra

Martínez-Vega

Díaz-Martínez

Rincón-Orozco

. Low levels of complement factor H in the first trimester of pregnancy are associated with spontaneous preterm birth. Int J Mol Sci. (2024) 25. doi: 10.3390/ijms251910549, PMID: 39408876 390 Lokki

Ren

Triebwasser

Daly

Perola

Auro

. Identification of complement factor H variants that predispose to pre-eclampsia: A genetic and functional study. Bjog. (2023) 130:1473–82. doi: 10.1111/1471-0528.17529, PMID: 37156755 391 Jääskeläinen

Heinonen

Kajantie

Kere

Kivinen

Pouta

. Cohort profile: the finnish genetics of pre-eclampsia consortium (FINNPEC). BMJ Open. (2016) 6:e013148. doi: 10.1136/bmjopen-2016-013148, PMID: 28067621 392 Dijkstra

Lokki

Gierman

Borggreven

van der Keur

Eikmans

. Circulating levels of anti-C1q and anti-factor H autoantibodies and their targets in normal pregnancy and preeclampsia. Front Immunol. (2022) 13. doi: 10.3389/fimmu.2022.842451, PMID: 35432365 393 Yasmin

Agostinis

Toffoli

Roy

Pegoraro

Balduit

. Protective role of complement factor H against the development of preeclampsia. Front Immunol. (2024) 15. doi: 10.3389/fimmu.2024.1351898, PMID: 38464530 394 Salmon

Heuser

Triebwasser

Liszewski

Kavanagh

Roumenina

. Mutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE cohort. PLoS Med. (2011) 8:e1001013. doi: 10.1371/journal.pmed.1001013, PMID: 21445332 395 Balduit

Agostinis

Mangogna

Zito

Stampalija

Ricci

. Systematic review of the complement components as potential biomarkers of pre-eclampsia: pitfalls and opportunities. Front Immunol. (2024) 15:1419540. doi: 10.3389/fimmu.2024.1419540, PMID: 38983853 396 Lokki

Teirilä

Triebwasser

Daly

Bhattacharjee

Uotila

. Dysfunction of complement receptors CR3 (CD11b/18) and CR4 (CD11c/18) in pre-eclampsia: a genetic and functional study. Bjog. (2021) 128:1282–91. doi: 10.1111/1471-0528.16660, PMID: 33539617 397 Burwick

. Complement receptors in pre-eclampsia: cleaning up placental debris. Bjog. (2021) 128:1292. doi: 10.1111/1471-0528.16664, PMID: 33624918 398 Lokki

Triebwasser

Daly

Kurki

Perola

Auro

. Understanding rare genetic variants within the terminal pathway of complement system in preeclampsia. Genes Immun. (2025) 26:22–6. doi: 10.1038/s41435-024-00310-6, PMID: 39690307 399 Larsen

Andersen

Hvas

Thiel

Lassen

Hvas

. Lectin pathway proteins of the complement system in normotensive pregnancy and pre-eclampsia. Am J Reprod Immunol. (2019) 81:e13092. doi: 10.1111/aji.13092, PMID: 30672631 400 Halmos

Rigó

Jr. Szijártó

Füst

Prohászka

Molvarec

. Circulating ficolin-2 and ficolin-3 in normal pregnancy and pre-eclampsia. Clin Exp Immunol. (2012) 169:49–56. doi: 10.1111/j.1365-2249.2012.04590.x, PMID: 22670778 401 Sziller

Babula

Hupuczi

Nagy

Rigó

Szabó

. Mannose-binding lectin (MBL) codon 54 gene polymorphism protects against development of pre-eclampsia, HELLP syndrome and pre-eclampsia-associated intrauterine growth restriction. Mol Hum Reprod. (2007) 13:281–5. doi: 10.1093/molehr/gam003, PMID: 17314117 402 van de Geijn

Dolhain

van Rijs

Hazes

de Groot

. Mannose-binding lectin genotypes and pre-eclampsia: a case-control study. Hum Immunol. (2007) 68:888–93. doi: 10.1016/j.humimm.2007.10.002, PMID: 18082567 403 Banadakoppa

Vidaeff

Yallampalli

Ramin

Belfort

Yallampalli

. Complement split products in amniotic fluid in pregnancies subsequently developing early-onset preeclampsia. Dis Markers. (2015) 2015:263109. doi: 10.1155/2015/263109, PMID: 26556948 404 Haeger

Bengtson

Karlsson

Heideman

. Complement activation and anaphylatoxin (C3a and C5a) formation in preeclampsia and by amniotic fluid. Obstet Gynecol. (1989) 73:551–6., PMID: 2784554 405 Guseh

Feinberg

Dawood

Yamamoto

Fichorova

Burwick

. Urinary excretion of C5b-9 is associated with the anti-angiogenic state in severe preeclampsia. Am J Reprod Immunol. (2015) 73:437–44. doi: 10.1111/aji.12349, PMID: 25521546 406 Burwick

Fichorova

Dawood

Yamamoto

Feinberg

. Urinary excretion of C5b-9 in severe preeclampsia: tipping the balance of complement activation in pregnancy. Hypertension. (2013) 62:1040–5. doi: 10.1161/HYPERTENSIONAHA.113.01420, PMID: 24060886 407 Burwick

Velásquez

Valencia

Gutiérrez-Marín

Edna-Estrada

Silva

. Terminal complement activation in preeclampsia. Obstet Gynecol. (2018) 132:1477–85. doi: 10.1097/AOG.0000000000002980, PMID: 30399106 408 Buurma

Cohen

Veraar

Schonkeren

Claas

Bruijn

. Preeclampsia is characterized by placental complement dysregulation. Hypertension. (2012) 60:1332–7. doi: 10.1161/HYPERTENSIONAHA.112.194324, PMID: 23006730 409 Lokki

Heikkinen-Eloranta

Jarva

Saisto

Lokki

Laivuori

. Complement activation and regulation in preeclamptic placenta. Front Immunol. (2014) 5:312. doi: 10.3389/fimmu.2014.00312, PMID: 25071773 410 Yonekura Collier

Zsengeller

Pernicone

Salahuddin

Khankin

Karumanchi

. Placental sFLT1 is associated with complement activation and syncytiotrophoblast damage in preeclampsia. Hypertens Pregnancy. (2019) 38:193–9. doi: 10.1080/10641955.2019.1640725, PMID: 31291799 411 Holmes

Simpson

Wainwright

Tate

Houlihan

Sawyer

. Preferential expression of the complement regulatory protein decay accelerating factor at the fetomaternal interface during human pregnancy. J Immunol. (1990) 144:3099–105. doi: 10.4049/jimmunol.144.8.3099, PMID: 1691227 412 Holmes

Simpson

Okada

Wainwright

Purcell

. Complement regulatory proteins at the feto-maternal interface during human placental development: distribution of CD59 by comparison with membrane cofactor protein (CD46) and decay accelerating factor (CD55). Eur J Immunol. (1992) 22:1579–85. doi: 10.1002/eji.1830220635, PMID: 1376264 413 Ma

Kong

Hong

Zhang

. Complement 5a-mediated trophoblasts dysfunction is involved in the development of pre-eclampsia. J Cell Mol Med. (2018) 22:1034–46. doi: 10.1111/jcmm.13466, PMID: 29168351 414 Girardi

Yarilin

Thurman

Holers

Salmon

. Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. J Exp Med. (2006) 203:2165–75. doi: 10.1084/jem.20061022, PMID: 16923853 415 Banadakoppa

Balakrishnan

Yallampalli

. Upregulation and release of soluble fms-like tyrosine kinase receptor 1 mediated by complement activation in human syncytiotrophoblast cells. Am J Reprod Immunol. (2018) 80:e13033. doi: 10.1111/aji.13033, PMID: 30099798 416 Matsuyama

Tomimatsu

Mimura

Yagi

Kawanishi

Kakigano

. Complement activation by an angiogenic imbalance leads to systemic vascular endothelial dysfunction: A new proposal for the pathophysiology of preeclampsia. J Reprod Immunol. (2021) 145:103322. doi: 10.1016/j.jri.2021.103322, PMID: 33887508 417 Saleh

Compagno

Pihl

Strevens

Persson

Wetterö

. Variation of complement protein levels in maternal plasma and umbilical cord blood during normal pregnancy: an observational study. J Clin Med. (2022) 11. doi: 10.3390/jcm11133611, PMID: 35806894 418 Miyano

Nakayama

Fujita

Kitajima

Imai

Shimizu

. Complement activation in fetuses: assessment by the levels of complement components and split products in cord blood. Diagn Clin Immunol. (1987) 5:86–90., PMID: 3497734 419 Holers

Girardi

Guthridge

Molina

Pierangeli

. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med. (2002) 195:211–20. doi: 10.1084/jem.200116116, PMID: 11805148 420 Cohen

Buurma

Goemaere

Girardi

le Cessie

Scherjon

. Classical complement activation as a footprint for murine and human antiphospholipid antibody-induced fetal loss. J Pathol. (2011) 225:502–11. doi: 10.1002/path.2893, PMID: 21688269 421 Elfving

Kariniemi

Kautiainen

Rantalaiho

Virta

Puolakka

. Pregnancies in patients with systemic lupus erythematosus during 2000–2018 in Finland: a case-control study. Rheumatol Int. (2024) 44:1101–9. doi: 10.1007/s00296-024-05564-x, PMID: 38565771 422 Teh

Wan

Cheong

Ling

. Systemic lupus erythematosus pregnancies: ten-year data from a single centre in Malaysia. Lupus. (2017) 26:218–23. doi: 10.1177/0961203316664996, PMID: 27522092 423 Ong

Ding

. Predictors of adverse pregnancy outcome in a cohort of women with systemic lupus erythematosus in Malaysia. Med J Malaysia. (2021) 76:466–73., PMID: 34305106 424 Liu

Zhao

Song

Zhang

Bian

Yang

. Pregnancy in women with systemic lupus erythematosus: a retrospective study of 111 pregnancies in Chinese women. J Matern Fetal Neonatal Med. (2012) 25:261–6. doi: 10.3109/14767058.2011.572310, PMID: 21504337 425 Al-Riyami

Salman

Al-Rashdi

Al-Dughaishi

Al-Haddabi

Hassan

. Pregnancy Outcomes in Systemic Lupus Erythematosus Women: A single tertiary centre experience. Sultan Qaboos Univ Med J. (2021) 21:e244–52. doi: 10.18295/squmj.2021.21.02.013, PMID: 34221472 426 Essouma

Nkeck

Motolouze

Bigna

Tchaptchet

Nkoro

. Outcomes of pregnancy and associated factors in sub-Saharan African women with systemic lupus erythematosus: a scoping review. Lupus Sci Med. (2020) 7. doi: 10.1136/lupus-2020-000400, PMID: 32540928 427 Salmon

Girardi

Holers

. Activation of complement mediates antiphospholipid antibody-induced pregnancy loss. Lupus. (2003) 12:535–8. doi: 10.1191/0961203303lu397oa, PMID: 12892394 428 Castellanos Gutierrez

Figueras

Morales-Prieto

Schleußner

Espinosa

Baños

. Placental damage in pregnancies with systemic lupus erythematosus: A narrative review. Front Immunol. (2022) 13:941586. doi: 10.3389/fimmu.2022.941586, PMID: 36059466 429 Ostensen

Clowse

. Pathogenesis of pregnancy complications in systemic lupus erythematosus. Curr Opin Rheumatol. (2013) 25:591–6. doi: 10.1097/BOR.0b013e328363ebf7, PMID: 23917157 430 Steegers

von Dadelszen

Duvekot

Pijnenborg

. Pre-eclampsia. Lancet. (2010) 376:631–44. doi: 10.1016/S0140-6736(10)60279-6, PMID: 20598363 431 Sibai

Dekker

Kupferminc

. Pre-eclampsia. Lancet. (2005) 365:785–99. doi: 10.1016/S0140-6736(05)17987-2, PMID: 15733721 432 Sibai

. Diagnosis, controversies, and management of the syndrome of hemolysis, elevated liver enzymes, and low platelet count. Obstet Gynecol. (2004) 103:981–91. doi: 10.1097/01.AOG.0000126245.35811.2a, PMID: 15121574 433 Douglas

Redman

. Eclampsia in the United Kingdom. Bmj. (1994) 309:1395–400. doi: 10.1136/bmj.309.6966.1395, PMID: 7819845 434 Vaught

Gavriilaki

Hueppchen

Blakemore

Yuan

Seifert

. Direct evidence of complement activation in HELLP syndrome: A link to atypical hemolytic uremic syndrome. Exp Hematol. (2016) 44:390–8. doi: 10.1016/j.exphem.2016.01.005, PMID: 26921648 435 Vaught

Braunstein

Chaturvedi

Blakemore

Brodsky

. A review of the alternative pathway of complement and its relation to HELLP syndrome: is it time to consider HELLP syndrome a disease of the alternative pathway. J Matern Fetal Neonatal Med. (2022) 35:1392–400. doi: 10.1080/14767058.2020.1755650, PMID: 32338085 436 Burwick

Java

Gray

Combs

Rincon

Roberts

. HELLP syndrome is characterized by a unique pattern of complement protein biomarkers. Am J Obstetrics Gynecology. (2022) 226:S484–5. doi: 10.1016/j.ajog.2021.11.802 437 Chen

Zheng

Yingdong

Chen

. Dysregulation of complement system in HELLP syndrome. Hypertension Pregnancy. (2021) 40:303–11. doi: 10.1080/10641955.2021.1983593, PMID: 34697959 438 Shah

Boyer

Chen

Chaturvedi

Vaught

Braunstein

. Complement activation drives progression of pre-eclampsia to HELLP syndrome. Blood. (2021) 138:772–2. doi: 10.1182/blood-2021-148162 439 Vaught

Braunstein

Jasem

Yuan

Makhlin

Eloundou

. Germline mutations in the alternative pathway of complement predispose to HELLP syndrome. JCI Insight. (2018) 3. doi: 10.1172/jci.insight.99128, PMID: 29563339 440 Gerber

Brodsky

Vaught

. Complement C5 Inhibition in early onset HELLP Syndrome. Blood Adv. (2025) 9(13):3304–7. doi: 10.1182/bloodadvances.2024014746, PMID: 40088468 441 Jivraj

Anstie

Cheong

Y-C

Fairlie

Laird

. Obstetric and neonatal outcome in women with a history of recurrent miscarriage: a cohort study. Hum Reprod. (2001) 16:102–6. doi: 10.1093/humrep/16.1.102, PMID: 11139545 442 Mao

Deppong

Friend

Dolecki

Nelson

. Negligible role of antibodies and C5 in pregnancy loss associated exclusively with C3-dependent mechanisms through complement alternative pathway. Immunity. (2003) 19:813–22. doi: 10.1016/S1074-7613(03)00321-2, PMID: 14670299 443 Zhou

Xie

Liu

Jiang

Zheng

. Expression and correlation of complement C3 and C4 in serum and maternal-fetal interface in patients with unexplained recurrent spontaneous abortion: A prospective cohort study. CEOG. (2023) 50. doi: 10.31083/j.ceog5011252 444 Sugiura-Ogasawara

Nozawa

Nakanishi

Hattori

Ozaki

. Complement as a predictor of further miscarriage in couples with recurrent miscarriages. Hum Reprod. (2006) 21:2711–4. doi: 10.1093/humrep/del229, PMID: 16790609 445 Krog

Flachs

Kolte

de Jager

Meyaard

Christiansen

. Angiogenic factors and the lectin pathway of complement in women with secondary recurrent pregnancy loss. J Reprod Immunol. (2024) 163:104221. doi: 10.1016/j.jri.2024.104221, PMID: 38447288 446 Mohlin

Mercier

Fremeaux-Bacchi

Liszewski

Atkinson

Gris

. Analysis of genes coding for CD46, CD55, and C4b-binding protein in patients with idiopathic, recurrent, spontaneous pregnancy loss. Eur J Immunol. (2013) 43:1617–29. doi: 10.1002/eji.201243196, PMID: 23508668 447 Mohlin

Gros

Mercier

Gris

Blom

. Analysis of C3 gene variants in patients with idiopathic recurrent spontaneous pregnancy loss. Front Immunol. (2018) 9:1813. doi: 10.3389/fimmu.2018.01813, PMID: 30131807 448 Lewis

Narayanaswamy

Farewell

Rees

. Complement activation in polycystic ovary syndrome occurs in the postprandial and fasted state and is influenced by obesity and insulin sensitivity. Clin Endocrinol (Oxf). (2021) 94:74–84. doi: 10.1111/cen.14322, PMID: 32865246 449 Butler

Moin

ASM

Sathyapalan

Atkin

. Complement dysregulation in obese versus nonobese polycystic ovary syndrome patients. Cells. (2023) 12. doi: 10.3390/cells12152002, PMID: 37566081 450 Moin

ASM

Sathyapalan

Butler

Atkin

. Classical and alternate complement factor overexpression in non-obese weight matched women with polycystic ovary syndrome does not correlate with vitamin D. Front Endocrinol (Lausanne). (2022) 13:935750. doi: 10.3389/fendo.2022.935750, PMID: 36619572 451 O’Brien

Ray

Chan

. Maternal body mass index and the risk of preeclampsia: a systematic overview. Epidemiology. (2003) 14:368–74. doi: 10.1097/01.EDE.0000059921.71494.D1, PMID: 12859040 452 Canto-Cetina

Coral-Vázquez

Rojano-Mejía

Pérez Godoy

Coronel

Canto

. Higher prepregnancy body mass index is a risk factor for developing preeclampsia in Maya-Mestizo women: a cohort study. Ethn Health. (2018) 23:682–90. doi: 10.1080/13557858.2017.1315367, PMID: 28385076 453 Vinturache

Moledina

McDonald

Slater

Tough

. Pre-pregnancy Body Mass Index (BMI) and delivery outcomes in a Canadian population. BMC Pregnancy Childbirth. (2014) 14:422. doi: 10.1186/s12884-014-0422-y, PMID: 25528667 454 Schiavone

Pérez

Aquieri

Nosetto

Pronotti

Mazzei

. The role of obesity in the development of preeclampsia. Curr Hypertens Rep. (2024) 26:247–58. doi: 10.1007/s11906-024-01299-z, PMID: 38512586 455 Shim

Begum

Yang

Wang

. Complement activation in obesity, insulin resistance, and type 2 diabetes mellitus. World J Diabetes. (2020) 11:1–12. doi: 10.4239/wjd.v11.i1.1, PMID: 31938469 456 Mamane

Chung Chan

Lavallee

Morin

Huang

. The C3a anaphylatoxin receptor is a key mediator of insulin resistance and functions by modulating adipose tissue macrophage infiltration and activation. Diabetes. (2009) 58:2006–17. doi: 10.2337/db09-0323, PMID: 19581423 457 Phieler

Chung

Chatzigeorgiou

Klotzsche-von Ameln

Garcia-Martin

Sprott

. The complement anaphylatoxin C5a receptor contributes to obese adipose tissue inflammation and insulin resistance. J Immunol. (2013) 191:4367–74. doi: 10.4049/jimmunol.1300038, PMID: 24043887 458 Lynch

Eckel

Murphy

Gibbs

West

Giclas

. Prepregnancy obesity and complement system activation in early pregnancy and the subsequent development of preeclampsia. Am J Obstet Gynecol. (2012) 206:428.e421–428. doi: 10.1016/j.ajog.2012.02.035, PMID: 22542119 459 Olson

Redman

Sones

. Obesity “complements” preeclampsia. Physiol Genomics. (2019) 51:73–6. doi: 10.1152/physiolgenomics.00102.2018, PMID: 30716010 460 Robinson

Klein

. Pregnancy and pregnancy-associated hormones alter immune responses and disease pathogenesis. Horm Behav. (2012) 62:263–71. doi: 10.1016/j.yhbeh.2012.02.023, PMID: 22406114 461 Abu-Raya

Michalski

Sadarangani

Lavoie

. Maternal immunological adaptation during normal pregnancy. Front Immunol. (2020) 11. doi: 10.3389/fimmu.2020.575197, PMID: 33133091 462 Sherer

Posillico

Schwarz

. An examination of changes in maternal neuroimmune function during pregnancy and the postpartum period. Brain Behavior Immun. (2017) 66:201–9. doi: 10.1016/j.bbi.2017.06.016, PMID: 28669797 463 Brunton

. Neuroactive steroids and stress axis regulation: Pregnancy and beyond. J Steroid Biochem Mol Biol. (2016) 160:160–8. doi: 10.1016/j.jsbmb.2015.08.003, PMID: 26259885 464 Kopaliani

Elsaid

Speier

Deussen

. Immune and metabolic mechanisms of endothelial dysfunction. Int J Mol Sci. (2024) 25. doi: 10.3390/ijms252413337, PMID: 39769104 465 Rizzoni

De Ciuceis

Szczepaniak

Paradis

Schiffrin

Guzik

. Immune system and microvascular remodeling in humans. Hypertension. (2022) 79:691–705. doi: 10.1161/HYPERTENSIONAHA.121.17955, PMID: 35098718 466 Zeng

Han

Jiang

Liu

Long

. Serum complement proteomics reveal biomarkers for hypertension disorder of pregnancy and the potential role of Clusterin. Reprod Biol Endocrinol. (2021) 19:56. doi: 10.1186/s12958-021-00742-z, PMID: 33874952 467 Zeng

Pan

Liu

Yin

Jiang

Long

. Role of clusterin in the regulation of trophoblast development and preeclampsia. Biochem Biophys Res Commun. (2021) 583:128–34. doi: 10.1016/j.bbrc.2021.10.064, PMID: 34735874 468 Watanabe

Hamada

Yamada

Sohda

Yamakawa-Kobayashi

Yoshikawa

. Proteome analysis reveals elevated serum levels of clusterin in patients with preeclampsia. PROTEOMICS. (2004) 4:537–43. doi: 10.1002/pmic.200300565, PMID: 14760726 469 Oztas

Ozler

Ersoy

Iskender

Sucak

Ergin

. Increased levels of serum clusterin is associated with intrauterine growth restriction and adverse pregnancy outcomes in preeclampsia. J Perinatal Med. (2016) 44:269–75. doi: 10.1515/jpm-2015-0120, PMID: 26352072 470 Yao

Chen

Cao

Yang

Lei

. Clusterin from endometrial glands plays a critical role in decidualization via Trem2. BMC Genomics. (2024) 25:969. doi: 10.1186/s12864-024-10827-9, PMID: 39415084 471 Dolgyras

Anyfanti

Lazaridis

Gavriilaki

Koletsos

Triantafyllou

. Endothelial dysfunction and complement activation are independently associated with disease duration in patients with systemic vasculitis. Microvasc Res. (2024) 154:104692. doi: 10.1016/j.mvr.2024.104692, PMID: 38705254 472 Konukoglu

Uzun

. Endothelial dysfunction and hypertension. Adv Exp Med Biol. (2017) 956:511–40. doi: 10.1007/5584_2016_90, PMID: 28035582 473 Wang

Zhang

Wei

. Endothelial-derived complement factor D contributes to endothelial dysfunction in Malignant nephrosclerosis via local complement activation. Hypertension Res. (2023) 46:1759–70. doi: 10.1038/s41440-023-01300-3, PMID: 37188751 474 Cervia-Hasler

Brüningk

Hoch

Fan

Muzio

Thompson

. Persistent complement dysregulation with signs of thromboinflammation in active Long Covid. Science. (2024) 383:eadg7942. doi: 10.1126/science.adg7942, PMID: 38236961 475 Baillie

Davies

Keat

SBK

Ladell

Miners

Jones

. Complement dysregulation is a prevalent and therapeutically amenable feature of long COVID. Med. (2024) 5:239–253.e235. doi: 10.1016/j.medj.2024.01.011, PMID: 38359836 476 Wenzel

Kemper

Bode

. The role of complement in arterial hypertension and hypertensive end organ damage. Br J Pharmacol. (2021) 178:2849–62. doi: 10.1111/bph.15171, PMID: 32585035 477 Karthikeyan

Lip

. Endothelial damage/dysfunction and hypertension in pregnancy. Front Biosci (Elite Ed). (2011) 3:1100–8. doi: 10.2741/314, PMID: 21622117 478 Ramos

Youssef

Molina

Martinez-Sanchez

Moreno-Castaño

Blasco

. Endothelial damage and complement dysregulation in fetuses from pregnancies complicated by preeclampsia. Acta Obstetricia Gynecologica Scandinavica. (2025) 104(5):829–38. doi: 10.1111/aogs.15072, PMID: 40007223 479 Chen

Fukuda

Matsumoto

Abe

. Role of complement 3 in the pathogenesis of hypertension. Hypertension Res. (2020) 43:255–62. doi: 10.1038/s41440-019-0371-y, PMID: 31853040 480 Penning

Chua

van Kooten

Zandbergen

Buurma

Schutte

. Classical complement pathway activation in the kidneys of women with preeclampsia. Hypertension. (2015) 66:117–25. doi: 10.1161/HYPERTENSIONAHA.115.05484, PMID: 25941343 481 Dusse

Rios

DRA

Pinheiro

Cooper

Lwaleed

. Pre-eclampsia: Relationship between coagulation, fibrinolysis and inflammation. Clinica Chimica Acta. (2011) 412:17–21. doi: 10.1016/j.cca.2010.09.030, PMID: 20888809 482 Drury-Stewart

Hoppe

Lannert

Chung

Gammill

Johnsen

. Pregnancies complicated by severe preeclampsia exhibit perturbed von willebrand factor (VWF)-associated parameters. Blood. (2013) 122:3525. doi: 10.1182/blood.V122.21.3525.3525 483 Soleimani Samarkhazan

Khaksari

Rahmati

Esfahani

Solouki

Aghaei

. Von Willebrand disease (VWD) and pregnancy: a comprehensive overview. Thromb J. (2025) 23:41. doi: 10.1186/s12959-025-00727-7, PMID: 40296027 484 MCKAY

. Hematologic evidence of disseminated intravascular coagulation in eclampsia. Obstetrical Gynecological Survey. (1972) 27:399–417. doi: 10.1097/00006254-197206000-00001, PMID: 4614142 485 He

Bremme

Blombäck

. Acquired deficiency of antithrombin in association with a hypercoagulable state and impaired function of liver and/or kidney in preeclampsia. Blood coagulation fibrinolysis. (1997) 8:232–8. doi: 10.1097/00001721-199706000-00004, PMID: 9199820 486 Carson

Johnson

. Consecutive enzyme cascades: complement activation at the cell surface triggers increased tissue factor activity. Blood. (1990) 76:361–7. doi: 10.1182/blood.V76.2.361.361, PMID: 2369639 487 Heurich

McCluskey

. Complement and coagulation crosstalk – Factor H in the spotlight. Immunobiology. (2023) 228:152707. doi: 10.1016/j.imbio.2023.152707, PMID: 37633063 488 Muhlfelder

Niemetz

Kreutzer

Beebe

Ward

Rosenfeld

. C5 chemotactic fragment induces leukocyte production of tissue factor activity: a link between complement and coagulation. J Clin Invest. (1979) 63:147–50. doi: 10.1172/JCI109269, PMID: 762243 489 Ikeda

Nagasawa

Horiuchi

Tsuru

Nishizaka

Niho

. C5a induces tissue factor activity on endothelial cells. Thromb Haemost. (1997) 77:394–8., PMID: 9157602 490 Foley

Walton

Aleman

O’Byrne

Lei

Harrasser

. Complement activation in arterial and venous thrombosis is mediated by plasmin. EBioMedicine. (2016) 5:175–82. doi: 10.1016/j.ebiom.2016.02.011, PMID: 27077125 491 Amara

Flierl

Rittirsch

Klos

Chen

Acker

. Molecular intercommunication between the complement and coagulation systems. J Immunol. (2010) 185:5628–36. doi: 10.4049/jimmunol.0903678, PMID: 20870944 492 Amara

Rittirsch

Flierl

Bruckner

Klos

Gebhard

. Interaction between the coagulation and complement system. Adv Exp Med Biol. (2008) 632:71–9. doi: 10.1007/978-0-387-78952-1_6, PMID: 19025115 493 Youssef

Miranda

Blasco

Paules

Crovetto

Palomo

. Complement and coagulation cascades activation is the main pathophysiological pathway in early-onset severe preeclampsia revealed by maternal proteomics. Sci Rep. (2021) 11:3048. doi: 10.1038/s41598-021-82733-z, PMID: 33542402 494 Quintanilla

Greenstein

Tripathi

Bartosh

Yuan

Zarate

. Assessment of complement cascade components in patients with major depressive disorder. Brain Behavior Immun. (2025) 127:229–37. doi: 10.1016/j.bbi.2025.03.009, PMID: 40064429 495 Rondung

Massoudi

Nieminen

Wickberg

Peira

Silverstein

. Identification of depression and anxiety during pregnancy: A systematic review and meta-analysis of test accuracy. Acta Obstetricia Gynecologica Scandinavica. (2024) 103:423–36. doi: 10.1111/aogs.14734, PMID: 38014572 496 Gaynes

Gavin

Meltzer-Brody

Lohr

Swinson

Gartlehner

. Perinatal depression: prevalence, screening accuracy, and screening outcomes. Evid Rep Technol Assess (Summ). 2005(119):1–8. doi: 10.1037/e439372005-001, PMID: 15760246